<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>BRPI9611114B1 - 
  METHOD FOR THE BIOTRATING WITH STONES, METHOD FOR THE BIOACCURATION, DETERGENT COMPOSITION, METHOD FOR THE TREATMENT OF TEXTILE MATERIAL CONTAINING CELLULOSE FIBER AND METHOD FOR THE TREATMENT OF WOOD PULP OR FIBER DERIVED FROM WOOD
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/BRPI9611114B1/en">
    <meta name="description" content="
   
    &quot;Cellulases, the genes encoding them and their uses&quot;. genes encoding the cellulases, and a gene encoding a protein that facilitates the action of such cellulases, the cellulases and a protein that facilitates the action of such cellulases, and enzyme preparations containing such proteins are described. The native hosts and the culture medium of said hosts containing said cellulases are also described. These proteins are especially useful in the textile and detergent industry, and in the pulp and paper industry.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  METHOD FOR THE BIOTRATING WITH STONES, METHOD FOR THE BIOACCURATION, DETERGENT COMPOSITION, METHOD FOR THE TREATMENT OF TEXTILE MATERIAL CONTAINING CELLULOSE FIBER AND METHOD FOR THE TREATMENT OF WOOD PULP OR FIBER DERIVED FROM WOOD
 
     ">
    <meta name="DC.date" content="1996-10-17" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    &quot;Cellulases, the genes encoding them and their uses&quot;. genes encoding the cellulases, and a gene encoding a protein that facilitates the action of such cellulases, the cellulases and a protein that facilitates the action of such cellulases, and enzyme preparations containing such proteins are described. The native hosts and the culture medium of said hosts containing said cellulases are also described. These proteins are especially useful in the textile and detergent industry, and in the pulp and paper industry.
   
 
   ">
    <meta name="citation_patent_application_number" content="BR:PI9611114-3A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/97/67/b1/699225b5dba7c6/BRPI9611114B1.pdf">
    <meta name="citation_patent_publication_number" content="BR:PI9611114:B1">
    <meta name="DC.date" content="2017-08-01">
    <meta name="DC.contributor" content="Miettinen-Oinonen Arja" scheme="inventor">
    <meta name="DC.contributor" content="Londesborough Jonh" scheme="inventor">
    <meta name="DC.contributor" content="Vehmaanpera Jari" scheme="inventor">
    <meta name="DC.contributor" content="Haakana Heli" scheme="inventor">
    <meta name="DC.contributor" content="Mantyla Arja" scheme="inventor">
    <meta name="DC.contributor" content="Lantto Raija" scheme="inventor">
    <meta name="DC.contributor" content="Elovainio Minna" scheme="inventor">
    <meta name="DC.contributor" content="Joutsjoki Vesa" scheme="inventor">
    <meta name="DC.contributor" content="Paloheimo Marja" scheme="inventor">
    <meta name="DC.contributor" content="Suominen Pirkko" scheme="inventor">
    <meta name="DC.contributor" content="Ab Enzymes Oy" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  METHOD FOR THE BIOTRATING WITH STONES, METHOD FOR THE BIOACCURATION, DETERGENT COMPOSITION, METHOD FOR THE TREATMENT OF TEXTILE MATERIAL CONTAINING CELLULOSE FIBER AND METHOD FOR THE TREATMENT OF WOOD PULP OR FIBER DERIVED FROM WOOD
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Portuguese</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA225821021" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">patente de inveno: &lt;b&gt;"celulases, os genes codificando-as e os usos das mesmas"&lt;d&gt; . so descritos os genes codificando as celulases, e um gene codificando uma protena que facilita a ao de tais celulases, as celulases e uma protena que facilita a ao de tais celulases, e as preparaes de enzimas contendo tais protenas. so tambm descritos os hospedeiros nativos e o meio de cultivo dos ditos hospedeiros contendo as ditas celulases. estas protenas so especialmente teis na indstria txtil e de detergentes, e na indstria de polpa e papel.</span>"Cellulases, the genes encoding them and their uses". genes encoding the cellulases, and a gene encoding a protein that facilitates the action of such cellulases, the cellulases and a protein that facilitates the action of such cellulases, and enzyme preparations containing such proteins are described. The native hosts and the culture medium of said hosts containing said cellulases are also described. These proteins are especially useful in the textile and detergent industry, and in the pulp and paper industry.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result" hidden="">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Micro-Organisms Or Cultivation Processes Thereof"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Micro-Organisms Or Cultivation Processes Thereof
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Enzymes And Modification Thereof"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Enzymes And Modification Thereof
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline" style="" hidden="">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">BRPI9611114B1</h2>
                  <p class="tagline style-scope patent-result">Brazil</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Granted divisional patent</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/97/67/b1/699225b5dba7c6/BRPI9611114B1.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;cellulase&quot;,&quot;dna&quot;,&quot;protein&quot;,&quot;activity&quot;,&quot;cellulases&quot;]" data-before="19951017"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/BRPI9611114B1"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BRPI9611114B1/pt"><a id="link" href="#" class="style-scope state-modifier">Portuguese</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Miettinen-Oinonen Arja"><a id="link" href="#" class="style-scope state-modifier">Miettinen-Oinonen Arja</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Londesborough Jonh"><a id="link" href="#" class="style-scope state-modifier">Londesborough Jonh</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Vehmaanpera Jari"><a id="link" href="#" class="style-scope state-modifier">Vehmaanpera Jari</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Haakana Heli"><a id="link" href="#" class="style-scope state-modifier">Haakana Heli</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Mantyla Arja"><a id="link" href="#" class="style-scope state-modifier">Mantyla Arja</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Lantto Raija"><a id="link" href="#" class="style-scope state-modifier">Lantto Raija</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Elovainio Minna"><a id="link" href="#" class="style-scope state-modifier">Elovainio Minna</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Joutsjoki Vesa"><a id="link" href="#" class="style-scope state-modifier">Joutsjoki Vesa</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Paloheimo Marja"><a id="link" href="#" class="style-scope state-modifier">Paloheimo Marja</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Suominen Pirkko"><a id="link" href="#" class="style-scope state-modifier">Suominen Pirkko</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">1996</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI9611114B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline" this="">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BRPI9611114-3A</div>
                <div class="style-scope application-timeline">Filing date: 1996-10-17</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application BRPI9611114-3A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">1996-10-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Ab Enzymes Oy"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Ab Enzymes Oy</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">1996-10-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO1997014804A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from PCT/FI1996/000550</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2017-08-01</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI9611114B1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of BRPI9611114B1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=BR&amp;NR=PI9611114B1&amp;KC=B1&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/BR/PI9611114/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/BRPI9611114B1">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Portuguese</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES128438102" lang="EN" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Relatrio Descritivo da Patente de Inveno para "VETOR, MICROORGANISMO TRANSFORMADO, MTODO PARA O BIOTRATA-MENTO COM PEDRAS, MTODO PARA O BIOACABAMENTO, COMPOSIO DETERGENTE, MTODO PARA O TRATAMENTO DE MATERIAL TXTIL CONTENDO FIBRA CELULSICA E MTODO PARA O TRATAMENTO DE POLPA OU FIBRA DERIVADA DE MADEIRA".</span>Report of the Invention Patent for "VECTOR, TRANSFORMED MICROORGANISM, METHOD FOR STONE BIOTRACTION, METHOD FOR BIOACHABILITY, DETERGENT COMPOSITION, METHOD FOR TREATMENT OF TEXTILE FIBRUS AND CELL FIBRUS MATERIALS WOODEN".</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fundamentos da Inveno Campo da Inveno A presente inveno est relacionada aos genes codificando as novas celulases neutras e s composies contendo as novas celulases neutras. Estas composies so especialmente teis nas indstrias txteis, de detergentes e de polpa e papel. Tcnica Relacionada A celulose  um polissacardeo linear de resduos de glicose conectados por ligaes -1,4. Na natureza, a celulose est normalmente associada com a lignina, juntamente com as hemiceluloses, tais como os xilanos e os glicomananos. O uso prtico das celulases tem sido dificultado pela natureza das celulases conhecidas, as quais so frequentemente misturas de celulases tendo uma variedade de atividades e especificidades de substrato. Por aquela razo,  desejvel identificar fontes a partir das quais as celulases tendo somente as atividades desejadas possam ser obtidas.</span>BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to genes encoding novel neutral cellulases and compositions containing novel neutral cellulases. These compositions are especially useful in the textile, detergent and pulp and paper industries. Related Art Cellulose is a linear polysaccharide of glucose residues connected by -1,4 bonds. In nature, cellulose is usually associated with lignin, along with hemicelluloses such as xylans and glycomananes. The practical use of cellulases has been hampered by the nature of known cellulases, which are often mixtures of cellulases having a variety of substrate activities and specificities. For that reason, it is desirable to identify sources from which cellulases having only the desired activities can be obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uma ampla variedade de celulases  conhecida na tcnica, a maior parte das quais so celulases cidas. Entretanto, algumas celulases neutras e alcalinas foram tambm identificadas. A Celluzyme  uma preparao de celulase comercialmente disponvel a partir de Humicola insolens (Novo Nordisk, A/S). A GB 2.075.028 e a EP 406.314 descrevem o uso de uma celulase de Humicola insolens como um aditivo enzimtico em um detergente de lavagem para reduzir a aspereza (dureza) dos tecidos contendo algodo. A clonagem de uma celulase contendo atividade de endoglicanase a partir de Humicola insolens  descrita no WO 93/11249 e na EP 531.372. A EP 510.091 descreve uma celulase a partir do Bacillus spp. NCIMB 40250 que  til nas composies detergentes. A EP 220.016 descreve celulases que so teis como agentes de clarificao para tecidos coloridos. O WO 94/07998 descreve celulases modificadas que possuem uma atividade alcalina aperfeioada. O WO 95/02675 descreve composies detergentes que contm duas celulases diferentes: uma primeira celulase que  cataliticamente receptvel  remoo da sujeira em partculas, e uma segunda celulase que  cataliticamente receptvel  clarificao da cor. O WO 92/18599 descreve uma preparao detergente que contm tanto uma celulase quanto uma protease. As celulases tambm tm sido usadas industrialmente como um auxiliar para a remoo de espessante de pasta de estampagem e corante em excesso aps a estampagem txtil (EP 576.526). A EP 383 828 descreve composies detergentes granulares, as quais contm agente ativo na superfcie, um material de argila amaciante de tecido, e granulados de celulase contendo carbonato de clcio. A US 5.433.750 descreve composies detergentes contendo um agente ativo na superfcie, um sistema de "builder", uma argila amaciante, um agente de floculao de argila e uma celulase com alta atividade, preferivelmente a celulase de Humicola insolens. A US 5.520.838 descreve composies detergentes granulares, compreendendo agente ativo na superfcie, um "builder" e uma celulase, preferivelmente uma celulase de Humicola insolens, as ditas composies estando em uma forma compacta, tendo uma densidade relativamente alta e contendo uma quantidade pequena de sal de carga inorgnico.</span>A wide variety of cellulases are known in the art, most of which are acid cellulases. However, some neutral and alkaline cellulases have also been identified. Celluzyme is a commercially available cellulase preparation from Humicola insolens (Novo Nordisk, A / S). GB 2,075,028 and EP 406,314 describe the use of a Humicola insolens cellulase as an enzymatic additive in a wash detergent to reduce the harshness (hardness) of cotton containing fabrics. Cloning of a cellulase containing endoglycanase activity from Humicola insolens is described in WO 93/11249 and EP 531,372. EP 510,091 describes a cellulase from Bacillus spp. NCIMB 40250 which is useful in detergent compositions. EP 220,016 describes cellulases which are useful as clarifying agents for colored fabrics. WO 94/07998 describes modified cellulases having improved alkaline activity. WO 95/02675 describes detergent compositions containing two different cellulases: a first cellulase that is catalytically receptive to the removal of particulate dirt, and a second cellulase that is catalytically receptive to color clarification. WO 92/18599 describes a detergent preparation containing both a cellulase and a protease. Cellulases have also been used industrially as an aid for the removal of printing paste thickener and excess dye after textile printing (EP 576,526). EP 383,828 describes granular detergent compositions which contain surface active agent, a fabric softening clay material, and calcium carbonate-containing cellulase granules. US 5,433,750 describes detergent compositions containing a surface active agent, a builder system, a softening clay, a flocculating clay agent and a high activity cellulase, preferably Humicola insolens cellulase. US 5,520,838 describes granular detergent compositions comprising surface active agent, a builder and a cellulase, preferably a Humicola insolens cellulase, said compositions being in a compact form having a relatively high density and containing a small amount. of inorganic filler salt.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As enzimas celulases so usadas em uma ampla variedade de indstrias, alm da indstria txtil. Por exemplo, as celulases so usadas industrialmente para a retirada de tinta de jornais e revistas (EP 521.999), para o aperfeioamento da drenagem de polpa (WO 91/14822, WO 91/17243), e como um tratamento para o alimento de animais.</span>Cellulase enzymes are used in a wide variety of industries in addition to the textile industry. For example, cellulases are used industrially for ink removal from newspapers and magazines (EP 521,999), for improving pulp drainage (WO 91/14822, WO 91/17243), and as a feed treatment. .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As propriedades nicas de cada celulase tornam algumas mais adequadas para certos propsitos do que outras. Embora as enzimas difiram em diversas formas, uma das diferenas mais importante  o pH timo. As celulases neutras tm atividade de celulase til na faixa de pH de 6-8, as celulases alcalinas tm atividade de celulase til na faixa de pH de 7,5-10. As celuiases cidas so ativas na faixa de pH de 4,5-6, porm tm pouca atividade de celuiase nos valores de pH maiores.</span>The unique properties of each cellulase make some more suitable for certain purposes than others. Although enzymes differ in several ways, one of the most important differences is the optimal pH. Neutral cellulases have useful cellulase activity in the pH range of 6-8, alkaline cellulases have useful cellulase activity in the pH range of 7.5-10. Acid celluiases are active in the pH range 4.5-6, but have little celluase activity at higher pH values.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As celuiases neutras e cidas so especialmente teis na indstria txtil, Klahorst, S. e col., Textile Chemist and Coforist 26: 13-18, 1994; Nilsson, T.E., Aachen Textile Conference, DWI Reports 114: 85-88 (1995); Videbaek, T. e col., ITB Dyeing/Printing/Finishing, janeiro de 1994, pginas 25-29; Klahorst, S. e col., AATCC Int. Conf &amp; Exhibit, 4-7 de outubro de 1992, pg. 243, Atlanta, GA; Kochavi, D. e col., Am. Dyestuff Resporter, setembro de 1990, pginas 26-28; Tundall, R. Michael, Textile Chemists and Colorist 24:23 (1992); Lange, N.K., em Proc. Second TRICEL Symp. on Trichoderma reesei Ceilulases and Other Hydrolases, Espoo, Finlndia, 1993, ed. P. Suominen e col,, Foundation for Biotechnical and Industrial Fermentation Research vol. 8, 1993, pginas 263-272. Quando usadas para tratar o tecido, as celuiases atacam as cadeias de molculas da celulose que formam as fibras de algodo, desse modo afetando as caractersticas do tecido.</span>Neutral and acid celluiases are especially useful in the textile industry, Klahorst, S. et al., Textile Chemist and Coforist 26: 13-18, 1994; Nilsson, T.E., Aachen Textile Conference, DWI Reports 114: 85-88 (1995); Videbaek, T. et al., ITB Dyeing / Printing / Finishing, January 1994, pages 25-29; Klahorst, S. et al., AATCC Int. Conf &amp; Exhibit, 4-7 October 1992, p. 243, Atlanta, GA; Kochavi, D. et al., Am. Dyestuff Resporter, September 1990, pages 26-28; Tundall, R. Michael, Textile Chemists and Colorist 24:23 (1992); Lange, N.K., in Proc. Second TRICEL Symp. on Trichoderma reesei Ceilulases and Other Hydrolases, Espoo, Finland, 1993, ed. P. Suominen et al., Foundation for Biotechnical and Industrial Fermentation Research vol. 8, 1993, pages 263-272. When used to treat tissue, celluliases attack the chains of cellulose molecules that form cotton fibers, thereby affecting the characteristics of the tissue.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tradicionalmente, na "lavagem com pedras", as pdras-pome tm sido usadas para alterar as caractersticas do tecido. Gradualmente, as celuiases esto substituindo as pedras-pome, as quais proporcionam ao tecido o seu aspecto final desejado, porm podem causar estrago s mquinas, s roupas e aos equipamento de processamento das guas servidas. As US 4.832.864, US 4.912.056, US 5.006.126, US 5.122.159, US 5.213.581 e EP 307.564 divulaam o uso de celuiases biotratamento com pedras.</span>Traditionally, in "stone washing", pomegranates have been used to alter the characteristics of the fabric. Gradually, celuiases are replacing pumice stones, which give the fabric its desired final appearance, but can cause damage to wastewater processing machines, clothing and equipment. US 4,832,864, US 4,912,056, US 5,006,126, US 5,122,159, US 5,213,581 and EP 307,564 disclose the use of stone biotreatment celluiases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As celuiases so especialmente teis para lavar com pedras o brim tingido com ndigo, uma vez que o corante, na maior parte, permanece sobre a superfcie do fio e no penetra nas fibras bem. Quando usadas para tratar o tecido de algodo, as celuiases neutras geralmente requerem um tempo de lavagem mais longo do que o fazem as celuiases cidas. Entretanto, as celuiases neutras disponveis so menos agressivas (ativas) contra o algodo do que as celuiases cidas, e so descritas no comprometer a resistncia do tecido to rapidamente quanto as celuiases cidas. As celulases neutras tm um perfil mais amplo de pH e assim o aumento do pH que ocorre durante o biotratamento com pedras tem pouco efeito sobre a atividade da enzima neutra. O uso de celulases cidas  dificultado por sua tendncia a promover a colorao de volta e um enfraquecimento dos tecidos. Ademais, o pH deve ser ajustado para uma faixa adequada para a funo das celulases cidas. Consequentemente, h uma clara demanda por preparaes de enzimas de celulases neutras que no causem a colorao de volta ou o enfraquecimento dos tecidos.</span>Celluiases are especially useful for washing indigo-dyed denim with stones, as the dye mostly remains on the surface of the yarn and does not penetrate the fibers well. When used to treat cotton fabric, neutral celluiases generally require a longer wash time than acid celluiases do. However, available neutral celluiases are less aggressive (active) against cotton than acidic celluiases, and are reported not to compromise tissue resistance as rapidly as acid celluiases. Neutral cellulases have a broader pH profile and thus the increase in pH that occurs during stone biotreatment has little effect on neutral enzyme activity. The use of acid cellulases is hampered by their tendency to promote back staining and a weakening of tissues. In addition, the pH should be adjusted to an appropriate range for the function of acid cellulases. Consequently, there is a clear demand for neutral cellulase enzyme preparations that do not cause back staining or tissue weakening.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Embora tenha se tornado popular usar celulases na indstria txtil, simplesmente alterar-se a mistura de celulases que  usada pode produzir um acabamento diferente. Estes problemas tm focado uma ateno crescente sobre a busca por misturas reproduzveis de celulases com propriedades desejadas. Assim, h uma clara demanda, especialmente na indstria txtil e de detergentes, por novas celulases ativas nos valores de pH neutros e alcalinos, que no comprometam a resistncia dos tecidos, com boas propriedades de limpeza e/ou cuidado dos tecidos e de reduo da aspereza.</span>Although it has become popular to use cellulases in the textile industry, simply changing the cellulose mixture that is used can produce a different finish. These problems have focused increasing attention on the search for reproducible mixtures of cellulases with desired properties. Thus, there is a clear demand, especially in the textile and detergent industry, for new active cellulases at neutral and alkaline pH values, which do not compromise tissue resistance, with good tissue cleaning and / or care properties and reduction of tissue roughness.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sumrio da Inveno Reconhecendo a importncia de identificar enzimas teis no bio-acabamento e no biotratamento txteis, e nas aplicaes detergentes, os inventores examinaram espcies fngicas para celulases neutras e alcalinas com caractersticas enzimticas que seriam teis em tais tecnologias.</span>Summary of the Invention Recognizing the importance of identifying enzymes useful in textile bio-finishing and biotreatment, and in detergent applications, the inventors examined fungal species for neutral and alkaline cellulases with enzymatic characteristics that would be useful in such technologies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estes estudos resultaram em novas celulases originando-se dos gneros Mvceliophthora, Myriococcum, Melanocarpus, Sporotrichum e Chaetomium. A inveno  adicionalmente dirigida ao meio de cultura esgotado ou preparaes de enzimas preparadas a partir dos hospedeiros nativos produzindo tais novas celulases. A inveno  adicionalmente dirigida ao uso de tal meio de cultura ou ao uso de tais preparaes de enzimas na indstria txtil e de detergentes, e nas indstrias de polpa e papel.</span>These studies resulted in new cellulases originating from the genera Mvceliophthora, Myriococcum, Melanocarpus, Sporotrichum and Chaetomium. The invention is further directed to depleted culture medium or enzyme preparations prepared from native hosts producing such novel cellulases. The invention is further directed to the use of such culture medium or the use of such enzyme preparations in the textile and detergent industries, and in the pulp and paper industries.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estes estudos adicionalmente resultaram na identificao de trs novas celulases que so especialmente teis na indstria txtil e de detergentes. As preparaes purificadas a partir da Melanocarpus sp. ou da Myriococcum sp. revelaram uma celulase de 20 kDa com atividade de endoglicanase (designada aqui como "celulase de 20K"), uma celulase de 50 kDa ("celulase de 50K"), e uma segunda celulase de 50 kDa ("celulase B de 50K"). Um novo produto de gene com alta homologia  famlia das celulases, aqui chamado "protena com CBD" (onde CBD significa "domnio de ligao  celulose"), foi tambm verificado.  um objetivo da inveno proporcionar preparaes de enzimas que contenham uma ou mais das novas celulases da inveno, especialmente a celulase de 20K, a celulase de 50K, a celulase B de 50K e/ou a protena com CBD.  um objetivo adicional desta inveno proporcionar um mtodo para utilizar tais preparaes para o acabamento de produtos txteis, especialmente o biotratamento de brim, para o uso das ditas preparaes nas composies detergentes, e especialmente os mtodos que usam a celulase de 20K, a celulase de 50K, a celulase B de 50K e/ou a protena com CBD. A inveno est tambm dirigida a outras celulases neutras e/ou alcalinas tendo uma ou mais das sequncias de aminocidos conforme descritas aqui. A inveno  adicionalmente dirigida aos genes codificando a celulase de 20K, a celulase de 50K, a celulase B de 50K e a protena com CBD. A inveno  adicionalmente dirigida aos novos vetores de expresso compreendendo tais genes e aos novos hospedeiros transformados com os vetores, especialmente os hospedeiros que sejam capazes de altos nveis de expresso das protenas codificadas por tais genes. A inveno  adicionalmente dirigida ao meio de cultura esgotado de tais hospedeiros transformados, ao meio de cultura contendo a celulase de 20K, a celulase de 50K, a celulase B de 50K e/ou a protena com CBD, ou composies de enzimas (preparaes de enzimas) contendo uma ou mais destas protenas que tenham sido preparadas a partir de tais meios de cultura. A inveno  adicionalmente dirigida ao uso de tal meio de cultura ou ao uso de tais preparaes de enzimas na indstria txtil e de detergentes, e nas indstrias de polpa e papel.</span>These studies further resulted in the identification of three novel cellulases that are especially useful in the textile and detergent industry. Preparations purified from Melanocarpus sp. or from Myriococcum sp. disclosed a 20 kDa cellulase with endoglycanase activity (referred to herein as "20K cellulase"), a 50 kDa cellulase ("50K cellulase"), and a second 50 kDa cellulase ("50K cellulase B"). A novel gene product with high cell homology homology, here called "CBD protein" (where CBD means "cellulose binding domain"), has also been verified. It is an object of the invention to provide enzyme preparations containing one or more of the novel cellulases of the invention, especially 20K cellulase, 50K cellulase, 50K cellulase B and / or CBD protein. It is a further object of this invention to provide a method for utilizing such textile finishing preparations, especially denim biotreatment, for the use of said preparations in detergent compositions, and especially methods using 20K cellulase, 50K, 50K cellulase B and / or CBD protein. The invention is also directed to other neutral and / or alkaline cellulases having one or more of the amino acid sequences as described herein. The invention is further directed to genes encoding 20K cellulase, 50K cellulase, 50K cellulase B and protein with CBD. The invention is further directed to novel expression vectors comprising such genes and novel hosts transformed with vectors, especially hosts that are capable of high expression levels of proteins encoded by such genes. The invention is further directed to the depleted culture medium of such transformed hosts, the culture medium containing 20K cellulase, 50K cellulase, 50K cellulase B and / or CBD protein, or enzyme compositions (preparations of enzymes) containing one or more of these proteins that have been prepared from such culture media. The invention is further directed to the use of such culture medium or the use of such enzyme preparations in the textile and detergent industries, and in the pulp and paper industries.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Breve Descrio das Figuras As Figuras 1 (A e B) mostram as dependncias do pH (Figura 1A) e da temperatura (Figura 1B) das atividades de endoglicanase de ALK04179, CBS 689.95.</span>Brief Description of the Figures Figures 1 (A and B) show the pH (Figure 1A) and temperature (Figure 1B) dependencies of the endoglycanase activities of ALK04179, CBS 689.95.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 2 (A e B) mostram as dependncias do pH (Figura 2A) e da temperatura (Figura 2B) das atividades de endoglicanase de ALK04124, CBS 687.95.</span>Figures 2 (A and B) show the pH (Figure 2A) and temperature (Figure 2B) dependencies of the endoglycanase activities of ALK04124, CBS 687.95.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 3 (A e B) mostram as dependncias do pH (Figura 3A) e da temperatura (Figura 3B) das atividades de endoglicanase de ALK04237, CBS 685.95.</span>Figures 3 (A and B) show the pH (Figure 3A) and temperature (Figure 3B) dependencies of the endoglycanase activities of ALK04237, CBS 685.95.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 4 (A e B) mostram as dependncias do pH (Figura 4A) e da temperatura (Figura 4B) das atividades de endoglicanase de ALK04265, CBS 730.95.</span>Figures 4 (A and B) show the pH (Figure 4A) and temperature (Figure 4B) dependencies of the endoglycanase activities of ALK04265, CBS 730.95.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 5 (A e B) mostram as dependncias do pH (Figura 5A) e da temperatura (Figura 5B) das atividades de endoglicanase de ALK04125, CBS 688.95.</span>Figures 5 (A and B) show the pH (Figure 5A) and temperature (Figure 5B) dependencies of the endoglycanase activities of ALK04125, CBS 688.95.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 6 (A e B) mostram o efeito da lavagem e da colorao de volta (Figura 6A) e a pigmentao azul (Figura 6B) com as celulases neutras.</span>Figures 6 (A and B) show the effect of back washing and staining (Figure 6A) and blue pigmentation (Figure 6B) with neutral cellulases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 7 (A e B) mostram o efeito da lavagem e da colorao de volta (Figura 7A) e a pigmentao azul (Figura 7B) com Ecostone L com dosagens de enzima gradualmente crescentes. 1X corresponde  dosagem de enzima das celulases neutras nas Figuras 6A e 6B. A Figura 8 mostra a purificao da celulase de 20K a partir do Pico II por cromatografia em SP-Sepharose Uma amostra contendo 11,7 g de protena e 576.000 ECU foi aplicada a uma coluna de 4,5 x 31 cm, a qual foi desenvolvida conforme descrito no Exemplo 9. As fraes de 15 ml foram coletadas. As atividades de endoglicanase no pico nas fraes 148 - 161 foram subestimadas porque a cristalizao ocorreu antes que a enzima pudesse ser suficientemente diluda para o ensaio. O material cristalino a partir destas fraes continha 486.000 ECU.</span>Figures 7 (A and B) show the effect of backwashing and staining (Figure 7A) and blue pigmentation (Figure 7B) with Ecostone L with gradually increasing enzyme dosages. 1X corresponds to the enzyme dosage of the neutral cellulases in Figures 6A and 6B. Figure 8 shows the purification of 20K cellulase from Pico II by SP-Sepharose chromatography. A sample containing 11.7 g protein and 576,000 ECU was applied to a 4.5 x 31 cm column which was developed as described in Example 9. The 15 ml fractions were collected. Peak endoglycanase activities in fractions 148 - 161 were underestimated because crystallization occurred before the enzyme could be sufficiently diluted for the assay. The crystalline material from these fractions contained 486,000 ECU.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 9 (A e B) mostram a anlise por SDS-PAGE da celulase de 20K. As massas moleculares dos padres so mostradas em kDa. A O material parcialmente cristalino precipitou-se a partir das fraes de S-Sepharose ativa (caminho 1). B Fraes da cromatografia do material parcialmente cristalino sobre G50 Sephadex. As fraes mostradas nos caminhos 19 e 25 no continham nenhuma atividade de endoglicanase. Para as outras fraes, a quantidade de atividade (em ECU) aplicada ao gel foi como se segue; frao 27, 0,4; 29, 2,4 (como 3,0 pg de protena); 30, 2,1; 31, 1,9; 33, 0,46; e 35, 1,1. A Figura 10 mostra a separao da celulase de 50K e da celulase B de 50K do Pico lll/IV por cromatografia em SP-Sepharose. Uma amostra contendo 200 mg de protena e 14.800 ECU foi aplicada  coluna de 2,5 x 11 cm, a qual foi desenvolvida conforme descrito no Exemplo 9. As fraes de 6,8 ml foram coletadas. Uma quantidade pequena de celulase de 50K eluiu antes do gradiente de NaCI, ao passo que a maior parte da celulase de 50K eluiu em NaCI em torno de 50 mM. A celulase B de 50K foi encontrada no pico principal de protena em NaCI em torno de 80 mM. A Figura 11 mostra uma anlise por SDS-PAGE da celulase de 50K purificada (11 A) e da celulase B de 50K (11B). Os nmeros dos caminhos indicam as fraes (3,3 ml) eludas de Phenyl-Sepharose. Para as fraes 36-41, 2,5  de cada frao foram aplicados ao gel. Para as outras fraes, 2  foram aplicados. O pico de celulase de 50K foi encontrado nas fraes 37-38 (11 A) (contendo 780 e 880 ECU/mi, respectivamente). O pico de ceiulase B de 50K estava nas fraes 30 e 31 (11B), as quais continham uma atividade insignificante (menos do que 4 ECU/ml). A Figura 12 mostra a dependncia de temperatura da atividade da endoglicanase da ceiulase de 50K em pH 7,0 e um tempo de reao de 60 min. A Figura 13 mostra a dependncia de pH da atividade de endoglicanase da ceiulase de 50K a 50C (-) e 70C (&lt;). A Figura 14 mostra uma anlise de Western usando o anti-soro de ceiulase de 20K como uma sonda. Os caminhos 1, 2 e 3 contm 25 pg de uma protena dos picos de DEAE-Sepharose I, III e IV, respectivamente. Os caminhos 4 e 5 contm 2,0 e 0,2 pg de ceiulase de 50K pura e o caminho 6 contm 0,6 pg de ceiulase B de 50K. Os caminhos 7 e 8 contm cerca de 25 pg de protena a partir do meio de crescimento completo de ALK04237 e ALK04124, respectivamente. A Figura 15 mostra a dependncia da temperatura da atividade de endoglicanase da ceiulase de 20K em pH 7 (tempos de reao de 10 min.).</span>Figures 9 (A and B) show SDS-PAGE analysis of 20K cellulase. The molecular masses of the standards are shown in kDa. A Partially crystalline material precipitated from the active S-Sepharose fractions (lane 1). B Chromatography fractions of partially crystalline material on G50 Sephadex. The fractions shown on pathways 19 and 25 contained no endoglycanase activity. For the other fractions, the amount of activity (in ECU) applied to the gel was as follows; fraction 27, 0.4; 29, 2.4 (as 3.0 pg protein); 30, 2.1; 31, 1.9; 33, 0.46; and 35, 1.1. Figure 10 shows the separation of 50K cellulase and 50K cellulase B from Pico III / IV by SP-Sepharose chromatography. A sample containing 200 mg protein and 14,800 ECU was applied to the 2.5 x 11 cm column, which was developed as described in Example 9. 6.8 ml fractions were collected. A small amount of 50K cellulase eluted before the NaCl gradient, while most of the 50K cellulase eluted at around 50 mM. 50K cellulase B was found at the main protein peak in NaCI around 80 mM. Figure 11 shows an SDS-PAGE analysis of purified 50K cellulase (11 A) and 50K cellulase B (11B). Path numbers indicate fractions (3.3 ml) eluting from Phenyl Sepharose. For fractions 36-41, 2.5  of each fraction were applied to the gel. For the other fractions, 2  were applied. The 50K cellulase peak was found in fractions 37-38 (11 A) (containing 780 and 880 ECU / mi, respectively). The 50K cellulase B peak was in fractions 30 and 31 (11B), which contained negligible activity (less than 4 ECU / ml). Figure 12 shows the temperature dependence of 50K cellulase endoglycanase activity at pH 7.0 and a reaction time of 60 min. Figure 13 shows the pH dependence of cellulase endoglycanase activity from 50K at 50  C (- ) and 70  C (&lt;). Figure 14 shows a Western analysis using 20K cellulase antiserum as a probe. Lanes 1, 2 and 3 contain 25 pg of a DEAE-Sepharose I, III and IV peak protein, respectively. Lanes 4 and 5 contain 2.0 and 0.2 pg of pure 50K cellulase and lane 6 contains 0.6 pg of 50K cellulase B. Lanes 7 and 8 contain about 25 pg of protein from the complete growth medium of ALK04237 and ALK04124, respectively. Figure 15 shows the temperature dependence of 20K cellulase endoglycanase activity at pH 7 (10 min reaction times).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 16 (A e B) mostram a dependncia do pH da atividade de endoglicanase da ceiulase de 20K para o tempo de reao de (a) 10 minutos ou (b) 60 minutos. A Figura 17 mostra os dados da sequncia de aminocidos derivados do seqnciamento da ceiulase de 20K descrito no material ilustrativo aqui contido. A seqncia 429  a partir da extremidade com N da protena e as outras seqncias so a partir dos peptdeos trpticos internos. A Figura 18 mostra os mapas de restrio do DNA de Melanocarpus albomyces nos plasmdios pALK1221, pALK1222 e pALK1223, os quais carregam o gene de ceiulase de 20K. A Figura 19 mostra a seqncia de DNA do gene de ceiulase de 20K. A seta indica o stio de processamento de peptidase de sinal predito. A Figura 20 mostra os mapas de restrio do DNA de Melanocarpus albomyces nos plasmdios pALK1233, pALK1234 e pALK1235, os quais carregam o gene de celulase de 50K.</span>Figures 16 (A and B) show the pH dependence of 20K cellulase endoglycanase activity for the reaction time of (a) 10 minutes or (b) 60 minutes. Figure 17 shows the amino acid sequence data derived from the 20K cellulase sequencing described in the illustrative material contained herein. Sequence 429 is from the N-terminus of the protein and the other sequences are from the internal tryptic peptides. Figure 18 shows DNA restriction maps of Melanocarpus albomyces on plasmids pALK1221, pALK1222 and pALK1223, which carry the 20K cellulase gene. Figure 19 shows the DNA sequence of the 20K cellulase gene. The arrow indicates the predicted signal peptidase processing site. Figure 20 shows DNA restriction maps of Melanocarpus albomyces on plasmids pALK1233, pALK1234 and pALK1235, which carry the 50K cellulase gene.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 21 (A e B) mostram a seqncia de DNA do gene de celulase de 50K. A seta indica o stio de processamento de peptidase de sinal predito. A Figura 22 mostra os mapas de restrio do DNA de Melanocarpus albomyces nos plasmdios pALK1229 e pALK1236, os quais carregam o gene de celulase B de 50K.</span>Figures 21 (A and B) show the DNA sequence of the 50K cellulase gene. The arrow indicates the predicted signal peptidase processing site. Figure 22 shows DNA restriction maps of Melanocarpus albomyces on plasmids pALK1229 and pALK1236, which carry the 50K cellulase B gene.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As Figuras 23 (A e B) mostram a seqncia de DNA do gene de celulase B de 50K. A seta indica o stio de processamento de peptidase de sinal predito. A Figura 24 mostra o mapa de plasmdio de pTTcOi. A Figura 25 mostra o mapa de plasmdio de pMS2, A Figura 26 mostra o mapa de restrio do DNA de Melanocarpus albomyces no plasmdio pALK123Q, o qual carrega o DNA codificando a protena com CBD. A seqncia apresentada na Figura 27  marcada com uma seta na Figura 26. A Figura 27 mostra a seqncia de DNA do gene de celulase da protena com CBD em pALK123Q. A Figura 28 mostra o mapa de plasmdio de pALK1231. A Figura 29 mostra o mapa de plasmdio de pALK1235. A Figura 30 mostra uma anlise de Western usando o anti-soro de celulase de 20K como uma sonda. Os caminhos 1 e 2 contm cerca de 10 pg de protena a partir do meio de crescimento completo dos transformantes ALKO3620/pALK1235/49 e ALK03620/pALK1235/40. O caminho 3 contm cerca de 10 pg de protena a partir do meio de crescimento completo de ALKO3620. Os caminhos 4 e 5 contm cerca de 10 pg de protena a partir do meio de crescimento completo dos transformantes ALKO3620/pALK1231/16 e ALKO3620/pALK1231/14. O caminho 6 contm 100 g de celulase de 20K pura. A Figura 31 mostra o mapa de plasmdio de pALK1238. A Figura 32 mostra o mapa de plasmdio de pALK1240.</span>Figures 23 (A and B) show the DNA sequence of the 50K cellulase B gene. The arrow indicates the predicted signal peptidase processing site. Figure 24 shows the plasmid map of pTTcOi. Figure 25 shows the plasmid map of pMS2. Figure 26 shows the DNA restriction map of Melanocarpus albomyces on plasmid pALK123Q, which carries the DNA encoding the protein with CBD. The sequence shown in Figure 27 is marked with an arrow in Figure 26. Figure 27 shows the DNA sequence of the CBD protein cellulase gene in pALK123Q. Figure 28 shows the plasmid map of pALK1231. Figure 29 shows the plasmid map of pALK1235. Figure 30 shows a Western analysis using 20K cellulase antiserum as a probe. Lanes 1 and 2 contain about 10 pg of protein from the complete growth medium of the ALKO3620 / pALK1235 / 49 and ALK03620 / pALK1235 / 40 transformants. Lane 3 contains about 10 pg of protein from the complete growth medium of ALKO3620. Lanes 4 and 5 contain about 10 pg of protein from the complete growth medium of the ALKO3620 / pALK1231 / 16 and ALKO3620 / pALK1231 / 14 transformants. Lane 6 contains 100 g of pure 20K cellulase. Figure 31 shows the plasmid map of pALK1238. Figure 32 shows the plasmid map of pALK1240.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Depsitos ALK04179, Myceliophthora thermophila foi depositado como CBS 689.95 em 12 de outubro de 1995, no Centraalbureau voor Schimmelcultures, Caixa Postal 273.3740 AG BAARN. ALK04124, Myriococcum sp. foi depositado como CBS 687.95 em 12 de outubro de 1995, no Centraalbureau voor Schimmelcultures, Caixa Postal 273.3740 AG BAARN. ALK04237, Melanocarpus albomyces (= Myriococcum albomyces = Thieiavia albomyces; Guarro e col., 1996, Mycol. Res. 100(1):75) foi depositado como CBS 685.95 em 11 de outubro de 1995, no Centraalbureau voor Schimmelcultures, Caixa Postal 273.3740 AG BAARN. ALK04125, Sporotrichum thermophile foi depositado como CBS 688.95 em 12 de outubro de 1995, no Centraalbureau voor Schimmelcultures, Caixa Postal 273.3740 AG BAARN. ALK04265, Chaetomium thermophilum La Touche foi depositado como CBS 730.95 em 8 de novembro de 1995, no Centraalbureau voor Schimmelcultures, Caixa Postal 273.3740 AG BAARN. O plasmdio pALK1221 foi depositado como DSM 11024 em 21 de junho de 1996 e  X4237/5.1 foi depositado como DSM 11012 em 21 de junho de 1996, no Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Alemanha. Ambos contm o gene de celulase de 20K a partir de Melanocarpus albomyces CBS 685.95. O plasmdio pALK1227 foi depositado como DSM 11025 em 21 de junho de 1996 e  4237/35 foi depositado como DSM 11014 em 21 de junho de 1996, no Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Alemanha. Ambos contm o gene de celulase de 50K a partir de Melanocarpus albomyces CBS 685.95. O plasmdio pALK1229 foi depositado como DSM 11026 em 21 de junho de 1996 e  4237/3 foi depositado como DSM 11011 em 21 de junho de 1996, e  X4237/18 foi depositado como DSM 11013 em 21 de junho de 1996, no Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Alemanha. O pALK1229 contm o DNA codificando para a celulase B de 50K,  4237/3 e  4237/18 contm o gene de celulase B de 50K a partir do Melanocarpus albomyces CBS 685.95. O plasmdio pALK1230 foi depositado como DSM 11027 em 21 de junho de 1996 no Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Alemanha. O pALK1230 contm o gene de protena com CBD a partir de Melanocarpus albomyces CBS 685.95.</span>Deposits ALK04179, Myceliophthora thermophila was deposited as CBS 689.95 on October 12, 1995 at the Centraalbureau voor Schimmelcultures, PO Box 273.3740 AG BAARN. ALK04124, Myriococcum sp. was deposited as CBS 687.95 on October 12, 1995 at the Centraalbureau voor Schimmelcultures, PO Box 273.3740 AG BAARN. ALK04237, Melanocarpus albomyces (= Myriococcum albomyces = Thieiavia albomyces; Guarro et al., 1996, Mycol Res. 100 (1): 75) was deposited as CBS 685.95 on October 11, 1995, at Centraalbureau voor Schimmelcultures, PO Box 273.3740 AG BAARN. ALK04125, Sporotrichum thermophile was deposited as CBS 688.95 on October 12, 1995 at the Centraalbureau voor Schimmelcultures, PO Box 273.3740 AG BAARN. ALK04265, Chaetomium thermophilum La Touche was deposited as CBS 730.95 on November 8, 1995 at the Centraalbureau voor Schimmelcultures, PO Box 273.3740 AG BAARN. Plasmid pALK1221 was filed as DSM 11024 on June 21, 1996 and  X4237 / 5.1 was filed as DSM 11012 on June 21, 1996 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Germany . Both contain the 20K cellulase gene from Melanocarpus albomyces CBS 685.95. Plasmid pALK1227 was filed as DSM 11025 on June 21, 1996 and  4237 / 35 was filed as DSM 11014 on June 21, 1996 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Germany . Both contain the 50K cellulase gene from Melanocarpus albomyces CBS 685.95. Plasmid pALK1229 was deposited as DSM 11026 on June 21, 1996 and  4237 / 3 was deposited as DSM 11011 on June 21, 1996, and  X4237 / 18 was deposited as DSM 11013 on June 21, 1996 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Germany. PALK1229 contains the 50K cellulase B-encoding DNA,  4237 / 3 and  4237 / 18 contain the 50K cellulase B gene from Melanocarpus albomyces CBS 685.95. Plasmid pALK1230 was filed as DSM 11027 on June 21, 1996 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Germany. PALK1230 contains the CBD protein gene from Melanocarpus albomyces CBS 685.95.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Descrio Detalhada das Modalidades Preferidas Na descrio que se segue, diversos termos usados na tecnologia da indstria txtil so extensivamente usados. A fim de proporcionar um entendimento claro e consistente do relatrio descritivo e reivindicaes, incluindo o escopo a ser dado a tais termos, as seguintes definies so proporcionadas.</span>Detailed Description of Preferred Embodiments In the following description, various terms used in textile industry technology are used extensively. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given to such terms, the following definitions are provided.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Biotratamento com pedras. O "biotratamento com pedras" do tecido ou pea de roupa significa o uso de enzimas no lugar do, ou alm do, uso de pedras-pome para o tratamento do tecido ou pea de roupa, especialmente o brim.</span>Biotreatment with stones. "Biotreatment with stones" of the fabric or garment means the use of enzymes in place of or in addition to the use of pumice to treat the fabric or garment, especially denim.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bio-acabamento. O "bioaeabamento" refere-se ao uso de enzimas em uma hidrlise controlada de fibras de celulose a fim de modificar o tecido ou a superfcie do fio, em uma forma que impea a formao de bolas permanente, aperfeioe o manuseio do tecido, como a maciez e a lisura, clareie a estrutura da superfcie por reduo da desfiadura, o que resulta na clarificao das cores, aperfeioe a capacidade de conformao do tecido, aperfeioe a capacidade de absoro da umidade, e que aperfeioe tambm a capacidade de tingir.</span>Bio finishing. "Bio-etching" refers to the use of enzymes in a controlled hydrolysis of cellulose fibers to modify the fabric or surface of the yarn in a way that prevents permanent ball formation, improves tissue handling such as smoothness and smoothness, lighten the surface structure by reducing fraying, which results in color clarification, improves fabric conformability, improves moisture absorption, and also improves dyeing ability.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Colorao de volta. O corante liberado tem uma tendncia a depositar novamente sobre a superfcie das fibras de tecido. Este efeito  chamado "colorao de volta".  dada na Patente ,S, N- 5.433.750, uma tista adequada de tensoatvos  dada na Patente U.S. Na 3.664.961, Preparao de enzimas. Por "preparao de enzimas"  significado uma composio contendo enzimas. De preferncia, as enzimas foram extradas a partir de (parcial ou completamente purificadas a partir de) um micrbio ou do meio usado para desenvolver tal micrbio. "Extradas a partir de" significa que as enzimas desejadas so separadas da massa celular. Isto pode ser efetuado por qualquer mtodo que atinja este objetivo, incluindo rompendo-se as clulas e tambm simplesmente removendo-se o meio de cultura das clulas gastas. Portanto, o termo "preparao de enzimas" inclui as composies contendo o meio previamente usado para cultivar (um) micrbio(s) desejado(s) e quaisquer enzimas que tenham sido liberadas das clulas microbianas em tal meio durante o cultivo ou as etapas de processamento a jusante.</span>Coloring back. The released dye has a tendency to settle again on the surface of the fabric fibers. This effect is called "back coloring". is given in U.S. Patent No. 5,433,750, a suitable range of surfactants is given in U.S. Patent No. 3,664,961, Enzyme Preparation. By "enzyme preparation" is meant an enzyme-containing composition. Preferably, the enzymes were extracted from (partially or completely purified from) a microbe or the medium used to develop such a microbe. "Extracted from" means that the desired enzymes are separated from the cell mass. This can be done by any method that achieves this goal, including disrupting the cells and also simply removing the culture medium from the spent cells. Therefore, the term "enzyme preparation" includes compositions containing the medium previously used to cultivate a desired microbe (s) and any enzymes that have been released from microbial cells in such medium during cultivation or the steps of downstream processing.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por um hospedeiro que seja "substancialmente incapaz" de sintetizar uma ou mais enzimas  significado um hospedeiro em que a atividade de uma ou mais das enzimas listadas  depreciada, deficiente, ou ausente quando comparadas ao tipo selvagem, Por uma sequncia de aminocdos que seja um "equivalente" de uma sequncia de aminocdos especfica  significado uma sequncia de aminocdos que no seja idntica  sequncia de aminocdos especfica, porm, mais exatamente, contenha pelo menos algumas alteraes dos aminocdos (delees, substituies, inverses, inseres, etc.) que no afetem essencialmente a atividade biolgica da protena em comparao a uma atividade similar da seqncia de aminocidos especfica, quando usada para um propsito desejado. A atividade biolgica de uma celutase  sua atividade cataltica, e/ou sua capacidade de iigar-se ao material celulsico. A atividade biolgica da cetulase B de 50K adicionalmente inclui a sua capacidade de atuar de forma sinrgica com as ceiulases. De preferncia, uma seqncia de aminocdos equivalente contm pelo menos 80%-99% de identidade, no nvel de aminocido,  seqncia de aminocdos especfica, mais preferivelmente pelo menos 90% de uma celulase  sua atividade cataltica, e/ou sua capacidade de ligar-se ao material celulsico. A atividade biolgica da celulase B de 50K adicionaimente inclui a sua capacidade de atuar de forma sinrgica com as celulases. De preferncia, uma sequncia de aminocidos equivalente contm pelo menos 80%-99% de identidade, no nvel de aminocido,  seqncia de aminocidos especfica, mais preferivelmente pelo menos 90% e em uma modalidade especial e altamente prefervel, pelo menos 95% de identidade, no nvel de aminocido.</span>By a host that is "substantially unable" to synthesize one or more enzymes is meant a host in which the activity of one or more of the listed enzymes is depreciated, deficient, or absent compared to wild type. By an amino acid sequence that is an "equivalent" of a specific amino acid sequence is meant an amino acid sequence that is not identical to the specific amino acid sequence, but more accurately contains at least some amino acid changes (deletions, substitutions, inversions, insertions, etc.). that do not essentially affect the biological activity of the protein compared to a similar activity of the specific amino acid sequence when used for a desired purpose. The biological activity of a cellutase is its catalytic activity, and / or its ability to bind to cellulosic material. The biological activity of 50K ketulase B additionally includes its ability to act synergistically with the cellulases. Preferably, an equivalent amino acid sequence contains at least 80% -99% identity at the amino acid level to the specific amino acid sequence, more preferably at least 90% of a cellulase is its catalytic activity, and / or its ability to function. bind to cellulosic material. The biological activity of 50K cellulase B further includes its ability to act synergistically with cellulases. Preferably, an equivalent amino acid sequence contains at least 80% -99% identity at the amino acid level to the specific amino acid sequence, more preferably at least 90% and in a special and highly preferred embodiment at least 95% of the amino acid sequence. identity at the amino acid level.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Veculo de clonagem. Um veculo de clonagem  um DNA de plasmdio ou de fago ou outra seqncia de DNA (tal como um DNA linear) que proporcione um meio carregador de cido nuclico apropriado para a transferncia de um gene de interesse para uma clula hospedeira. Os veculos de clonagem da inveno podem ser projetados para replicar de forma autnoma em hospedeiros procariticos e eucariticos. Nos hospedeiros fngicos, tais como Trichoderma, os veculos de clonagem geralmente no replicam-se de forma autnoma e, ao invs disso, meramente proporcionam um veculo para o transporte do gene de interesse para o hospedeiro de Trichoderma para uma insero subsequente no genoma do Trichoderma. O veculo de clonagem pode ser adicional mente caracterizado por um ou um pequeno nmero de stios de identificao de endonuclease, nos quais tais sequncias de DNA possam ser cortadas em uma forma determinvel sem perda de uma funo biolgica essencial do veculo, e nos quais o DNA possa ser unido a fim de efetuar a replicao e a clonagem de tal DNA. O veculo de clonagem pode, alm disso, conter um marcador adequado para uso na identificao de clulas transformadas com o veculo de clonagem. Os marcadores, por exemplo, so a resistncia ao antibitico. Alternativamente, tais marcadores podem ser proporcionados em um veculo de clonagem que seja separado daquele fornecendo o gene de interesse. A palavra "vetor"  algumas vezes usada para "veculo de clonagem".</span>Cloning vehicle. A cloning vehicle is a plasmid or phage DNA or other DNA sequence (such as a linear DNA) that provides an appropriate nucleic acid carrier medium for transferring a gene of interest to a host cell. The cloning vehicles of the invention may be designed to autonomously replicate in prokaryotic and eukaryotic hosts. In fungal hosts, such as Trichoderma, cloning vehicles generally do not replicate autonomously and instead merely provide a vehicle for transporting the gene of interest to the Trichoderma host for subsequent insertion into the Trichoderma genome. . The cloning vehicle may further be characterized by one or a small number of endonuclease identification sites, in which such DNA sequences may be cut to a determinable form without loss of essential biological function of the vehicle, and in which DNA can be joined in order to effect replication and cloning of such DNA. The cloning vehicle may further contain a marker suitable for use in identifying cells transformed with the cloning vehicle. Markers, for example, are antibiotic resistance. Alternatively, such markers may be provided in a cloning vehicle that is separate from that providing the gene of interest. The word "vector" is sometimes used for "cloning vehicle".</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Veculo de expresso. Um veculo de expresso  um veculo de clonagem ou vetor similar a um veculo de clonagem, porm que seja capaz de expressar um gene de interesse, aps a transformao em um hospedeiro desejado, Quando um hospedeiro fngico for usado, o gene de interesse  preferivelmente proporcionado a um hospedeiro fngico como parte de um veculo de clonagem ou de expresso que integre-se no cromossomo fngico, ou permita que o gene de interesse integre-se no cromossomo hospedeiro. As sequncias que so parte do veculo de clonagem ou do veculo de expresso podem tambm estar integradas com o gene de interesse durante o processo de integrao. No T. reesei, os stios de integrao, para os quais o gene de interesse pode ser orientado, incluem os locais cbh e/ou egl. Mais preferivelmente, o gene de interesse  orientado para substituir um ou mais genes codificando as caractersticas desejadas. O gene de interesse  tambm preferivelmente colocado sob o controle de (isto , ligado de forma opervel ) certas sequncias de controle, tais como as seqncias promotoras proporcionadas pelo vetor (que integram-se com o gene de interesse). Alternativamente, as seqncias de controle podem ser aquelas no stio de insero.</span>Expression vehicle. An expression vehicle is a cloning vehicle or vector similar to a cloning vehicle, but capable of expressing a gene of interest upon transformation into a desired host. When a fungal host is used, the gene of interest is preferably provided to a fungal host as part of a cloning or expression vehicle that integrates into the fungal chromosome, or allows the gene of interest to integrate into the host chromosome. Sequences that are part of the cloning vehicle or expression vehicle may also be integrated with the gene of interest during the integration process. In T. reesei, integration sites to which the gene of interest can be targeted include the cbh and / or egl sites. More preferably, the gene of interest is oriented to replace one or more genes encoding the desired characteristics. The gene of interest is also preferably placed under the control of (i.e. operably linked to) certain control sequences, such as the promoter sequences provided by the vector (which integrate with the gene of interest). Alternatively, control sequences may be those at the insertion site.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As seqncias de controle da expresso de um vetor de expresso variaro, dependendo de se o vetor  projetado para expressar um certo gene em um hospedeiro procaritico ou em um eucaritico (por exemplo, um vetor em vaivm pode proporcionar um gene para a seleo em hospedeiros bacterianos. As seqncias de controle da expresso podem conter elementos reguladores transcricionais, tais como, promotores, elementos intensificadores, e seqncias de terminao transcricional, e/ou elementos reguladores da traduo, tais como, por exemplo, os stios de iniciao e terminao de traduo.</span>Expression control sequences of an expression vector will vary depending on whether the vector is designed to express a certain gene in a prokaryotic or a eukaryotic host (for example, a shuttle vector may provide a gene for selection in hosts). Expression control sequences may contain transcriptional regulatory elements, such as promoters, enhancer elements, and transcriptional termination sequences, and / or translation regulatory elements, such as, for example, translation initiation and termination sites. .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De acordo com a inveno, so proporcionados celulases neutras e alcalinas, e mtodos para a produo de tais celulases neutras e alcalinas teis, que so desejveis para o tratamento de materiais txteis.</span>In accordance with the invention, neutral and alkaline cellulases are provided, and methods for producing such useful neutral and alkaline cellulases, which are desirable for the treatment of textile materials.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os hospedeiros nativos que produzem as protenas da inveno so: X 1) ALK04179, Myceliophthora thermophila; depositado como CBS 689.95 no Centraalbureau voor Schimmelcultures, Caixa Postal 273.3740 AG BAARN. 2) ALK04124, Myriococcum sp.; depositado como CBS 687.95;</span>Native hosts producing the proteins of the invention are: X 1) ALK04179, Myceliophthora thermophila; deposited as CBS 689.95 at the Centraalbureau voor Schimmelcultures, PO Box 273.3740 AG BAARN. 2) ALK04124, Myriococcum sp .; filed as CBS 687.95;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3) ALK04237, Melanocarpus albomyces, depositado como CBS 685.95;</span>3) ALK04237, Melanocarpus albomyces, filed as CBS 685.95;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4) ALK04125, Sporotrchum thermophile, depositado como CBS 688.95; e 5) ALK04265, Chaetomium thermophilum La Touche, depositado como CBS 730.95 Uma modalidade especfica preferida da inveno  o meio de cultura esgotado dos hospedeiros nativos ou das preparaes de enzimas preparadas a partir do meio de cultura.</span>4) ALK04125, Sporotrichum thermophile, filed as CBS 688.95; and 5) ALK04265, Chaetomium thermophilum La Touche, filed as CBS 730.95 A preferred specific embodiment of the invention is the culture medium depleted from native hosts or enzyme preparations prepared from the culture medium.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nas modalidades preferidas especficas da inveno, a celulase de 20K, a celulase de 50K, a celulase B de 50K e/ou a protena com CBD purificadas so proporcionadas. Estas protenas podem ser obtidas, por exemplo, a partir de Melanocarpus sp. ou Myriococcum sp., conforme descrito aqui, e especialmente no Exemplo 9.</span>In specific preferred embodiments of the invention, 20K cellulase, 50K cellulase, 50K cellulase B and / or purified CBD protein are provided. These proteins can be obtained, for example, from Melanocarpus sp. or Myriococcum sp. as described herein, and especially Example 9.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os dados da sequncia de aminocidos foram gerados a partir das celulases descritas aqui. Assim, a inveno est tambm dirigida s celulases neutras ou alcalinas contendo uma ou mais das sequncias de aminocidos mostradas aqui. Assim, a inveno  pretendida ser dirigida  qualquer celulase neutra ou alcalina que seja um equivalente funcional da celulase de 20K, da celulase de 50K, da celulase B de 50K e/ou da protena com CBD, e tendo uma ou mais das seqncias de aminocidos descritas aqui, ou substancialmente a mesma sequncia. Tais celulases neutras ou alcalinas podem ser derivadas de outras cepas da mesma espcie ou de organismos divergentes.</span>Amino acid sequence data were generated from the cellulases described herein. Thus, the invention is also directed to neutral or alkaline cellulases containing one or more of the amino acid sequences shown herein. Thus, the invention is intended to be directed to any neutral or alkaline cellulase that is a functional equivalent of 20K cellulase, 50K cellulase, 50K cellulase B and / or protein with CBD, and having one or more of the sequences of amino acids described herein, or substantially the same sequence. Such neutral or alkaline cellulases may be derived from other strains of the same species or from divergent organisms.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nas modalidades adicionais preferidas, a celulase de 20K  proporcionada com o material de picos separados formados durante os procedimentos de purificao exemplificados (por exemplo, as Combinaes de DEAE-Sepharose I, III, ou IV na Tabela VIII aqui contida). Nas modalidades ainda adicionais, outras protenas no meio com Melanocarpus albomyces ALKO 4237 podem ser usadas, sozinhas ou em combinao com outras tais protenas.</span>In preferred additional embodiments, the 20K cellulase is provided with the separated peak material formed during the exemplified purification procedures (e.g., DEAE-Sepharose I, III, or IV Combinations in Table VIII herein). In still further embodiments, other proteins in the medium with Melanocarpus albomyces ALKO 4237 may be used alone or in combination with other such proteins.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nas modalidades adicionais preferidas, a celulase de 50K  proporcionada com o material de picos separados formados durante os procedimentos de purificao exemplificados. Nas modalidades ainda adicionais, outras protenas no meio com ALKO 4237 podem ser usadas, sozinhas ou em combinao com outras tais protenas.</span>In preferred additional embodiments, the 50K cellulase is provided with separate peak material formed during the exemplified purification procedures. In still further embodiments, other proteins in the medium with ALKO 4237 may be used alone or in combination with other such proteins.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nas modalidades adicionais preferidas, a celulase B de 50K  proporcionada com o material de picos separados formados durante os procedimentos de purificao exemplificados. Nas modalidades ainda adicionais, outras protenas no meio com ALKO 4237 podem ser usadas, sozinhas ou em combinao com outras tais protenas.</span>In preferred additional embodiments, 50K cellulase B is provided with the separated peak material formed during the exemplified purification procedures. In still further embodiments, other proteins in the medium with ALKO 4237 may be used alone or in combination with other such proteins.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Conforme descrito aqui, o ALKO 4265, Chaetomium thermophilum La Touche, depositado como CBS 730.95,  usado aqui como um exemplo de uma celulase neutra que no  preferida no mtodo de biotratamento com pedras da inveno, porque ele causa a colorao de volta. Entretanto, h evidncia que ele  til em outras aplicaes (por exemplo, nos detergentes). O processo para manipular geneticamente os hospedeiros da inveno  facilitado atravs da clonagem de sequncias genticas que codificam a protena desejada, e atravs da expresso de tais seqncias genticas. Conforme usado aqui, o termo "seqncias genticas"  pretendido referir-se a uma molcula de cido nuclico (preferivelmente o DNA). As seqncias genticas que codificam a protena desejada so derivadas a partir de uma variedade de fontes. Estas fontes incluem o DNA genmico, o cDNA, o DNA sinttico e as suas combinaes. Os sistemas de vetores podem ser usados para produzir hospedeiros para a produo das preparaes de enzimas da inveno. Tal construo de vetores (a) pode adicionalmente proporcionar uma construo de vetores separada (b) que codifique pelo menos um gene desejado a ser integrado ao genoma do conectada a uma seqnca (ou sequncias) reguladora em urna forma tal de modo a colocar a expresso da sequncia sob a influncia ou o controle da sequncia reguladora. Duas sequncias de DNA (tais como uma sequncia de codificao de protena e uma seqnca da regio promotora ligada  extremidade 5' da sequncia de codificao) so ditas serem ligadas de forma opervet se a induo da funo promotora resulte na transcrio do mRNA da sequncia de codificao da protena, e se a natureza da ligao entre as duas sequncias de DNA no (1) resulte na introduo de uma mutao com mudana do quadro, (2) interfira com a capacidade das sequncias reguladoras da expresso de orientar a expresso do mRNA, do RNA sem sentido, ou da protena, ou (3) interfira com a capacidade do molde de ser transcrito pela sequncia da regio promotora. Assim, uma regio promotora seria ligada de forma opervel a uma sequncia de DNA se o promotor fosse capaz de efetuar a transcrio daquela seqnca de DNA. A natureza precisa das regies reguladoras, necessrias para a expresso do gene, pode variar entre as espcies ou os tipos celulares, porm, em geral, incluir, conforme necessrio, as sequncias de no transcrio em 5 e de no traduo (no codificao) em 5' envolvidas com o incio da transcrio e da traduo, respectivamente. A expresso da protena nos hospedeiros transformados requer o uso de regies reguladoras funcionais em tais hospedeiros. Uma ampla variedade de sequncias reguladoras transcriconais e de traduo pode ser empregada. Nos eucariotos, onde a transcrio no est ligada  traduo, tais regies de controle podem ou no proporcionar um cdon de metionina iniciador (AUG), dependendo de se a seqnca clonada contm uma tal metionina. Tais regies incluiro, em geral, uma regio promotora suficiente para orientar a iniciao da sntese de RNA na clula hospedeira.</span>As described herein, ALKO 4265, Chaetomium thermophilum La Touche, deposited as CBS 730.95, is used herein as an example of a neutral cellulase which is not preferred in the stone biotreatment method of the invention because it causes back staining. However, there is evidence that it is useful in other applications (eg detergents). The process for genetically manipulating the hosts of the invention is facilitated by cloning gene sequences encoding the desired protein, and by expressing such gene sequences. As used herein, the term "gene sequences" is intended to refer to a nucleic acid molecule (preferably DNA). Genetic sequences encoding the desired protein are derived from a variety of sources. These sources include genomic DNA, cDNA, synthetic DNA and their combinations. Vector systems may be used to produce hosts for producing the enzyme preparations of the invention. Such a vector construct (a) may additionally provide a separate vector construct (b) that encodes at least one desired gene to be integrated into the genome of the connected to a regulatory sequence (or sequences) in such a form as to place the expression. sequence under the influence or control of the regulatory sequence. Two DNA sequences (such as a protein coding sequence and a promoter region sequence linked to the 5 'end of the coding sequence) are said to be operably linked if the induction of the promoter function results in mRNA transcription of the coding sequence. protein coding, and if the nature of the binding between the two DNA sequences does not (1) result in the introduction of a frame-shifting mutation, (2) interferes with the ability of expression regulatory sequences to direct mRNA expression, nonsense RNA, or protein, or (3) interferes with the ability of the template to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of transcribing that DNA sequence. The precise nature of the regulatory regions needed for gene expression may vary between species or cell types, but will generally include, as necessary, the 5 'non-transcriptional and non-coding (non-coding) sequences. 5 'involved with the onset of transcription and translation, respectively. Expression of the protein in transformed hosts requires the use of functional regulatory regions in such hosts. A wide variety of transcriptional and translation regulatory sequences may be employed. In eukaryotes, where transcription is not linked to translation, such control regions may or may not provide a primer methionine codon (AUG), depending on whether the cloned sequence contains such a methionine. Such regions will generally include a promoter region sufficient to guide the initiation of RNA synthesis in the host cell.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Conforme  amplamente sabido, a traduo do mRNA eucaritico  iniciada no cdon que codifica a primeira metionina. Por esta razo,  prefervel assegurar que a ligao entre um promotor eucaritico e uma seqnca de DNA que codifica a protena, ou um derivado funcional da de controle podem ou no proporcionar um cdon de metionina iniciador (AUG), dependendo de se a seqncia clonada contm uma tal metionina. Tais regies incluiro, em geral, uma regio promotora suficiente para orientar a iniciao da sntese de RNA na clula hospedeira.</span>As is widely known, translation of the eukaryotic mRNA is initiated at the codon encoding the first methionine. For this reason, it is preferable to ensure that the binding between a eukaryotic promoter and a protein-encoding DNA sequence, or a control functional derivative, may or may not provide a primer methionine codon (AUG), depending on whether the cloned sequence contains such a methionine. Such regions will generally include a promoter region sufficient to guide the initiation of RNA synthesis in the host cell.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Conforme  amplamente sabido, a traduo do mRNA eucaritico  iniciada no cdon que codifica a primeira metionina. Por esta razo,  prefervel assegurar que a ligao entre um promotor eucaritico e uma seqncia de DNA que codifica a protena, ou um derivado funcional da mesma, no contenha nenhum cdon interveniente que seja capaz de codificar uma metionina. A presena de tais cdons resulta em uma formao de uma protena de fuso (se o cdon de AUG estiver no mesmo quadro de leitura que a seqncia de DNA de codificao da protena) ou uma mutao com alterao do quadro (se o cdon de AUG no estiver no mesmo quadro de leitura que a seqncia de codificao da protena).</span>As is widely known, translation of the eukaryotic mRNA is initiated at the codon encoding the first methionine. For this reason, it is preferable to ensure that the binding between a eukaryotic promoter and a DNA sequence encoding the protein, or a functional derivative thereof, does not contain any intervening codon capable of encoding a methionine. The presence of such codons results in either a fusion protein formation (if the AUG codon is in the same reading frame as the protein coding DNA sequence) or a frame-altering mutation (if the AUG codon does not). same reading frame as the protein coding sequence).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Em uma modalidade preferida, uma protena desejada  secretada no meio circundante devido  presena de uma seqncia de sinal de secreo. Se uma protena desejada no possuir sua prpria seqncia de sinal, ou se tal seqncia de sinal no funcionar bem no hospedeiro, ento a seqncia de codificao da protena pode ser ligada de forma opervel a uma seqncia de sinal homloga ou heterloga ao hospedeiro. A seqncia de codificao desejada pode ser ligada por qualquer seqncia de sinal que permitir a secreo da protena a partir do hospedeiro. Tais seqncias de sinal podem ser projetadas com ou sem stios especficos de protease, tal que a seqncia de peptdeo de sinal seja receptvel  remoo subseqente. Alternativamente, um hospedeiro que disperse a protena no meio pode ser usado, por exemplo, um hospedeiro com uma mutao em sua membrana.</span>In a preferred embodiment, a desired protein is secreted into the surrounding medium due to the presence of a secretion signal sequence. If a desired protein does not have its own signal sequence, or if such a signal sequence does not work well in the host, then the protein coding sequence can be operably linked to a homologous or heterologous signal sequence to the host. The desired coding sequence can be linked by any signal sequence that will allow protein secretion from the host. Such signal sequences may be designed with or without specific protease sites, such that the signal peptide sequence is amenable to subsequent removal. Alternatively, a host that disperses the protein in the medium may be used, for example, a host with a mutation in its membrane.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se desejado, as regies no transcritas e/ou no traduzidas em 3' para a seqncia codificando para uma protena podem ser obtidas pelos mtodos de clonagem acima descritos. A regio no transcrita em 3' pode ser retida por seus elementos da seqncia reguladora de terminao transcricional; a regio no traduzida em 3 pode ser retida por seus elementos da seqncia reguladora de terminao de traduo, ou por aqueles elementos que orientam a poliadenilao nas clulas eucariticas.</span>If desired, the 3 'untranscribed and / or untranslated regions for the protein coding sequence can be obtained by the cloning methods described above. The non-transcribed 3 'region may be retained by its transcriptional terminating regulatory sequence elements; the untranslated region in 3 may be retained by its elements of the translation termination regulatory sequence, or by those elements that guide polyadenylation in eukaryotic cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os vetores da inveno podem adicionalmente compreender outros elementos reguladores ligados de forma opervel, tais como as seqncias intensificadoras.</span>The vectors of the invention may additionally comprise other operably linked regulatory elements, such as enhancer sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Em uma modalidade preferida, os transformantes geneticamente estveis so construdos, com o que um DNA da protena desejada  integrado no cromossomo do hospedeiro. A seqncia de codificao para a protena desejada pode ser de qualquer fonte adequada. Tal integrao pode ocorrer de novo dentro da clula ou, em uma modalidade mais preferida, ser auxiliada pela transformao com um vetor, o qual insere-se, numa forma funcionai, no cromossomo do hospedeiro, por exemplo, os elementos do DNA que promovem a integrao das seqncias de DNA nos cromossomos.</span>In a preferred embodiment, genetically stable transformants are constructed, whereby a desired protein DNA is integrated into the host chromosome. The coding sequence for the desired protein may be from any suitable source. Such integration may occur again within the cell or, in a more preferred embodiment, be aided by transformation with a vector, which inserts, in a functional form, into the host chromosome, for example, the DNA elements that promote the integration of DNA sequences into chromosomes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As clulas que integraram estavelmente o DNA introduzido em seus cromossomos so selecionadas tambm ntroduzindo-se um ou mais marcadores que permitam a seleo de clulas hospedeiras, as quais contm o vetor de expresso no cromossomo, por exemplo, o marcador pode proporcionar resistncia ao biocida, por exemplo, resistncia aos antibiticos, ou metais pesados, tais como o cobre, ou similares. O gene de marcador selecionvel pode ser diretamente ligado s seqncias de gene de DNA a serem expressas, ou introduzido na mesma clula por co-transformao.</span>Cells that have stably integrated the DNA introduced into their chromosomes are also selected by introducing one or more markers that allow selection of host cells, which contain the expression vector on the chromosome, for example, the marker may provide biocide resistance, for example, resistance to antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene may be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transformation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os fatores de importncia na seleo de um plasmdio ou vetor virtico particular incluem: a facilidade com a qual as clulas receptoras que contm o vetor podem ser identificadas e selecionadas a partir daquelas clulas receptoras, as quais no contm o vetor; o nmero de cpias do vetor que so desejadas em um hospedeiro particular; e se  desejvel ser capaz de "mover em vaivm" o vetor entre as clulas hospedeiras de diferentes espcies.</span>Factors of importance in selecting a particular viral plasmid or vector include: the ease with which receptor cells containing the vector can be identified and selected from those receptor cells that do not contain the vector; the number of vector copies that are desired on a particular host; and whether it is desirable to be able to "reciprocate" the vector between host cells of different species.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Assim que o vetor ou a seqncia de DNA contendo a(s) construo(es) for preparada para a expresso, a(s) construo(es) de DNA (so) introduzida(s) em uma clula hospedeira apropriada por quaisquer de uma variedade de meios adequados, incluindo a transformao conforme acima descrito. Aps a introduo do vetor, as clulas receptoras so desenvolvidas em um meio seletivo, o qual seleciona o desenvolvimento das clulas transformadas. A expresso da(s) seqncia(s) de gene clonado resulta na produo da protena desejada, ou na produo de um fragmento desta protena. Esta expresso pode ocorrer em uma forma contnua nas clulas transformadas, ou em uma forma controlada. . Assim, as sequncias de codificao da protena descritas aqui podem ser ligadas de forma opervel a qualquer vetor desejado e transformadas em um vetor selecionado, de forma a proporcionar a expresso de tais protenas naquele hospedeiro. O assunto da inveno so tambm as molculas de cido nuclico codificando para protenas tendo a atividade biolgica de uma celulase e que hibridizam para quaisquer das molculas de cido nuclico descritas acima ou que so definidas no que se segue: Uma molcula de cido nuclico codificando um polipeptdeo tendo a atividade enzimtica de uma celulase, selecionada do grupo consistindo em: (a) molculas de cido nuclico codificando um polipeptdeo compreendendo a sequncia de aminocidos conforme representada na Figura 19 ou 21; (b) molculas de cido nuclico codificando um polipeptdeo compreendendo a seqncia de aminocidos conforme representada na Figura 23 ou 27; (c) molculas de cido nuclico compreendendo a seqncia de codificao da seqncia de nucleotdeos conforme representada na Figura 19 ou 21; (d) molculas de cido nuclico compreendendo a seqncia de codificao da seqncia de nucleotdeos conforme representada na Figura 23 ou 27; (e) molculas de cido nuclico codificando um polipeptdeo compreendendo a seqncia de aminocidos codificada pelo inserto de DNA contido em DSM 11024, DSM 11012, DSM 11025ouDSM 11014; (f) molculas de cido nuclico codificando um polipeptdeo compreendendo a seqncia de aminocidos codificada pelo inserto de DNA contido em DSM 11026, DSM 11011, DSM 11013 ou DSM 11027; (g) molculas de cido nuclico compreendendo a seqncia de codificao do inserto de DNA contido em DSM 11024, DSM 11012, DSM 11025 ou DSM 11014; (h) molculas de cido nuclico compreendendo a seqncia de codificao do inserto de DNA contido em DSM 11026, DSM 11011, DSM 11013 ou DSM 11027; (i) molculas de cido nuclico hibridizando para uma molcula de qualquer um de (a), (c), (e) ou (g); e (j) molculas de cido nuclico cuja seqncia de codificao difere da seqncia de codificao de uma molcula de cido nuclico de qualquer um de (a) at (i) devido  degenerao do cdigo gentico. (k) molculas de cido nuclico codificando um polipeptdeo tendo atividade de celulase, e tendo uma seqncia de aminocidos que mostra pelo menos 80% de identidade a uma seqncia conforme representada na Figura 19, 21, 23 ou 27. O termo "hibridao" neste contexto significa a hibridao sob condies de hibridao convencionais, preferivelmente sob condies severas, tais como descritas por, por exemplo, Sambrook e col. (1989, Molecular Cloning, A Laboratory Manual 2~ Edio, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Estas molculas de cido nuclico que hibridizam para as molculas de cido nuclico de acordo com a presente inveno, em princpio, podem ser derivadas de qualquer organismo que possua tais molculas de cido nuclico. De preferncia, elas so derivadas de fungos, a saber, daqueles dos gneros Melanocarpus, Myriococcum, Sporotrichum, Myceliophthora e Chaetomium. As molculas de cido nuclico hibridizando para as molculas de cido nuclico da presente inveno podem ser isoladas, por exemplo, das bibliotecas genmicas ou das bibliotecas de cDNA de diversos organismos, a saber, os fungos.</span>Once the vector or DNA sequence containing the construct (s) is prepared for expression, the DNA construct (s) is introduced into an appropriate host cell by any of a variety of suitable media, including transformation as described above. After the introduction of the vector, the receptor cells are developed in a selective medium, which selects the development of the transformed cells. Expression of the cloned gene sequence (s) results in the production of the desired protein or in the production of a fragment of this protein. This expression can occur in a continuous form in transformed cells, or in a controlled form. . Thus, the protein coding sequences described herein can be operably linked to any desired vector and transformed into a selected vector to provide expression of such proteins in that host. The subject matter of the invention is also nucleic acid molecules encoding proteins having the biological activity of a cellulase and which hybridize to any of the nucleic acid molecules described above or which are defined as follows: A nucleic acid molecule encoding a polypeptide having the enzymatic activity of a cellulase selected from the group consisting of: (a) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence as depicted in Figure 19 or 21; (b) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence as depicted in Figure 23 or 27; (c) nucleic acid molecules comprising the nucleotide sequence coding sequence as depicted in Figure 19 or 21; (d) nucleic acid molecules comprising the nucleotide sequence coding sequence as depicted in Figure 23 or 27; (e) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence encoded by the DNA insert contained in DSM 11024, DSM 11012, DSM 11025 or DSM 11014; (f) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence encoded by the DNA insert contained in DSM 11026, DSM 11011, DSM 11013 or DSM 11027; (g) nucleic acid molecules comprising the DNA insert coding sequence contained in DSM 11024, DSM 11012, DSM 11025 or DSM 11014; (h) nucleic acid molecules comprising the DNA insert coding sequence contained in DSM 11026, DSM 11011, DSM 11013 or DSM 11027; (i) nucleic acid molecules hybridizing to a molecule of any of (a), (c), (e) or (g); and (j) nucleic acid molecules whose coding sequence differs from the coding sequence of a nucleic acid molecule from any of (a) to (i) due to the degeneration of the genetic code. (k) nucleic acid molecules encoding a polypeptide having cellulase activity, and having an amino acid sequence showing at least 80% identity to a sequence as depicted in Figure 19, 21, 23 or 27. The term "hybridization" in this context means hybridization under conventional hybridization conditions, preferably under severe conditions, as described by, for example, Sambrook et al. (1989, Molecular Cloning, A Laboratory Manual 2 - Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Such nucleic acid molecules which hybridize to nucleic acid molecules according to the present invention can in principle be derived from any organism having such nucleic acid molecules. Preferably, they are derived from fungi, namely those of the genera Melanocarpus, Myriococcum, Sporotrichum, Myceliophthora and Chaetomium. Nucleic acid molecules hybridizing to the nucleic acid molecules of the present invention can be isolated, for example, from genomic libraries or cDNA libraries from various organisms, namely fungi.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tais molculas de cido nuclico podem ser identificadas e isoladas utilizando-se as molculas de cido nuclico da presente inveno ou fragmentos destas molculas ou os complementos contrrios destas molculas, por exemplo, por hibridao de acordo com as tcnicas padro (ver Sambrook e col. (1989)).</span>Such nucleic acid molecules can be identified and isolated using the nucleic acid molecules of the present invention or fragments of these molecules or the counterparts of these molecules, for example, by hybridization according to standard techniques (see Sambrook et al. ( 1989)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como sonda de hibridao, por exemplo, as molculas de cido nuclico podem ser usadas, as quais tm exata ou substancialmente a mesma sequncia de nucleotdeos indicada nas Figuras ou fragmentos da dita sequncia. Os fragmentos usados como sondas de hibridao podem tambm ser fragmentos sintticos obtidos por tcnicas de sntese convencionais, e cuja sequncia  substancialmente idntica quela das molculas de cido nuclico de acordo com a inveno. Assim que os genes hibridizando para as molculas de cido nuclico da inveno tiverem sido identificados e isolados,  necessrio determinar a sequncia e analisar as propriedades das protenas codificadas pela dita sequncia. O termo "molcula de DNA de hibridao" inclui os fragmentos, os derivados e as variantes allicas das molculas de cido nuclico acima descritas, os quais codificam para a protena acima descrita ou um seu fragmento biologicamente ativo. Os fragmentos so entendidos serem partes de molculas de cido nuclico grandes o suficiente para codificar para a protena descrita ou um seu fragmento biologicamente ativo. O termo "derivado" significa neste contexto que as sequncias de nucleotdeos destas molculas diferem das seqncias das molculas de cido nuclico acima descritas em uma ou mais posies e so altamente homlogas  dita seqncia. A homologia  entendida referir-se a uma identidade de sequncia de pelo menos 40%, particularmente uma identidade de pelo menos 60%, preferivelmente mais do que 80%, e ainda mais preferivelmente mais do que 90%. Os desvios das molculas de cido nuclico descritas acima podem ser o resultado de deleo, substituio, insero, adio ou combinao. A homologia, alm disso, significa que as sequncias de nucleotdeos respectivas ou as protenas codificadas so funcional e/ou estruturalmente equivalentes. As molculas de cido nuclico que so homlogas s molculas de cido nuclico descritas acima, e que so derivadas das ditas molculas de cido nuclico, so regularmente variaes das ditas molculas que representam modificaes tendo a mesma funo biolgica. Elas podem ser variaes de ocorrncia natural, tais como as sequncias de outros organismos ou mutaes. Estas mutaes podem ocorrer naturalmente ou podem ser obtidas por mutagnese especfica. Ademais, estas variaes podem ser sequncias sinteticamente produzidas. As variantes allicas podem ser variantes de ocorrncia natural, bem como variantes sinteticamente produzidas ou geneticamente manipuladas.</span>As a hybridization probe, for example, nucleic acid molecules may be used which have exactly or substantially the same nucleotide sequence indicated in the Figures or fragments of said sequence. The fragments used as hybridization probes may also be synthetic fragments obtained by conventional synthesis techniques, and whose sequence is substantially identical to that of the nucleic acid molecules of the invention. Once the genes hybridizing to the nucleic acid molecules of the invention have been identified and isolated, it is necessary to determine the sequence and analyze the properties of the proteins encoded by said sequence. The term "hybridizing DNA molecule" includes the fragments, derivatives and allelic variants of the nucleic acid molecules described above which encode the protein described above or a biologically active fragment thereof. The fragments are understood to be parts of nucleic acid molecules large enough to encode for the described protein or a biologically active fragment thereof. The term "derivative" means in this context that the nucleotide sequences of these molecules differ from the sequences of the nucleic acid molecules described above at one or more positions and are highly homologous to said sequence. Homology is understood to refer to a sequence identity of at least 40%, particularly an identity of at least 60%, preferably more than 80%, and even more preferably more than 90%. Deviations from the nucleic acid molecules described above may be the result of deletion, substitution, insertion, addition or combination. Homology further means that the respective nucleotide sequences or encoded proteins are functionally and / or structurally equivalent. Nucleic acid molecules which are homologous to the nucleic acid molecules described above, and which are derived from said nucleic acid molecules, are regularly variations of said molecules which represent modifications having the same biological function. They can be naturally occurring variations, such as the sequences of other organisms or mutations. These mutations may occur naturally or may be obtained by specific mutagenesis. In addition, these variations may be synthetically produced sequences. Allelic variants may be naturally occurring variants as well as synthetically produced or genetically engineered variants.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As protenas codificadas pelas diversas variantes das molculas de cidos nuciicos da inveno compartilham caractersticas comuns especficas, tais como atividade enzimtica, peso molecular, reatividade imunolgica, conformao, etc., bem como propriedades fsicas, tais como mobilidade eletrofortica, comportamento cromatogrfico, coeficientes de sedimentao, solubilidade, propriedades espectroscpicas, estabilidade, pH timo, temperatura tima, etc. A atividade enzimtica da celulase pode ser detectada, por exemplo, conforme descrito na pgina 11 e nos Exemplos 1 e 25. A presente inveno adicionalmente refere-se s molculas de cido nuclico, cujas sequncias diferem das sequncias das molculas acima identificadas devido  degradao do cdigo gentico, e as quais codificam para uma protena tendo a atividade biolgica de uma celulase.</span>Proteins encoded by the various variants of the nucleic acid molecules of the invention share specific common characteristics such as enzymatic activity, molecular weight, immune reactivity, conformation, etc., as well as physical properties such as electrophoretic mobility, chromatographic behavior, sedimentation coefficients. , solubility, spectroscopic properties, stability, optimal pH, optimal temperature, etc. Enzymatic activity of cellulase can be detected, for example, as described on page 11 and Examples 1 and 25. The present invention additionally relates to nucleic acid molecules, whose sequences differ from the sequences of the molecules identified above due to the degradation of the genetic code, and which code for a protein having the biological activity of a cellulase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As molculas de cido nuclico da inveno so preferivelmente as molculas de RNA ou de DNA, mais preferivelmente o DNA genmico ou o cDNA. A presente inveno tambm refere-se aos antibiticos que especificamente identificam uma das protenas acima descritas de acordo com a inveno, bem como aos fragmentos de anticorpos que tm esta propriedade. Estes anticorpos podem ser monoclonais ou policlonais. Os mtodos para a sua produo so bem conhecidos na tcnica e so descritos em detalhe, por exemplo, em Harlow e Lane "Antibodies, A Laboratory Manual', CSH Press, Cold Spring Harbor Laboratory (1988).</span>The nucleic acid molecules of the invention are preferably RNA or DNA molecules, more preferably genomic DNA or cDNA. The present invention also relates to antibiotics which specifically identify one of the proteins described above according to the invention, as well as antibody fragments having this property. These antibodies may be monoclonal or polyclonal. Methods for their production are well known in the art and are described in detail, for example, in Harlow and Lane Antibodies, A Laboratory Manual, CSH Press, Cold Spring Harbor Laboratory (1988).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ademais, a presente inveno refere-se aos oligonucleotdeos que especificamente hibridizam com uma molcula de cido nuclico de acordo com a inveno, ou com a fita complementar de uma tal molcula de cido nuclico. Neste aspecto, o termo "especificamente hibridizam" significa que um tal oligonucleotdeo hibridiza sob condies de hibridao severas especificamente para uma molcula de cido nuclico da inveno e no mostra, sob tais condies, uma hibridao cruzada com as seqncias codificando para outros polipeptdeos. De preferncia, tais oligonucleotdeos tm um comprimento de pelo menos 10 nucleotdeos, mais preferivelmente de pelo menos 15 nucleotdeos, e mais preferivelmente ainda de pelo menos 30 nucleotdeos. Eles so preferivelmente no maiores do que 100 nucleotdeos, mais preferivelmente no maiores do que 80 nucleotdeos, e mais preferivelmente ainda no maiores do que 60 nucleotdeos. A fim de assegurar que eles hibridizem especificamente para uma molcula de cido nuclico da presente inveno, tais oligonucleotdeos mostram sobre o seu comprimento total uma identidade de pelo menos 80%, preferivelmente de pelo menos 95%, e mais preferivelmente de pelo menos 99% com uma sequncia de nucleotdeos correspondente de uma molcula de cido nuclico da presente inveno. Estes oligonucleotdeos podem ser usados, por exemplo, como sondas para o exame quanto s seqncias codificando as celulases nas bibliotecas genmicas ou de cDNA, ou como primers por PCR.</span>Further, the present invention relates to oligonucleotides that specifically hybridize to a nucleic acid molecule according to the invention, or to the complementary strand of such a nucleic acid molecule. In this regard, the term "specifically hybridize" means that such an oligonucleotide hybridizes under harsh hybridization conditions specifically to a nucleic acid molecule of the invention and does not, under such conditions, cross-hybridize to sequences encoding other polypeptides. Preferably, such oligonucleotides have a length of at least 10 nucleotides, more preferably at least 15 nucleotides, and most preferably at least 30 nucleotides. They are preferably no larger than 100 nucleotides, more preferably no larger than 80 nucleotides, and more preferably not yet larger than 60 nucleotides. In order to ensure that they specifically hybridize to a nucleic acid molecule of the present invention, such oligonucleotides show over their entire length an identity of at least 80%, preferably at least 95%, and more preferably at least 99% with a corresponding nucleotide sequence of a nucleic acid molecule of the present invention. These oligonucleotides may be used, for example, as probes for examination of sequences encoding cellulases in genomic or cDNA libraries, or as PCR primers.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As seqncias de codificao de protena descritas aqui podem ser fundidas em quadro a outras seqncias, de modo a construir um DNA codificando uma protena de fuso. Por exemplo, um vetor recombinante codificando uma celulase de 50K, uma celulase de 20K, uma celulase B de 50K ou o gene da protena com CBD, pode ser preparado conforme acima descrito, exceto que a sequncia de codificao de protena  fundida com a seqncia de uma celulase, hemicelulase ou mananase de T. reesei, ou pelo menos um domnio funcional de tais celulase, hemicelulase, ou mananase, conforme descrito na US 5.298.405, no WO 93/24622 e na submisso de GenBank L25310, cada um incorporado aqui por referncia. Especialmente, a celulase, a hemicelulase, ou a mananase  selecionada do grupo consistindo em CBHI, CBHII, EGI, EGII, XYLI, XYLII e MANI, ou um seu domnio, tal como o sinal de secreo ou a seqncia de ncleo. A mananase tem a mesma estrutura de domnio que aquela das celulases: um domnio de ncleo, contendo o stio ativo, um domnio de articulao contendo uma regio rica em serina-treonina, e uma extremidade, contendo o domnio de ligao.</span>The protein coding sequences described herein may be fused in frame to other sequences to construct a DNA encoding a fusion protein. For example, a recombinant vector encoding a 50K cellulase, a 20K cellulase, a 50K cellulase B or the CBD protein gene may be prepared as described above except that the protein coding sequence is fused to the sequence. of a T. reesei cellulase, hemicellulase or mannanase, or at least one functional domain of such cellulase, hemicellulase, or mannanase, as described in US 5,298,405, WO 93/24622 and the submission of GenBank L25310, each incorporated here by reference. In particular, cellulase, hemicellulase, or mannanase is selected from the group consisting of CBHI, CBHII, EGI, EGII, XYLI, XYLII and MANI, or a domain thereof, such as the secretion signal or nucleus sequence. Mannanase has the same domain structure as that of cellulases: a nucleus domain, containing the active site, a joint domain containing a serine-threonine-rich region, and one end, containing the binding domain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Peptdeos de fuso podem ser construdos que contenham um domnio de ncleo de mananase, ou de celobiohidrolase, ou de endoglicanase, ou de xilanase, ou o ncleo e os domnios de articulao a partir das mesmas, fundido  seqncia de codificao de protena desejada da inveno. O resultado  uma protena que contm ncleo de mananase, ou de celobiohidrolase, ou de endoglicanase, ou de xilanase, ou as regies de ncleo e articulao, e uma seqncia de celulase de 50K, celulase de 20K, celulase B de 50K ou de protena com CBD. A protena de fuso contm tanto a mananase ou a celobiohidrolase ou a endoglicanase ou a xilanase, quanto as atividades de celulase de 50K, celulase de 20K, celulase B de 50K ou da protena com CBD dos diversos domnios conforme proporcionados na construo de fuso.</span>Fusion peptides may be constructed that contain a mannanase, cellobiohydrolase, or endoglycanase, or xylanase nucleus domain, or the nucleus and articulation domains thereof fused to the desired protein coding sequence of the invention. . The result is a protein containing mannanase, or cellobiohydrolase, or endoglycanase, or xylanase nucleus, or nucleus and joint regions, and a sequence of 50K cellulase, 20K cellulase, 50K cellulase B, or protein with CBD. The fusion protein contains either mannanase or cellobiohydrolase or endoglycanase or xylanase, as well as the activities of 50K cellulase, 20K cellulase, 50K cellulase B or CBD protein from the various domains as provided in the fusion construct.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As protenas de fuso podem tambm ser construdas de modo tal que a extremidade de mananase, ou de celobiohidrolase, ou de endoglicanase, ou de xilanase, ou um seu fragmento desejado, seja includa, colocada antes da seqncia de celulase de 50K, celulase de 20K, celulase B de 50K ou da protena com CBD, especialmente de modo a permitir o uso de um stio no especfico de protease na extremidade como um stio de protease, para a recuperao da sequncia da celuiase de 50K, celulase de 20K, celuiase B de 50K ou da protena com CBD a partir da protena de fuso expressa. Alternativamente, as protenas de fuso podem ser construdas de modo que proporcionem um stio de protease em um ligador que seja colocado antes da sequncia de celulase de 50K, celulase de 20K, celulase B de 50K ou da protena com CBD, com ou sem as sequncias da extremidade.</span>Fusion proteins may also be constructed such that the end of mannanase, or cellobiohydrolase, or endoglycanase, or xylanase, or a desired fragment thereof, is included, placed before the 50K cellulase sequence, 20K cellulase. 50K cellulase B or protein with CBD, especially to allow the use of a non-specific endpoint protease site as a protease site, for the recovery of the 50K cellulase sequence, 20K cellulase B cellulase B 50K or CBD protein from the expressed fusion protein. Alternatively, fusion proteins may be constructed such that they provide a protease site on a linker that is placed before the 50K cellulase sequence, 20K cellulase, 50K cellulase B or CBD protein, with or without the sequences. from the end.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Novas propriedades para as celulases de 20K e de 50K e para a celulase B de 50K podem ser criadas por fuso de domnios, tais como um domnio de ligao  celulose (CBD), preferivelmente com seu ligador, s protenas da inveno. De preferncia, tais CBD's e ligadores so o CBD e os domnios de ligador correspondentes de uma celulase, mananase de Trchoderma, ou da protena com CBD de Melanocarpus albomyces. A inveno proporciona mtodos para a produo de preparaes de enzimas que sejam parcial ou completamente deficientes em uma atividade celuloltica indesejvel (ou seja, na capacidade de degradar a celulose), e enriquecidas na protena de celulase de 50K, celulase de 20K, celulase B de 50K ou da protena com CBD, conforme desejado para a indstria txtil ou de detergentes, ou para o processamento de polpa e papel. Por "deficiente na atividade celuloltica"  significado uma capacidade reduzida, diminuda ou reprimida de degradar a celulose em oligossacardeos menores. Tais preparaes deficientes em atividade celuloltica, e a fabricao das mesmas por mtodos de DNA recombinante, so descritas na US 5.298.405, incorporada aqui por referncia. De preferncia, a preparao  deficiente em atividades de EG, e/ou atividade de CBH1.</span>New properties for 20K and 50K cellulases and 50K cellulase B can be created by fusing domains, such as a cellulose binding domain (CBD), preferably with its linker, to the proteins of the invention. Preferably, such CBD's and linkers are the CBD and the corresponding linker domains of a cellulase, Trichoderma mannanase, or the Melanocarpus albomyces CBD protein. The invention provides methods for producing enzyme preparations which are partially or completely deficient in undesirable cellulolytic activity (i.e., the ability to degrade cellulose), and enriched in 50K cellulase protein, 20K cellulase B, cellulase B 50K or CBD protein as desired for the textile or detergent industry or for pulp and paper processing. By "deficient in cellulolytic activity" is meant a reduced, diminished or suppressed ability to degrade cellulose into smaller oligosaccharides. Such preparations deficient in cellulolytic activity, and the manufacture thereof by recombinant DNA methods, are described in US 5,298,405, incorporated herein by reference. Preferably, the preparation is deficient in EG activities, and / or CBH1 activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Conforme descrito aqui, a celulase de 50K, a celulase de 20K, a celulase B de 50K ou a protena com CBD pode ser proporcionada diretamente pelos hospedeiros da inveno. Alternativamente, o meio esgotado a partir do desenvolvimento dos hospedeiros, ou a celulase de 50K, a celulase de 20K, a celulase B de 50K ou a protena com CBD purificada a partir dos mesmos, pode ser usada. Ademais, se as atividades desejadas estiverem presentes em mais do que um hospedeiro recombinante, tais preparaes podem ser isoladas dos hospedeiros apropriados e combinadas antes do uso no mtodo da inveno.</span>As described herein, 50K cellulase, 20K cellulase, 50K cellulase B or CBD protein may be provided directly by the hosts of the invention. Alternatively, medium depleted from host development, either 50K cellulase, 20K cellulase, 50K cellulase B or protein with CBD purified from them may be used. Furthermore, if the desired activities are present in more than one recombinant host, such preparations may be isolated from the appropriate hosts and combined prior to use in the method of the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para obter as preparaes de enzima da inveno, os hospedeiros nativos ou recombinantes descritos acima, tendo as propriedades desejadas (ou seja, hospedeiros capazes de expressar economicamente quantidades viveis da celulase de 50K, celulase de 20K, celulase B de 50K ou protena com CBD desejada, e opcionalmente, aqueles que sejam substancialmente incapazes de expressar uma ou mais outras enzimas celulases no desejadas) so cultivados sob condies adequadas, as enzimas desejadas so secretadas a partir dos hospedeiros para o meio de cultivo, e a preparao de enzimas  recuperada a partir do dito meio de cultura por mtodos conhecidos na tcnica.</span>To obtain the enzyme preparations of the invention, the native or recombinant hosts described above having the desired properties (ie hosts capable of economically expressing viable amounts of 50K cellulase, 20K cellulase, 50K cellulase B or desired CBD protein , and optionally, those which are substantially unable to express one or more other undesired cellulase enzymes) are cultured under suitable conditions, the desired enzymes are secreted from the hosts into the culture medium, and the enzyme preparation is recovered from said culture medium by methods known in the art.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de enzimas da inveno podem ser produzidas por cultivo dos hospedeiros recombinantes ou cepas nativas em um fermentador, sobre um meio de desenvolvimento adequado (tal como, por exemplo, mostrado no Exemplo 1 ou no Exemplo 30). A preparao de enzimas pode ser o meio de cultura sem ou com as clulas hospedeiras nativas ou transformadas, ou  recuperada a partir do mesmo pela aplicao de mtodos bem conhecidos na tcnica. Entretanto, porque a celulase de 50K, a celulase de 20K ou a celulase B de 50 K so secretadas nos meios de cultura e mostram atividade nas condies ambientes do lquido celuloltico,  uma vantagem da inveno que as preparaes de enzima da inveno possam ser utilizadas diretamente a partir do meio de cultura sem nenhuma purificao adicional. Se desejado, tais preparaes podem ser liofilizadas ou a atividade enzimtica de outra forma concentrada e/ou estabilizada para armazenagem. As preparaes de enzima da inveno so muito econmicas de proporcionar e utilizar porque (1) as enzimas podem ser usadas em uma forma bruta; o isolamento de uma enzima especfica do meio de cultura  desnecessrio, e, (2) porque as enzimas so secretadas no meio de cultura, somente o meio de cultura precisa ser recuperado para obter a preparao de enzimas desejada; no h nenhuma necessidade de extrair uma enzima dos hospedeiros. De preferncia, o hospedeiro para tal produo  o Trchoderma, e especialmente o T. reesei.</span>Enzyme preparations of the invention may be produced by culturing the recombinant hosts or native strains in a fermenter over a suitable growth medium (such as, for example, shown in Example 1 or Example 30). The enzyme preparation may be the culture medium without or with native or transformed host cells, or is recovered therefrom by applying methods well known in the art. However, because 50K cellulase, 20K cellulase or 50K cellulase B are secreted in the culture media and show activity under ambient conditions of the cellulolytic liquid, it is an advantage of the invention that the enzyme preparations of the invention can be used. directly from the culture medium without any further purification. If desired, such preparations may be lyophilized or the enzyme activity otherwise concentrated and / or stabilized for storage. The enzyme preparations of the invention are very economical to provide and use because (1) the enzymes may be used in a crude form; isolation of a specific enzyme from the culture medium is unnecessary, and (2) because the enzymes are secreted into the culture medium, only the culture medium needs to be recovered to obtain the desired enzyme preparation; There is no need to extract an enzyme from the hosts. Preferably, the host for such production is Trichoderma, and especially T. reesei.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de enzima da inveno podem ser proporcionadas como um lquido ou como um slido, por exemplo, em uma forma de p seco, ou granular, ou lquida, especialmente os grnulos de no pulverizao, ou um lquido estabilizado, ou a preparao de enzimas pode ser, de outra forma, concentrada ou estabilizada para armazenagem ou uso. Imagina-se que as preparaes de enzima, contendo uma ou mais das celulases neutras da inveno, possam ser adicional mente enriquecidas ou tornadas parcial ou completamente deficientes em atividades enzimticas especficas, de modo a satisfazer as exigncias de uma utilidade especfica em diversas aplicaes, por exemplo, na indstria txtil. Uma mistura de atividades de enzimas secretadas por um hospedeiro, e especialmente um fungo, pode ser escolhida ser vantajosa em uma aplicao industrial particular, por exemplo, o biotratamento com pedras.</span>The enzyme preparations of the invention may be provided as a liquid or as a solid, for example, in a dry, granular or liquid powder form, especially non-spray granules, or a stabilized liquid, or enzyme preparation. may otherwise be concentrated or stabilized for storage or use. Enzyme preparations, containing one or more of the neutral cellulases of the invention, may be thought to be further enriched or partially or completely deficient in specific enzyme activities to meet the requirements of specific utility in various applications, for example. example in the textile industry. A mixture of enzyme activities secreted by a host, and especially a fungus, may be chosen to be advantageous in a particular industrial application, for example, stone biotreatment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de enzimas da inveno podem ser ajustadas para satisfazer as exigncias de necessidades especficas em diversas aplicaes na indstria txtil, de detergentes ou de polpa e papel.</span>The enzyme preparations of the invention may be adjusted to meet the requirements of specific needs in various textile, detergent or pulp and paper applications.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As combinaes podem ser preparadas com outras macromolculas que no sejam todas secretadas do mesmo hospedeiro (por exemplo, outras enzimas, tais como as endoglicanases, as proteases, as lipases, as peroxidases, as oxidases ou as amilases), ou substncias qumicas que possam aumentar o desempenho, a estabilidade, ou o tamponamento da preparao de enzimas desejada. Os grnulos de no pulverizao podem ser revestidos. As preparaes de enzimas lquidas podem ser estabilizadas por adio de um poliol, tal como o propileno glicol, um acar ou o lcool de acar, o cido ltico ou o cido brico, de acordo com mtodos estabelecidos. Os detergentes lquidos geralmente contm at 90% de gua e 0-20% de solvente orgnico. As formas protegidas das enzimas da inveno podem ser preparadas conforme descrito na EP 238.216.</span>Combinations may be prepared with other macromolecules that are not all secreted from the same host (for example, other enzymes such as endoglycans, proteases, lipases, peroxidases, oxidases or amylases), or chemicals that may increase. the performance, stability, or buffering of the desired enzyme preparation. Non-spray granules may be coated. Liquid enzyme preparations may be stabilized by the addition of a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Liquid detergents usually contain up to 90% water and 0-20% organic solvent. Protected forms of the enzymes of the invention may be prepared as described in EP 238,216.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de enzimas da inveno podem conter um tensoativo, o qual pode ser aninico, no-inico, catinico, anfotrico ou uma mistura destes tipos, especialmente quando usadas como uma composio detergente. As composies detergentes teis so descritas, por exemplo, na WO 94/07998, na Patente U.S. Na 5,443.750 e na Patente U.S. Ns 3.664.961.</span>The enzyme preparations of the invention may contain a surfactant which may be anionic, nonionic, cationic, amphoteric or a mixture of these types, especially when used as a detergent composition. Useful detergent compositions are described, for example, in WO 94/07998, U.S. Patent No. 5,443,750 and U.S. Patent No. 3,664,961.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se requerido, uma enzima desejada pode ser adicional mente purificada de acordo com as condies convencionais, tais como extrao, precipitao, cromatografia, cromatografia por afinidade, eletroforese, ou similares.</span>If required, a desired enzyme may be further purified according to conventional conditions such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis, or the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de enzimas desta inveno so especialmente teis na indstria txtil, preferivelmente na indstria de biotratamento com pedras e na de bioacabamento, ou na de detergentes. As outras reas teis so na indstria de polpa e papel. A lavagem com pedras no enzimtica tem trs etapas: desengomagem, desgaste e ps-tratamento. A primeira etapa, a desengomagem, envolve a remoo do revestimento de amido, ou daquele de seus derivados, por amilases. A segunda etapa, o desgaste, quando efetuada sem celulase,  geralmente realizada por lavagem do brim com pedras-pome, e, quando o branqueamento for desejado, alvejante. O efeito de desgaste  o resultado no somente do efeito das pedras, como tambm da esfregao junto do tecido de brim. O desgaste  geralmente seguido pela terceira etapa, uma etapa de lavagem para remover o corante em excesso, durante a qual podem ser adicionados os amaciantes ou os avivadores ticos.</span>The enzyme preparations of this invention are especially useful in the textile industry, preferably in the stone and bio-finish biotreatment industry, or in the detergent industry. The other useful areas are in the pulp and paper industry. Non-enzymatic stone washing has three stages: degumming, wear and after treatment. The first step, degumming, involves the removal of the starch coating or its derivatives by amylases. The second step, wear, when performed without cellulase, is generally performed by washing the denim with pumice, and, when bleaching is desired, bleach. The wear effect is the result not only of the effect of the stones, but also of rubbing along the denim fabric. Wear is generally followed by the third step, a wash step to remove excess dye, during which optical softeners or brighteners may be added.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Na lavagem com pedras enzimtica, ou biotratamento com pedras, o desgaste com pedras-pome  completa ou parcialmente eliminado e a celulase  adicionada para facilitar o desgaste do corante ndigo da superfcie da fibra. Aps este tratamento, a celulase  removida atravs de uma lavagem com detergente, para assegurar que a resistncia mecnica da fibra no seja adicionalmente comprometida pela presena continuada da enzima. O tratamento com (uma) celulase(s) pode completamente substituir o tratamento com as pedras-pome (por exemplo, 1 kg de enzima comercial por 100 kg de pedras). Entretanto, o tratamento com celulase pode ser combinado com o tratamento com pedras-pome quando for desejado produzir uma acabamento fortemente desgastado. Um efeito de revestimento de cor de pssego, no qual uma fina cobertura semelhante ao plo, saliente,  criada,  tambm obtido por uma combinao por lavagem de uma celulase neutra com as pedras-pome. As celulases desta inveno so teis especialmente para minimizar a colorao de volta e intensificar o branqueamento (desgaste) no biotratamento com pedras. O biotratamento com pedras  preferivelmente efetuado de cerca de pH 4,5-9,5, e mais preferivelmente entre pH 6,0-8,5. A temperatura da reao pode variar de cerca de 40-80C, preferivelmente entre 50-70C, e mais preferivelmente entre 50-60C. A razo de liquido (a razo do volume de lquido por peso de tecido) pode variar de cerca de 2:1 - 20:1, preferivelmente 4:1 -10:1, e mais preferivelmente 4:1 - 7:1. A dosagem de enzima pode variar de cerca de 25-1500 nkat/g de tecido, preferivelmente 50-500 nkat/g de tecido e mais preferivelmente 75-300 nkat/g de tecido.</span>In enzymatic stone washing or stone biotreatment, pumice stone wear is completely or partially eliminated and cellulase is added to facilitate wear of the indigo dye from the fiber surface. Following this treatment, the cellulase is removed by washing with detergent to ensure that the mechanical strength of the fiber is not further compromised by the continued presence of the enzyme. Treatment with (one) cellulase (s) may completely replace pumice treatment (for example, 1 kg of commercial enzyme per 100 kg of stones). However, cellulase treatment can be combined with pumice treatment when it is desired to produce a heavily worn finish. A peach-colored coating effect in which a thin, protruding fur-like covering is created is also obtained by a combination of washing a neutral cellulase with the pumice stones. The cellulases of this invention are especially useful for minimizing backstaining and enhancing bleaching (wear) in stone biotreatment. Biotreatment with stones is preferably carried out at about pH 4.5-9.5, and more preferably between pH 6.0-8.5. The reaction temperature may range from about 40-80  C, preferably from 50-70  C, and more preferably from 50-60  C. The liquid ratio (the ratio of liquid volume to tissue weight) may range from about 2: 1 - 20: 1, preferably 4: 1 - 10: 1, and more preferably 4: 1 - 7: 1. The enzyme dosage may range from about 25-1500 nkat / g tissue, preferably 50-500 nkat / g tissue and more preferably 75-300 nkat / g tissue.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As celulases da inveno so teis na indstria txtil para o bio-acabamento de tecidos ou roupas, por exemplo, o impedimento de formao de bolas, a no formao de felpo, a clarificao da cor, a reduo da aspereza, a criao de diferentes acabamentos (por exemplo, um efeito de 'revestimento de cor de pssego', de 'usado', de 'lavado com pedras' ou de 'aspecto antigo'), e o bio-acabamento do fio (por exemplo, a reduo da pilosidade, aperfeioamento da maciez). As celulases desta inveno podem ser usadas no bio-acabamento nas condies acdicas e nas neutras.</span>The cellulases of the invention are useful in the textile industry for the biofinishing of fabrics or clothing, for example, preventing ball formation, not forming fuzz, clarifying color, reducing roughness, creating different finishes. (for example, a 'peach-colored', 'worn', 'stone-washed' or 'old-fashioned' effect), and yarn bio-finishing (e.g. hair reduction, softness improvement). The cellulases of this invention may be used for bio-finishing under acidic and neutral conditions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As celulases desta inveno so teis nas composies , detergentes para aperfeioar o efeito de limpeza dos produtos txteis, por exemplo, a remoo de sujeiras, para aperfeioar as propriedades de cuidado com o tecido por reduo da aspereza dos produtos txteis, as celulases tendo tambm efeitos de impedimento de formao de felpo e de clarificao da cor e de restaurao. O material txtil que  tratado com as preparaes de enzimas da inveno pode ser fabricado de fibras contendo celulose natural ou fibras contendo celulose feitas pelo homem, ou de suas misturas. Os exemplos de celulsicos naturais so o algodo, o linho, o cnhamo, a juta e o rami. Os exemplos de celulsicos feitos pelo homem so a viscose, o acetato de celulose, o triacetato de celulose, o raiom, o "cupro" e o "lyocell". Os celulsicos acima mencionados podem tambm ser empregados como combinaes de fibras sintticas, tais como o polister, a poliamida ou as fibras acrlicas. O material txtil pode ser um fio, ou tricotado, ou tecido, ou formado por outro meio.</span>The cellulases of this invention are useful in the compositions as detergents for enhancing the cleaning effect of textiles, for example the removal of dirt, for enhancing fabric care properties by reducing the harshness of textiles, the cellulases also having effects. preventing fouling and color clarification and restoration. The textile material that is treated with the enzyme preparations of the invention may be made from natural cellulose-containing fibers or man-made cellulose-containing fibers, or mixtures thereof. Examples of natural cellulosics are cotton, flax, hemp, jute and ramie. Examples of man-made cellulosics are viscose, cellulose acetate, cellulose triacetate, rayon, cupro and lyocell. The aforementioned cellulosics may also be employed as combinations of synthetic fibers, such as polyester, polyamide or acrylic fibers. The textile material may be a thread, or knitted, or woven, or otherwise formed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As celulases da inveno, alm de serem especialmente teis para o tratamento de tecido, so teis, em geral, em qualquer rea que requeira atividade de celulase. Na indstria de polpa e papel, as celulases neutras podem ser usadas, por exemplo, na retirada de tinta de diferentes papis e papeles reciclados tendo pH neutro ou alcalino, no aperfeioamento da qualidade da fibra, ou no aumento da drenagem na fabricao de papis. Os outros exemplos incluem a remoo do espessante de pasta de estampagem e do corante em excesso aps a estampagem txtil, e como um tratamento para o alimento de animais. Por exemplo, se a aplicao pretendida for o aperfeioamento da resistncia da polpa mecnica, ento as preparaes de celulase de 50k, de celulase de 20K, de celulase B de 50K ou da protena com CBD da inveno podem proporcionar uma ou mais destas protenas, de modo a aumentar ou facilitar a capacidade das fibras de celulose de se ligarem juntas. Em uma forma similar, na aplicao de refino de polpa, as preparaes de celulase de 50k, de celulase de 20K, de celulase B de 50K ou da protena com CBD da inveno podem proporcionar uma ou mais destas protenas em um nvel que aumente ou facilite tal intumescimento. A inveno  descrita em mais detalhe nos seguintes exemplos. Estes exemplos mostram somente algumas aplicaes concretas da inveno.  auto-evidente para algum versado na tcnica criar diversas aplicaes similares. Por conseguinte, os exemplos no devem ser interpretados para estreitar o escopo da inveno, somente para clarificar o uso da inveno.</span>The cellulases of the invention, in addition to being especially useful for tissue treatment, are generally useful in any area requiring cellulase activity. In the pulp and paper industry, neutral cellulases can be used, for example, to remove ink from different recycled papers and cartons having neutral or alkaline pH, to improve fiber quality, or to increase drainage in papermaking. Other examples include removal of the printing paste thickener and excess dye after textile printing, and as a treatment for animal feed. For example, if the intended application is mechanical pulp strength enhancement, then the 50k cellulase, 20K cellulase, 50K cellulase B, or CBD protein preparations of the invention may provide one or more of these proteins. to increase or facilitate the ability of cellulose fibers to bond together. In a similar form, in the pulp refining application, the 50k cellulase, 20K cellulase, 50K cellulase B, or CBD protein preparations of the invention may provide one or more of these proteins at a level that increases or facilitates such swelling. The invention is described in more detail in the following examples. These examples show only some concrete applications of the invention. It is self-evident for someone skilled in the art to create several similar applications. Accordingly, the examples should not be construed to narrow the scope of the invention, only to clarify the use of the invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplos Exemplo 1 Cultivos em Frasco com Agitao e em Fermentador Para a conservao, as cepas ALK04179, ALK04124, ALK04237, ALK04265 e ALK04125 foram riscadas sobre gar de esporulao (meio de ATCC 5, American Type Culture Collection ("Coleta de Cultura do Tipo Americano"), Catlogo de Fungos Filamentosos, 18a edio, eds., S.C. Jong e M.J, Edwards, (1991): 1 litro contm 1 g de extrato de levedura, 1 g de extrato de carne de boi, 2 g de triptose, uma quantidade em trao de FeS04, 10 g de glicose e 15 g de gar; o pH era 7,2. As inclinaes de gar foram incubadas a 45 por 3-6 dias.</span>Examples Example 1 Stirred and Fermented Bottle Cultures For preservation, strains ALK04179, ALK04124, ALK04237, ALK04265 and ALK04125 were streaked onto sporulation agar (ATCC 5 medium, American Type Culture Collection). "), Filamentous Fungi Catalog, 18th edition, eds., SC Jong and MJ, Edwards, (1991): 1 liter contains 1 g yeast extract, 1 g beef extract, 2 g tryptose, one trace amount of FeSO 4, 10 g glucose and 15 g agar, the pH was 7.2 Agar slants were incubated at 45  for 3-6 days.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para os testes de aplicaes de ALK04237 (Exemplos 3 e 4), uma colnia foi inoculada em 500 ml do seguinte meio mineral (Moloney, A.P. e col., Biotechnol, Bioeng. 25:1169 (1983)): 1 litro contm 15 g de KH2P04, 15 g de (NH4)2S04, 2,4 ml de MgSCXptfFfeO a 1 M, 5,4 ml de CaCI2 a 1 M, 20 g de flculo Solka, 15 g de p de macerao de milho, 1 g de extrato de levedura e 10 ml de 100 x soluo de elemento em trao 1, onde 1 litro de 100 x soluo de elemento em trao 1 contm 0,5 g de FeS04x7H20, 0,156 g de MnSO^HzO, 0,14 g de ZnSO^HaO e 0,49 g de CoSO^FkO; o pH foi ajustado para pH 6,5. O cultivo foi efetuado a 45C por 3 dias em um agitador rotativo (250 rpm). A atividade de endoglicanase de cerca de 20-25 nkat/ml foi obtida. A atividade de celulase foi rotineiramente medida como atividade de endoglicanase, de acordo com Bailey, M.J. e col., Enzyme Microb. Technol. 3:153 (1981), usando-se hidroxietilcelulose a 1% (p/v), HEC (Fluka AG #54290) como um substrato. As condies do ensaio eram, se no estabelecido de outra forma, pH 7,0 e 50C, com um tempo de reao de 10 minutos. Uma unidade de endoglicanase (1 nkat = 1 ECU)  definida como a quantidade de enzima que produz carboidratos de reduo tendo um poder de reduo correspondendo a um nanomol de glicose, em um segundo, a partir de HEC, sob as condies de ensaio. Entretanto, com as enzimas purificadas descritas nos Exemplos 9-12, as condies de ensaio de Bailey e col., Enzyme Microb. Technol. 3:153 (1981) excederam a faixa linear, e o ensaio foi, portanto, modificado conforme descrito no Exemplo 10. Com cada cepa, o ensaio da atividade em papel de filtro (que mede a hidrlise total de celulose e indica a presena de atividade de celobiohidrolase) estava sob o limite de deteco seguro ou era muito baixo.</span>For ALK04237 application tests (Examples 3 and 4), a colony was inoculated into 500 ml of the following mineral medium (Moloney, AP et al., Biotechnol, Bioeng. 25: 1169 (1983)): 1 liter contains 15 g of KH2PO4, 15 g of (NH4) 2 SO4, 2.4 ml of 1 M MgSCXptfF0 O, 5.4 ml of 1 M CaCl2, 20 g of Solka floccule, 15 g of maize maceration powder, 1 g of extract yeast and 10 ml of 100 x trace element solution 1, where 1 liter of 100 x trace element solution 1 contains 0.5 g FeSO4x7H20, 0.156 g MnSO4 HzO, 0.14 g ZnSO4 HaO and 0.49 g of CoSO4 FkO; pH was adjusted to pH 6.5. Cultivation was performed at 45  C for 3 days on a rotary shaker (250 rpm). Endoglycanase activity of about 20-25 nkat / ml was obtained. Cellulase activity was routinely measured as endoglycanase activity, according to Bailey, M.J. et al., Enzyme Microb. Technol. 3: 153 (1981), using 1% (w / v) hydroxyethylcellulose, HEC (Fluka AG # 54290) as a substrate. Assay conditions were, if not otherwise stated, pH 7.0 and 50  C, with a reaction time of 10 minutes. An endoglycanase unit (1 nkat = 1 ECU) is defined as the amount of reducing carbohydrate producing enzyme having a reducing power corresponding to one nanomol of glucose in one second from HEC under the test conditions. However, with the purified enzymes described in Examples 9-12, the assay conditions of Bailey et al. Enzyme Microb. Technol. 3: 153 (1981) exceeded the linear range, and the assay was therefore modified as described in Example 10. With each strain, the filter paper activity assay (which measures total cellulose hydrolysis and indicates the presence of cellobiohydrolase activity) was under safe detection limit or was too low.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para a determinao da dependncia de pH e de temperatura (Exemplo 2), bem como para os testes de aplicao das cepas ALK04179, ALK04124, ALK04265 e ALK04125 (Exemplos 3 e 4), as colnias foram inoculadas em 500 ml do termomeio B modificado (G. Szakacs, Technical Unversity of Budapest, Hungria): 1 litro continha 6 g de flculo Solka, 6 g de gro de trigo esgotado do destilador, 3 g de xilano de espelta de aveia, 2 g de CaC02, 1,5 g de farinha grossa de soja, 1,5 g de (NH4)2HP04, 1 g de farelo de cevada, 0,5 g de KH2P04, 0,5 g de MgSO^HaO, 0,5 g de NaCI, 0,5 ml de soluo de elemento em trao 1 (1 litro contm: 1,6 g de MnS02, 3,45 g de ZnSCXtxTHaO, e 2,0 g de CoCUxeHaO) e 0,5 ml de soluo de elemento em trao 2 (1 litro contm: 5,0 g de FeS04x7H20 e duas gotas de H2S04 concentrado); o pH foi ajustado para pH 6,5. Os cultivos foram efetuados a 45C por 3 dias em um agitador rotativo (250 rpm). Por causa do termomeio B, as atividades de endoglicanase das cepas ALK04179, ALK04124, e ALK04237 foram cerca de 5 nkat/ml, os filtrados das culturas foram concentrados cerca de 10 vezes em um concentrador Amicon usando um corte de 30 kDa. A atividade de endoglicanase obtida com ALKO 4265 foi cerca de 20 nkat/ml e com ALKO 4125 30-40 nkat/ml. O cultivo no fermentador de 1 litro de ALK04179 foi efetuado no seguinte meio: 1 litro continha 10 g de flculo Solka, 3 g de celobiose, 4 g de p de macerao de milho, 1,5 g de (NH4)2P04, 0,3 g de MgSO^^O, 0,5 g de NaCI, 2 g de CaC03, 0,5 ml de soluo de elemento em trao 1 e 0,5 ml de soluo de elemento em trao 2, 0,5 g de KN03, 0,3 g de CaCI2, 1 g de Tween 80; o pH foi ajustado para pH 6,5. O cultivo no fermentador de 1 litro de ALK04124 foi efetuado no termomeio B modificado: 1 litro continha: 10 g de flculo Solka, 1 g de xilano de Roth, 40 g de soro de leite, 40 g de farinha grossa de soja, 2 g de CaC03, 5 g de (NH4)2S04, 0,5 g de KH2P04, 1,0 g de MgS04x7H20, 1,0 g de NaCI, 1 g de antiespuma, 0,5 ml de soluo de elemento em trao 1 e 0,5 ml de soluo de elemento em trao 2. O cultivo no fermentador de 1 litro de ALK04237 foi efetuado no meio mineral mencionado acima. Inculo a 10% (v/v) foi usado. O pH foi mantido em pH 6,5  0,4 pela adio de amnia [12,5% (v/v)] e cido fosfrico [17% (v/v)]. A temperatura de fermentao era 45C. O fermentador (Biostat , B. Braun, Melsungen, Alemanha) foi agitado  400 rpm e o fluxo de ar como 1 vvm. As atividades de endoglicanase obtidas eram as seguintes: ALK04179 cerca de 40 nkat/mi, ALK04124 cerca de 90 nkat/ml e ALK04237 cerca de 30 nkat/ml. O ALK04265 e o ALK04125 no foram cultivados em um fermentador. ALK04179, ALK04124, ALK04237 e ALK04125 foram cultivados em um fermentador piloto de 100 litros nos meios e nas condies descritos acima. As atividades de endoglicanase obtidas foram cerca de 40 nkat/m com ALK04179 e ALK04237, cerca de 90 nkat/ml com ALK04124 e cerca de 100 nkat/ml com ALK04125. Os filtrados das culturas foram concentrados 10-20 vezes em um ultra filtro Millipore PUF100 e um concentrador de cassete Pellicon Us usando um corte de 10 kDa.</span>For determination of pH and temperature dependence (Example 2), as well as for application tests of the ALK04179, ALK04124, ALK04265 and ALK04125 strains (Examples 3 and 4), colonies were inoculated into 500 ml of modified termome B ( G. Szakacs, Technical University of Budapest, Hungary): 1 liter contained 6 g of Solka floccule, 6 g of distilled wheat grain from the distiller, 3 g of oat spelled xylan, 2 g of CaCO 2, 1.5 g of soybean meal, 1.5 g (NH4) 2HP04, 1 g barley bran, 0.5 g KH2 PO4, 0.5 g MgSO4 HaO, 0.5 g NaCl, 0.5 ml Trace element solution 1 (1 liter contains: 1.6 g MnSO2, 3.45 g ZnSCXtxTHaO, and 2.0 g CoCUxeHaO) and 0.5 ml trace element solution 2 (1 liter contains: 5.0 g FeSO4x7H2 O and two drops of concentrated H2 SO4); pH was adjusted to pH 6.5. Cultures were performed at 45  C for 3 days on a rotary shaker (250 rpm). Because of termome B, the endoglycanase activities of the ALK04179, ALK04124, and ALK04237 strains were about 5 nkat / ml, the culture filtrates were concentrated about 10-fold in an Amicon concentrator using a 30 kDa cutoff. The endoglycanase activity obtained with ALKO 4265 was about 20 nkat / ml and with ALKO 4125 30-40 nkat / ml. Cultivation in the 1 liter fermentor of ALK04179 was performed in the following medium: 1 liter contained 10 g Solka floccule, 3 g cellobiose, 4 g maize maceration powder, 1.5 g (NH4) 2P04, 0, 3 g MgSO4, 0.5 g NaCl, 2 g CaCO3, 0.5 ml trace element solution 1 and 0.5 ml trace element solution 2, 0.5 g KNO3 0.3 g CaCl 2, 1 g Tween 80; pH was adjusted to pH 6.5. Cultivation in the 1 liter fermentor of ALK04124 was carried out in modified termome B: 1 liter contained: 10 g Solka floccule, 1 g Roth xylan, 40 g whey, 40 g coarse soy flour, 2 g CaCl 3, 5 g (NH 4) 2 SO 4, 0.5 g KH 2 PO 4, 1.0 g MgSO 4 x 7 H 2 O, 1.0 g NaCl, 1 g antifoam, 0.5 ml trace element solution 1 and 0 0.5 ml trace element solution 2. Cultivation in the 1 liter fermentor of ALK04237 was carried out in the mineral medium mentioned above. 10% (v / v) inoculum was used. The pH was maintained at pH 6.5  0.4 by the addition of ammonia [12.5% (v / v)] and phosphoric acid [17% (v / v)]. The fermentation temperature was 45  C. The fermenter (Biostat, B. Braun, Melsungen, Germany) was stirred at 400 rpm and the air flow as 1 vvm. The endoglycanase activities obtained were as follows: ALK04179 about 40 nkat / ml, ALK04124 about 90 nkat / ml and ALK04237 about 30 nkat / ml. ALK04265 and ALK04125 were not grown in a fermenter. ALK04179, ALK04124, ALK04237 and ALK04125 were grown in a 100 liter pilot fermenter in the media and under the conditions described above. The endoglycanase activities obtained were about 40 nkat / m with ALK04179 and ALK04237, about 90 nkat / ml with ALK04124 and about 100 nkat / ml with ALK04125. The culture filtrates were concentrated 10-20 times on a Millipore PUF100 ultrafilter and a Pellicon Us cassette concentrator using a 10 kDa cutoff.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 2 Determinao da dependncia do pH e da temperatura das atividades de endoglicanase nos filtrados das culturas Para a determinao da dependncia de pH e temperatura, as cepas ALK04179, ALK04124, ALK04237, ALK04265 e ALK04125 foram desenvolvidas no termomeio B modificado. As amostras dos cultivos no frasco com agitao (filtrados das culturas) foram diludas em tampes de Mcllvain a 50 mM (cido ctrico a 50 mM-Na2HP04 a 100 mM) de faixa de pH 4,5-8,5. Os valores finais do pH das misturas de tampes com filtrados da cultura era, 4,3, 5,4, 6,3, 7,3, 8,1 e 8,7 para a cepa ALK04179; 4,3, 5,4, 6,4, 7.3, 8,1 e 8,5 para a cepa ALK04124; 4,4, 5,3, 6,2, 7,1, 8,0 e 8,5 para a cepa ALK04237; 4,3, 5,4, 6,3, 7,2, 8,1 e 8,5 para a cepa ALK04265 e 4,3, 5.4, 6,4, 7,3, 8,1 e 8,5 para a cepa ALK04125. O BSA foi adicionado como um carreador de protena at a concentrao de 100 pg/ml. A pepstatina A e o fluoreto de fenil metil sulfonila (PMSF) foram adicionados como inibidores de protease a 10 pg/ml e 174 pg/ml, respectivamente. A atividade de endoglicanase foi medida em cada pH a 50C, com tempo de reao de 60 minutos. A atividade de endoglicanase de ALK04179 exibiu mais do que 90% de seu mximo na faixa de pH de cerca de 4,5-7,5, a atividade mxima foi detectada em pH 5,4-6,3 (Figura 1A). A atividade de endoglicanase de ALK04124 exibiu mais do que 80% de sua atividade mxima na faixa de pH de cerca de 5,5-7,5, a atividade mxima foi detectada em torno de pH 6,4 (Figura 2A). A atividade de endoglicanase de ALK04265 exibiu mais do que 80% de sua atividade na faixa de pH de cerca de 4,5-7,0, a atividade mxima foi detectada em torno de pH 5,5-6,5 (Figura 4A). A atividade de endoglicanase de ALK04237 exibiu mais do que 80% de sua atividade na faixa de pH de cerca de 4,5-6,0, a atividade mxima foi detectada em torno de pH 5,3 (Figura 3A). A atividade de endoglicanase de ALK04125 exibiu cerca de 90% de seu mximo na faixa de pH de cerca de 4,5-7,5, a atividade mxima foi detectada em torno de pH 6,5 (Figura 5A).</span>Example 2 Determination of pH and Temperature Dependence of Endoglycanase Activities in Crop Filtrates For determination of pH and temperature dependence, strains ALK04179, ALK04124, ALK04237, ALK04265, and ALK04125 were developed in modified term B. Cultivation samples in the shake flask (culture filtrates) were diluted in 50 mM Mcllvain buffers (50 mM citric acid-100 mM Na2 HPO4) pH 4.5-8.5. Final pH values of buffer mixtures with culture filtrates were 4.3, 5.4, 6.3, 7.3, 8.1 and 8.7 for strain ALK04179; 4.3, 5.4, 6.4, 7.3, 8.1 and 8.5 for strain ALK04124; 4.4, 5.3, 6.2, 7.1, 8.0 and 8.5 for the ALK04237 strain; 4.3, 5.4, 6.3, 7.2, 8.1 and 8.5 for the ALK04265 strain and 4.3, 5.4, 6.4, 7.3, 8.1 and 8.5 for strain ALK04125. BSA was added as a protein carrier to a concentration of 100 pg / ml. Pepstatin A and phenyl methyl sulfonyl fluoride (PMSF) were added as protease inhibitors at 10 pg / ml and 174 pg / ml, respectively. Endoglycanase activity was measured at each pH at 50  C, with reaction time of 60 minutes. The endoglycanase activity of ALK04179 exhibited more than 90% of its maximum in the pH range of about 4.5-7.5, the maximum activity was detected at pH 5.4-6.3 (Figure 1A). The endoglycanase activity of ALK04124 exhibited more than 80% of its maximum activity in the pH range of about 5.5-7.5, the maximum activity was detected around pH 6.4 (Figure 2A). The endoglycanase activity of ALK04265 exhibited more than 80% of its activity in the pH range of about 4.5-7.0, the maximum activity was detected around pH 5.5-6.5 (Figure 4A). . The endoglycanase activity of ALK04237 exhibited more than 80% of its activity in the pH range of about 4.5-6.0, the maximum activity was detected around pH 5.3 (Figure 3A). The endoglycanase activity of ALK04125 exhibited about 90% of its maximum in the pH range of about 4.5-7.5, the maximum activity was detected around pH 6.5 (Figure 5A).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para a determinao da dependncia da temperatura da atividade de endoglicanase, as amostras dos filtrados das culturas foram diludas em tampo de Mcllvain  50 mM, pH 7,0, O BSA foi adicionado como um carreador de protena at a concentrao de 100 pg/ml. A pepstatina A e o fluoreto de fenil metil sulfonila (PMSF) foram adicionados como inibidores de protease para 10 pg/ml e 174 pg/ml, respectivamente. Os valores finais do pH das misturas de tampes com filtrados das culturas eram 7,3 (ALK04179, ALK04124, e ALK04125) e 7,2 (ALK04237 e ALK04265). As amostras foram incubadas a 40C, 50C e 60C por 60 minutos. A atividade de endoglicanase mxima de ALK04179 foi detectada a 50C e 60C, cerca de 30% da atividade foi mantida a 40C (Figura 1B). A atividade de endoglicanase mxima de ALK04124 foi detectada  60C, cerca de 70% da atividade foi mantida a 50C e 30% a 40C (Figura 2B). A atividade de endoglicanase mxima de ALK04237 foi detectada a 60C, cerca de 60% da atividade foi mantida a 50C e 40% a 40C (Figura 3B). A atividade de endoglicanase mxima de ALK04265 foi detectada a 60C, cerca de 50% da atividade foi mantida a 50C e 30% a 40C (Figura 4B). A atividade de endoglicanase mxima de ALK04125 foi detectada  60C, cerca de 80% da atividade foi mantida a 50C e 70% a 40C (Figura 5B). Exemplo 3 Liberao do Corante ndigo nas Condies Neutras As preparaes de celulase derivadas das cepas ALK04179, ALK04124, ALK04237, ALK04265 e ALK04125 (Exemplos 1 e 2) foram testadas quanto  sua capacidade de liberar o corante, nas condies neutras, a partir de tecido de brim contendo algodo tingido com ndigo para proporcionar um aspecto de lavado com pedras. O produto de celulase cida comercial Ecostone L (Primalco Ltd, Biotec, Finlndia) foi usado como um controle. O tecido de brim foi obtido da Lauffenmuehl (Alemanha). O tecido de teste foi pr-lavado 10 min. a 60C com Ecostone A 200 (1 ml/litro, Primalco Ltd, Biotec, Finlndia). O tecido foi ento cortado em amostras de 12x12 cm. A cor de ambos os lados das amostras de tecido foi medida como valores de reflecncia com o sistema Medidor de Intensidade da Cor CM 1000R L*a*b* da Minolta (Osaka, Japo).</span>To determine the temperature dependence of endoglycanase activity, culture filtrate samples were diluted in 50 mM Mcllvain buffer pH 7.0. BSA was added as a protein carrier to a concentration of 100 pg / ml. . Pepstatin A and phenyl methyl sulfonyl fluoride (PMSF) were added as protease inhibitors to 10 pg / ml and 174 pg / ml, respectively. The final pH values of the culture filtrate buffer mixtures were 7.3 (ALK04179, ALK04124, and ALK04125) and 7.2 (ALK04237 and ALK04265). Samples were incubated at 40  C, 50  C and 60  C for 60 minutes. The maximal endoglycanase activity of ALK04179 was detected at 50  C and 60  C, about 30% of the activity was maintained at 40  C (Figure 1B). The maximum endoglycanase activity of ALK04124 was detected at 60  C, about 70% of the activity was maintained at 50  C and 30% at 40  C (Figure 2B). Maximum endoglycanase activity of ALK04237 was detected at 60  C, about 60% of the activity was maintained at 50  C and 40% at 40  C (Figure 3B). Maximum endoglycanase activity of ALK04265 was detected at 60  C, about 50% of the activity was maintained at 50  C and 30% at 40  C (Figure 4B). ALK04125 maximal endoglycanase activity was detected at 60  C, about 80% of activity was maintained at 50  C and 70% at 40  C (Figure 5B). Example 3 Release of Indigo Dye under Neutral Conditions Cellulase preparations derived from strains ALK04179, ALK04124, ALK04237, ALK04265 and ALK04125 (Examples 1 and 2) were tested for their ability to release dye under neutral conditions from tissue. denim-containing cotton denim to provide a stone-washed appearance. The commercial acid cellulase product Ecostone L (Primalco Ltd, Biotec, Finland) was used as a control. The denim fabric was obtained from Lauffenmuehl (Germany). The test tissue was prewashed 10 min. at 60  C with Ecostone A 200 (1 ml / liter, Primalco Ltd, Biotec, Finland). The tissue was then cut into 12x12 cm samples. The color on both sides of the tissue samples was measured as reflectance values with Minolta's CM 1000R L * a * b * Color Intensity Meter system (Osaka, Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os tratamentos com celulase foram efetuados no Launder-Ometer LP-2 (Atlas, Illinois, EUA) como segue. Cerca de 7 g de amostras de brim foram carregados para o recipiente de 1,2 litro que continha 200 ml de tampo de citrato/fosfato  0,05 M em pH 7, ou, tampo de citrato  0,05 M em pH 5,2. 0,06 ml de Berol 08  10% (Berol Nobel AS, Sucia) foi adicionado como um tensoativo.</span>Cellulase treatments were performed on the Launder-Ometer LP-2 (Atlas, Illinois, USA) as follows. About 7 g of denim samples were loaded into the 1.2 liter container containing 200 ml 0.05 M citrate / phosphate buffer at pH 7, or 0.05 M citrate buffer at pH 5. ,2. 0.06 ml 10% Berol 08 (Berol Nobel AS, Sweden) was added as a surfactant.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uma quantidade de esferas de ao foi adicionada em cada recipiente para auxiliar na remoo da fibra. Finalmente, as solues de celulase foram adicionadas ao recipiente como unidades de atividade de endoglicanase (Exemplo 1). Os recipientes foram ento fechados e carregados para um banho de Launder-Ometer  50C. O Launder-Ometer foi corrido a 42 rpm por 2 horas.</span>A quantity of steel balls were added to each container to aid in fiber removal. Finally, cellulase solutions were added to the container as endoglycanase activity units (Example 1). The containers were then closed and charged to a Launder-Ometer bath at 50  C. The Launder-Ometer was run at 42 rpm for 2 hours.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aps a remoo das amostras dos recipientes, elas foram embebidas por 10 min em 200 ml de NaOH  0,01, e enxaguadas por 10 min com gua gelada. As amostras foram ento secas por 1 hora  105C e secas ao ar durante a noite. A cor de ambos os lados das amostras foi medida com o Medidor de Intensidade da Cor da Minolta. Os resultados das medies da cor dos tecidos de brim tratados so mostrados na Tabela I. Tabela I. Medio da Cor de Tecidos de Brim Tratados com Diferentes Preparaes de Celulase Tabela I - continuao _____________________________________________ Para comparar o aspecto final dos tecidos de brim aps a lavagem com as diferentes preparaes de celulases, a cor de ambos os lados (avesso e lado direito) foi medida. A partir dos resultados mostrados na Tabela I, pode ser visto que as unidades de branqueamento e de pigmentao azul so claramente aumentadas sobre o lado direito das roupas lavadas com as preparaes de celulases ALK04179, ALK04124, ALK04237 e ALK04125, mostrando um bom efeito de lavado com pedras. A unidade de pigmentao azul foi tambm aumentada sobre o lado direito do tecido lavado com a preparao de ALK04265, porm no houve nenhum aumento na unidade de branqueamento. Isto  provavelmente porque a enzima no funciona neste pH, porm ao mesmo tempo causa muita colorao de volta. No houve nenhum efeito de lavagem com pedras sobre o tecido com o produto cido comercial Ecostone L em pH 7, nesta atividade de ECU.</span>After removal of samples from the containers, they were soaked for 10 min in 200 ml 0.01 NaOH, and rinsed for 10 min with ice water. The samples were then dried for 1 hour at 105  C and air dried overnight. The color on both sides of the samples was measured with the Minolta Color Intensity Meter. The results of the color measurements of treated denim fabrics are shown in Table I. Table I. Color Measurement of Denim Fabrics Treated with Different Cellulase Preparations Table I - continued _____________________________________________ To compare the final appearance of denim fabrics after washing With the different cellulase preparations, the color on both sides (wrong side and right side) was measured. From the results shown in Table I, it can be seen that the bleaching and blue pigmentation units are clearly enlarged on the right side of the laundry washed with the ALK04179, ALK04124, ALK04237 and ALK04125 cellulose preparations, showing a good wash effect. with stones. The blue pigmentation unit was also increased on the right side of the fabric washed with the preparation of ALK04265, but there was no increase in the bleaching unit. This is probably because the enzyme does not work at this pH, but at the same time causes a lot of back staining. There was no stonewashing effect on tissue with the commercial acid product Ecostone L at pH 7 in this ECU activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Neste estudo, a colorao de volta sobre o avesso do tecido  usada como uma indicao do grau de colorao de volta sobre o lado direito do tecido. Para quantificar o nvel de colorao de volta, a cor foi medida sobre o avesso do tecido antes e aps o tratamento com a celulase. Conforme mostrado na Tabela I, quando as quantidades de ECU so as mesmas, no houve praticamente nenhuma colorao de volta nos tecidos tratados com as preparaes de ALK04179, ALK04124, ALK04237 e ALK04125 quando comparados aos tecidos tratados com as preparaes de ALK04265 e Ecostone L (pH 5,2 e 7).</span>In this study, back staining on the wrong side of the tissue is used as an indication of the degree of staining back on the right side of the tissue. To quantify the back staining level, color was measured on the wrong side of the tissue before and after treatment with cellulase. As shown in Table I, when the amounts of ECU are the same, there was virtually no back staining in tissues treated with the preparations of ALK04179, ALK04124, ALK04237 and ALK04125 as compared to tissues treated with the preparations of ALK04265 and Ecostone L ( pH 5.2 and 7).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 4 Liberao do Corante em Condies Neutras, Sem Berol A determinao experimental foi conforme descrita no Exemplo 3, exceto que nenhum Berol foi usado. Os resultados a partir das medies de cor dos tecidos de brim tratados so mostrados na Tabela II.</span>Example 4 Dye Release Under Neutral Conditions, No Berol Experimental determination was as described in Example 3, except that no Berol was used. Results from color measurements of treated denim fabrics are shown in Table II.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela II. Medio da Cor de Tecidos de Brim Tratados com Diferentes Preparaes de Celulase - sem Berol continuao da tabela !1 _____________________________________________ Quando comparados com os resultados obtidos com a incluso de Berol (Exemplo 3), os dados na Tabela II mostram que quase o mesmo efeito de lavagem com pedras pode ser obtido com as preparaes de celulase de ALK04179, ALK04124, ALK04237 e ALK04125 na ausncia do agente auxiliar Berol.</span>Table II Color Measurement of Jeans Fabrics Treated with Different Cellulase Preparations - Berol-Free continued from Table 1 _____________________________________________ When compared to the results obtained with the inclusion of Berol (Example 3), the data in Table II show that almost the same effect of Stone washing can be obtained with the cellulase preparations of ALK04179, ALK04124, ALK04237 and ALK04125 in the absence of Berol auxiliary agent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 5 Colorao de volta na lavagem do brim com diferentes celulases Na literatura,  descrito que a colorao de volta  dependente do pH e/ou do tipo de enzima. Entretanto, conforme mostrado aqui, foi verificado que a colorao de volta depende somente indiretamente do pH (Figuras 6A e 6B e 7A e 7B).</span>Example 5 Back staining in the washing of jean with different cellulases In the literature, it is described that back staining is pH and / or enzyme type dependent. However, as shown here, it has been found that backstaining depends only indirectly on pH (Figures 6A and 6B and 7A and 7B).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Duas preparaes de celulase neutra a partir de ALK04237 e a partir de ALK04265 e o produto de celulase cida Ecostone L foram estudados na lavagem de brim em pequena escala com uma dosagem igual de enzima em pH 5 e pH 7. 0 efeito de lavagem com pedras foi determinado por medio do aumento do branqueamento e da pigmentao azul como unidades de reflecncia sobre o lado direito do tecido, e a colorao de volta (deposio novamente de ndigo sobre a superfcie das fibras) foi determinada como o aumento da pigmentao azul e a diminuio do branqueamento sobre o avesso. Em pH 7, as celulases neutras a partir de ALK04237 causaram um claro aumento na pigmentao azul e no branqueamento sobre o lado direito, e nenhuma colorao de volta foi observada (Figuras 6A e 6B). Um efeito de lavagem com pedras similar foi verificado em pH 5, porm com uma ligeira colorao de volta. Em pH 7, a outra celulase neutra, ALK04265, avivou a pigmentao azul sobre o lado direito, porm coloriu de volta intensivamente sobre o avesso. Em pH 5, efeitos similares foram obtidos com ambas as preparaes de ALK04265 e ALK04237. Em pH 7, a celulase cida no coloriu de volta ou conferiu um branqueamento sobre o lado direito (quando usando-se dosagens similares de atividade de endoglicanase, como com o ALK04265 e o ALK04237, Figuras 7A e 7B, 1 x dosagem), provavelmente porque ela no funciona neste pH. Por outro lado, em pH 5, o branqueamento e a pigmentao azul foram aumentados sobre o lado direito e a colorao de volta estava claramente perceptvel sobre o avesso. Com base nestes resultados, a colorao de volta pode ocorrer em ambos os valores de pH, dependendo da preparao de celulase usada.</span>Two neutral cellulase preparations from ALK04237 and from ALK04265 and the Ecostone L acid cellulase product were studied in small-scale denim washing with an equal enzyme dosage at pH 5 and pH 7. The stone wash effect was determined by measuring the increase in bleaching and blue pigmentation as reflectance units on the right side of the fabric, and back staining (again indigo deposition on the fiber surface) was determined as the increase in blue pigmentation and the decrease bleaching inside out. At pH 7, neutral cellulases from ALK04237 caused a clear increase in blue pigmentation and bleaching on the right side, and no backstaining was observed (Figures 6A and 6B). A similar stonewashing effect was found at pH 5, but with a slight back color. At pH 7, the other neutral cellulase, ALK04265, brightened blue pigmentation on the right side, but stained back intensively on the reverse side. At pH 5, similar effects were obtained with both preparations of ALK04265 and ALK04237. At pH 7, acid cellulase did not stain back or bleach on the right side (when using similar dosages of endoglycanase activity as with ALK04265 and ALK04237, Figures 7A and 7B, 1 x dosage), probably because it does not work at this pH. On the other hand, at pH 5, bleaching and blue pigmentation were increased on the right side and back staining was clearly noticeable on the reverse side. Based on these results, backstaining may occur at both pH values, depending on the cellulase preparation used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 6 Uso das Preparaes de Enzimas Contendo Celulases Neutras no Bio~ Acabamento de Tecido Urdido Contendo Algodo O tecido urdido com 100% de algodo foi submetido ao tratamento com as celulases de ALK04237 (Exemplo 1) e ALK04467 no Launder-Ometer. O ALK04467  um mutante por UV com maior atividade de celulase derivado de ALK04125. O tecido urdido com 100% de algodo (obtido da Pirkanmaan Uusi Vrjm Ltd) foi pr-tratado como no Exemplo 7. As condies de tratamento com celulase eram conforme descritas no Exemplo 3, exceto que nenhum Berol foi usado e que a razo de lquido era 1:15 (volume de lquido por peso de tecido). As celulases foram dosadas como unidades de atividade de ECU (Exemplo 1).</span>Example 6 Using Enzyme Preparations Containing Neutral Cellulases in the Bio ~ Woven Fabric Finishing Containing Cotton The 100% cotton woven fabric was subjected to treatment with the cellulases of ALK04237 (Example 1) and ALK04467 in Launder-Ometer. ALK04467 is a UV mutant with higher cellulase activity derived from ALK04125. 100% cotton woven fabric (obtained from Pirkanmaan Uusi Vrjm Ltd) was pretreated as in Example 7. The cellulase treatment conditions were as described in Example 3 except that  no Berol was used and the ratio of net was 1:15 (volume of liquid by weight of tissue). Cellulases were dosed as ECU activity units (Example 1).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os seguintes mtodos foram usados para a avaliao do efeito das preparaes de enzimas no bio-acabamento do tecido de algodo: A perda de peso dos tecidos tratados foi definida como a percentagem a partir do peso do tecido antes e aps o teste (antes de pesar, os tecidos foram condicionados em uma atmosfera de 21+2C e 50+5% de UR). A avaliao do efeito de limpeza da superfcie dos tecidos tratados com a enzima foi efetuada por um jri consistindo em trs pessoas. Os tecidos foram classificados em uma classificao de 1 a 5, onde 5 proporcionou uma superfcie limpa. O mtodo de Esfregao de Martindale (SFS-4328) foi usado para a avaliao de formao de bolas. A formao de bolas foi avaliada por um jri aps 200 e 2000 ciclos de desgaste (1 = muitas bolas, 5 = nenhuma bola).</span>The following methods were used to evaluate the effect of enzyme preparations on cotton fabric bio-finishing: Weight loss of treated fabrics was defined as the percentage from the weight of the tissue before and after the test (before weighing). , the tissues were conditioned in an atmosphere of 21 + 2  C and 50 + 5% RH). Evaluation of the surface cleaning effect of enzyme-treated tissues was performed by a jury consisting of three persons. The fabrics were rated at a rating of 1 to 5, where 5 provided a clean surface. Martindale Scrubbing Method (SFS-4328) was used for the evaluation of ball formation. Ball formation was evaluated by a jury after 200 and 2000 wear cycles (1 = many balls, 5 = no balls).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Na Tabela III  mostrado que o tratamento do tecido de algodo com as preparaes de celulase de ALK04237 e ALK04467 resulta em uma boa limpeza da superfcie e em uma reduo acentuada na tendncia  formao de bolas em ambos os pH's 5 e 7.</span>In Table III it is shown that treatment of the cotton fabric with the cellulase preparations of ALK04237 and ALK04467 results in good surface cleaning and a marked reduction in the tendency to ball formation at both pH 5 and 7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela III. Perda de peso, efeito da limpeza da superfcie e tendncia  formao de bolas dos tecidos de algodo tratados com as celulases neutras no Launder-Ometer.  *2  Q  OD CD t Tj-_  - CO 0D  0_   CO -  CM JD -" &lt;" CO~ CO CO  Tf" Tf" CO  -" CO CO CO CO r~ Tf"  XJ</span>Table III. Weight loss, surface cleaning effect and tendency to ball formation of neutral cellulasis treated cotton fabrics in Launder-Ometer.  * 2  Q  OD CD t Tj-_  CO- CO 0D  0_  CO -  CM JD - "&lt;" CO ~ CO CO  Tf "Tf" CO  - "CO CO CO CO r ~ Tf " XJ</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">0 CO</span>0 CO</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">S I to y 1 S O 5 O O O N- h~ O CM CM O O CD o w co CM co U_ CM -' Tf" Tf' co" CO  Tf" Tf" Tf" Tf r-' CO Tf" CO CO~ t~~ CO  N  a. m c S jE 'o (0 t TQ 0 * CL B 3  jg oioiotocooocoiocoooooooo LU T5 T~" co" co" cm cm" t- MT Tf" CO" CO" -" CO Tf" CM" CM r- Tf co rj L_  o Q. CO  - Cl ^ 0 cocmcmot-^tooo to co oo ^ v~ co  3 O CM" co" t-' T-" o" MT C0 CO Tf O CsT CO" O" O" Tf sz 0. lOLOlOlOIOIOlOlOlOlOh-h-N-r^-N-Kr^. sz o Q.</span>SI to y 1 SO 5 OOO N- h ~ O CM CM OO CD ow co CM co U_ CM - 'Tf "Tf' co" CO  - Tf "Tf" Tf "Tf r- 'CO Tf" CO CO ~ t ~~ CO  N a. mc S jE 'o (0 t TQ 0 - * CL B 3  jg oioiotocooocoiocooooooo LU T5 T ~ "co" co "cm" cm "t-" MT Tf "CO" CO "-" CO Tf "CM" CM r- Tf co rj L_  o Q. CO  - Cl ^ 0 cocmcmot- ^ tooo to cooo ^ v ~ co   3 The CM" co "t- 'T-" o "MT C0 CO Tf O CsT CO "O" O "Tf sz 0.1OLOLOLOIOOOLOOLO1 -HNr2 -N-Kr2. Sz o Q.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E  I  r    CM CM CM CM CM      CM CM</span>E  I  r    CM CM CM CM CM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E  CO (0  oooo o o o o oooo o o oooo oooo oooo o Q i (M N ' i CM Tf CM Tf i CM Tf CM Tf iCM ,2 h- h~ N- h- h- h- i I ~- h- S, CO CO CD CD CO CO CD CD CO CO  CO (O CO</span>E  CO (0 oooo oooo oooo oo oooo oooo oooo Qi (MN 'CM CM Tf CM Tf i CM Tf CM Tf iCM, 2 h- h ~ N- h- h- h- i ) ~ - h- S, CO CO CD CD CO CO CD CD CO CO  CO (CO</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CO CM CM O- O- CM CM ' O" CM CM M" ' CM I- MT t ^  Tf Tf Tf M" Tf -^f M- Tf S OOOO OOOO OOOO O C I I I I 1 I 1 I  J I I _l - ,&lt;&lt;&lt;&lt;,&lt;&lt;&lt;&lt;,&lt;&lt;&lt;&lt;&lt; o 8    CN jQ ' CO CO</span>CO CM CM O- O- CM CM  'O "CM CM M"'  CM I- MT t ^    Tf Tf Tf M "Tf - ^ f M- Tf S OOOO OOOO OOOO OCIIII 1 I 1 I  JII _l -, &lt;&lt;&lt;&lt;, &lt;&lt;&lt;&lt;, &lt;&lt;&lt;&lt;  &lt;o 8   CN jQ  'CO CO</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CD  O CO</span>CD  The CO</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CO CO O -= CO o g - O o   00 LL N t t (O</span> CO CO O - = CO o g - o o  00 LL N t t (O</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CO</span>CO</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">N  c"  ,  CO ^ TJ &lt;D Q. O 3 4 ro co io co LU  '" CN co" co  CD o Q. w - O.</span>N  c ",  ^ CO ^ TJ &lt;D Q. 3 3 ro coo co LU   "" CN co "co  CD o Q. w - O.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13 oj O CM O F tj  cm co sz Q_ h h- h- SZ o Cl E</span>13 oj O CM O F tj  cm sz Q_ h h- h- SZ o Cl E</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CD</span>CD</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I CN CN CM</span>I CN CN CM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E</span>AND</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">O CD</span>The CD</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CO O) c&gt; CO (0 co o o o ^ o o o o .E Q N CM ' c o o ' iffl N- h&gt; t..</span> CO O) c&gt; CO (0 co o o o o o o o .E Q N CM c 'o o' iffl N- h&gt; t ..</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">= S, CO CD CD  CO CM ' ' (0 2: N N- N- ) 5 o O O</span>= S, CO CD CD - CO CM  '' (0 2: N N- N- ) 5 o O O</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CO 2. I I I h 0- &lt; &lt; &lt;</span>CO 2. I I I h  0- &lt;&lt;&lt;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 7 Uso das Preparaes de Enzimas Contendo Ceiulases Neutras da Inveno no Bio-Acabamento 7a. Uso das preparaes de enzimas no bio-acabamento de tecido urdido e malha.</span>Example 7 Use of Enzyme Preparations Containing Neutral Cellules of the Invention in Bio-Finishing 7a. Use of enzyme preparations in bio-finishing of woven and knitted fabric.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Um tecido urdido com 100% de algodo ou uma malha com 100% de algodo  submetido ao tratamento com as ceiulases da inveno (Exemplo 1), em uma lavadora com tambor, semi-industrial (Esteri 20 HS-P). As condies de tratamento so como seguem; A. Pr-tratamento (somente para os tecidos urdidos) 60C, 10 minutos, Ecostone A200 (Primalco Ltd, Biotec, Finlndia) 1 ml/l de gua. B. Tratamento com a enzima temperatura de 50-6QC, pH 7; razo de lquido de 5-20:1 (volume de lquido por peso de tecido); tempo de tratamento de 20-90 minutos, preferivelmente 30-60 minutos; e dosagem da enzima de 50-900 nkat/g de tecido ou malha, preferivelmente 200-600 nkat/g de tecido ou malha. C. Tratamento "Aps a Lavagem" 40C, 10 minutos, detergente alcalino D. Tratamento de Secagem Os seguintes mtodos padro so usados para a avaliao do efeito de limpeza da superfcie das preparaes de enzimas; Mtodo de Esfregao de Martindale (SFS-4328) e o Teste da Durabilidade da Lavagem de Roupas (SFS-3378), O tratamento com as preparaes de celulase da inveno resulta em um efeito de limpeza da superfcie, em um aperfeioamento na maciez e na suavidade do tecido e da malha, e em uma reduo na tendncia  formao de bolas. 7b. Uso das preparaes de enzimas no acabamento de tecidos e malhas de "lyoceir.</span>A 100% cotton woven fabric or 100% cotton knit is subjected to treatment with the inventive cellulases (Example 1) in a semi-industrial drum washer (Esteri 20 HS-P). Treatment conditions are as follows; A. Pretreatment (only for woven fabrics) 60  C, 10 minutes, Ecostone A200 (Primalco Ltd, Biotec, Finland) 1 ml / l water. B. Enzyme treatment temperature 50-6  C, pH 7; 5-20: 1 liquid ratio (volume of liquid by weight of tissue); treatment time 20-90 minutes, preferably 30-60 minutes; and enzyme dosage of 50-900 nkat / g tissue or mesh, preferably 200-600 nkat / g tissue or mesh. C. "After Washing" Treatment 40  C, 10 minutes, alkaline detergent D. Drying Treatment The following standard methods are used for the evaluation of the surface cleaning effect of enzyme preparations; Martindale Scrubbing Method (SFS-4328) and the Laundry Wash Durability Test (SFS-3378). Treatment with the cellulase preparations of the invention results in a surface cleaning effect, an improvement in softness and softness of the fabric and mesh, and a reduction in the tendency to ball formation. 7b. Use of enzyme preparations in finishing lyoceir fabrics and meshes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de celulase da inveno podem ser usadas no controle da fibrilao e nos diferentes processos de acabamentos de tecidos e malhas com 100% de "lyocell" e as suas combinaes. As seguintes condies de tratamento em uma lavadora com tambor, semi-industrial (Esteri 20 HS-P), so usadas a fim de criar o efeito de cor de pssego sobre o tecido de "lyocell": A. 2,5 g/l de carbonato de sdio; 60C, tempo de tratamento de 60 minutos; B. Enxaguadura; C. Tratamento com enzima: temperatura de 50-60C, pH 7, razo de lquido de 5-20:1, tempo de tratamento de 40-120 minutos, preferivelmente 45-90 minutos, e uma dosagem de enzima de 100-1500 nkat/g de tecido, preferivelmente 400-800 nkat/g de tecido; D. Ps-tratamento: Lavagem com detergente alcalino a 40C por 10 minutos; E. Enxaguadura; e F. Secagem. O resultado  um efeito de revestimento de cor de pssego.</span>The cellulase preparations of the invention may be used in the control of fibrillation and in the different processes of 100% lyocell knitting and fabric finishing and combinations thereof. The following treatment conditions in a semi-industrial drum washer (Esteri 20 HS-P) are used to create the peach-colored effect on lyocell fabric: A. 2.5 g / l sodium carbonate; 60  C, treatment time 60 minutes; B. rinse; C. Enzyme treatment: temperature 50-60  C, pH 7, liquid ratio 5-20: 1, treatment time 40-120 minutes, preferably 45-90 minutes, and an enzyme dosage of 100- 1500 nkat / g tissue, preferably 400-800 nkat / g tissue; D. Posttreatment: Wash with alkaline detergent at 40  C for 10 minutes; E. rinse; and F. Drying. The result is a peach-colored coating effect.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 8 Uso das Preparaes de Enzimas no Biotratamento com pedras As roupas de brim foram submetidas ao tratamento com as preparaes de celulase neutra (Exemplo 1) em uma lavadora com tambor, semi-industrial (Esteri 20 HS-P), para dar s roupas um aspecto de lavadas com pedras. Cerca de 1,0 kg de roupas de brim (continham dois tipos diferentes de tecido) foi usado por carga da mquina.</span>Example 8 Using Enzyme Preparations in Stone Biotreatment Denim garments were subjected to treatment with neutral cellulase preparations (Example 1) in a semi-industrial drum washer (Esteri 20 HS-P) to give the garments. a stone washed aspect. About 1.0 kg of denim clothing (contained two different types of fabric) was used per machine load.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As condies de tratamento eram como seguem: A. Desengomagem. 100 litros de gua, 60C, 10 minutos; 100 ml de Ecostone A200 (Primalco Ltd, Biotec, Finlndia). B. Tratamento com Celulase. 100 litros de gua, 50C, 45 minutos; 10 g de Berol 08 (Berol Nobel AS, Sucia); 30 g de cido ctrico + 128 g de Na2HP04 x 2 H20 para proporcionar um pH 7.</span>The treatment conditions were as follows: A. Degumming. 100 liters of water, 60  C, 10 minutes; 100 ml of Ecostone A200 (Primalco Ltd, Biotec, Finland). B. Cellulase Treatment. 100 liters of water, 50  C, 45 minutes; 10 g Berol 08 (Berol Nobel AS, Sweden); 30 g citric acid + 128 g Na 2 HPO 4 x 2 H 2 O to provide a pH 7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de celulase neutra foram dosadas como unidades de atividade de endoglicanase (ECU, Exemplo 1): 1. ALK04237, 260 ECU/g de pea de roupa 2. ALK04179, 260 ECU/g de pea de roupa 3. ALK04124, 300 ECU/g de pea de roupa 4. ALK04125, 250 ECU/g de pea de roupa C. Ps-lavagem. Lavagem com detergente alcalino, 40C, 10 minutos. D. Secagem.</span>Neutral cellulase preparations were dosed as endoglycanase activity units (ECU, Example 1): 1. ALK04237, 260 ECU / g of garment 2. ALK04179, 260 ECU / g of garment 3. ALK04124, 300 ECU / g of garment 4. ALK04125, 250 ECU / g of garment C. Post-wash. Wash with alkaline detergent, 40  C, 10 minutes. D. Drying.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os resultados foram avaliados por aspecto visual das roupas, e por medio da cor como valores de reflecncia com o sistema Medidor de Intensidade da Cor CM 1000R L*a*b da Minolta (Tabela IV). Um bom efeito de lavado com pedras foi obtido com todas estas roupas tratadas com celulase. Nenhuma colorao de volta (examinada sobre o lado de dentro da pea de roupa) pode ser vista visualmente em quaisquer destas peas de roupas tratadas com celulase. A partir dos resultados das medies da cor mostradas na Tabela IV, pode ser visto que as unidades de branqueamento e pigmentao azul so claramente aumentadas sobre o lado de fora das peas de roupas lavadas com as preparaes de celulase neutra, mostrando um bom efeito de lavadas com pedras.</span>Results were evaluated by visual appearance of clothing, and by color measurement as reflectance values with the Minolta CM 1000R L * a * b Color Intensity Meter system (Table IV). A good stonewashing effect was obtained with all these cellulase treated clothes. No back staining (examined on the inside of the garment) can be visually seen on any of these cellulase treated garments. From the results of the color measurements shown in Table IV, it can be seen that the bleaching and blue pigmentation units are clearly enlarged on the outside of garments washed with neutral cellulase preparations, showing a good wash effect. with stones.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela IV. Medio da Cor das Roupas de Brim com Diferentes Preparaes de Celulase Tabela IV - continuao_______________________________________________ L = Unidade de branqueamento da pea de roupa aps o tratamento (quanto maior o valor, mais clara a pea de roupa), b = Unidade de pigmentao azul aps o tratamento (quanto mais negativo o valor, mais pigmentao azul na pea de roupa).</span>Table IV. Color Measurement of Jeans with Different Cellulase Preparations Table IV - continued _______________________________________________ L = Garment bleaching unit after treatment (the higher the value, the lighter the garment), b = Blue pigmentation unit after the treatment. treatment (the more negative the value, the more blue pigmentation on the garment).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 9 Purificao das Celulases Neutras O meio de desenvolvimento concentrado a partir de ALK04237 foi fracionado a 7C sobre DEAE Sepharose CL6B com um gradiente linear de NaCI de zero a 0,5 M em Tris/HCI a 25 mM, pH 7,2. Quatro picos de atividade de endoglicanase em pH 4,8 foram encontrados. O Pico I, contendo cerca de 10 % da ECU recuperada, eluiu em NaCI  cerca de 150 mM, o Pico II (cerca e 30 % de ECU) em NaCI a 230 mM, o Pico III (cerca de 20% de ECU) em NaCI a 270 mM e o Pico IV (cerca de 40 % de ECU) em NaCI  320 mM. A Tabela V mostra os resultados quando estes picos foram testados quanto a sua utilidade no biotratamento com pedras em pH neutro e 50C.</span>Example 9 Purification of Neutral Cellulase Development medium concentrated from ALK04237 was fractionated at 7  C over DEAE Sepharose CL6B with a linear gradient of zero to 0.5 M NaCI in 25 mM Tris / HCl, pH 7.2. . Four peaks of endoglycanase activity at pH 4.8 were found. Peak I, containing about 10% of the recovered ECU, eluted in about 150 mM NaCl, Peak II (about 30% ECU) in 230 mM NaCI, Peak III (about 20% ECU) in 270 mM NaCl and Peak IV (about 40% ECU) in 320 mM NaCI. Table V shows the results when these peaks were tested for their utility in biotreatment with stones at neutral pH and 50  C.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estes resultados mostram que tanto em uma base de ECU quanto em uma base de protena total, o Pico II era mais efetivo do que qualquer outro pico ou do que o concentrado no-fracionado. Uma mistura dos Picos I e II contendo 70 ECU de cada/g de brim foi tambm testada. Isto resultou em um valor de L (direito) de 7,3 e b (avesso) de 2,5. Assim, esta mistura era mais efetiva do que qualquer pico sozinho. O procedimento de purificao foi escalonado para obter amostras homogneas de algumas das protenas desejadas nestes picos. 0 meio de desenvolvimento de ALK04237 concentrado (4,5 litros) foi fracionado com sulfato de amnio. As protenas que se precipitaram entre 17 g e 42 g de sulfato de amnio por 100 ml de concentrado foram suspensas em 0,9 litro de Tris/HCI a 25 mM, pH 7,2, contendo EDTA a 0,25 mM, e ento diludas com gua at uma condutividade de 4 mS/cm, e ajustadas com NaOH a 1M para pH 8,0. A soluo resultante (cerca de 45 litros) foi bombeada a 150 ml/min atravs de uma coluna de 6,3 litros de DEAE-Sepharose FF  temperatura ambiente. A atividade de endoglicanase no Pico I no se ligou sob estas condies. As protenas ligadas foram eludas  110 ml/min com um gradiente linear de NaCI de 0,0 at 0,5 M, em 20 litros de Tris/HCI a 25 mM, pH 7,7, contendo EDTA  0,25 mM. A endoglicanase no Pico II eluiu em torno de 14 mS/cm. Em vez dos Picos III e IV separados, vistos com as preparaes em pequena escala em DEAE no espao frio, um pico nico, chamado Pico lll/IV, eluiu em torno de 25 mS/cm.    &gt;    | -5 k   8 | - - V)    * 2 I 5  3 2  |   c a   c   5 (/) C  &gt; (1) )    '8, '0-0 0  . _ 3 - W 3  S (0    S I S   ^ 32 /   k c c  4=  xj  '  &lt;  3* c 2  - @   I rv:    -- c -C  3   Cl - J c &gt;  (  &amp; I I  LLI   D - 5 8 I  I g   ? 2    !  8 g 2 8    : 8 '&amp;  5 co  2 a 2   I g   C .   F XJ   ^  _   &lt;3 F   S m s 1  s *  " :    c r5 tj     ^ )  2  V S 3 ~  '0 8 Q m ?   % L-  J=  .      8 &gt;,  -S 2.   C ( ^ V- |s^  2   2 -  br G3  C 31   k   Q- c    - 5=    -D 3 i %       6 - , C   m C , 5   2  &lt;2 '   '    2 3 ! 8 I I '1 &gt; -   ==  2 _ hd  S   2  m     I |  ^ S w &lt;2  to -       1   As protenas no Pico II (3,5 litros) foram precipitadas com sulfato de amnio (450 g/litro) e suspensas em 170 ml de PIPES/KOH a 25 mM, pH 6,0, contendo EDTA a 1 mM. As pores deste material foram transferidas para acetato de sdio a 25 mM, pH 4,0, contendo EDTA a 1 mM, por filtrao em gel sobre uma coluna de 5 x 29 cm de G25 Sephadex (grosseira), e ento fracionadas sobre SP-Sepharose A Figura 8 mostra o resultado que foi obtido quando 11,7 g destas protenas foram aplicados a uma coluna de 4,5 x 31 cm de SP-Sepharose em acetato de sdio a 25 mM, pH 4,0,contendo EDTA a 1 mM em 150 ml/h, e a coluna desenvolveu-se a 75 ml/h com um gradiente linear de NaCI de 0,0  0,4 M em 3,4 litros do mesmo tampo. A maior parte da endoglicanase eluiu em NaCI  0,2 M. O ensaio modificado descrito no Exemplo 10 foi usado. Quando as fraes ativas foram armazenadas a 7C, um precipitado cristalino surgiu nelas e continha quase toda a atividade de endoglicanase. As fraes ativas (15 ml), nas quais a cristalizao era lenta, foram induzidas para formar cristais por semeadura com 30  de suspenso de fraes j contendo os cristais. Aps 2 a 3 dias, os cristais foram coletados por centrifugao, lavados com PIPES/KOH a 25 mM, pH 6,0, contendo EDTA a 1 mM, e dissolvidos em Tris/HCI a 25 mM, pH 7,2, contendo EDTA a 0,25 mM. A anlise por SDS-PAGE mostrou que os cristais lavados continham uma protena virtualmente homognea, com uma massa molecular aparente prxima a 20 kDa (o erro nas estimativas de SDS-PAGE da massa molecular  pelo menos  10%, e pode ser muito maior para as protenas no usuais). Esta protena  chamada a celulase de 20K. A protena de contaminao podera tambm ser removida por filtrao em gel sobre G50 Sephadex em PIPES/KOH a 50 mM, pH 6,0, contendo EDTA a 1 mM. Um exemplo disto  mostrado na Figura 9, onde os cristais no lavados foram purificados por filtrao em gel. A atividade de endoglicanase co-eluiu com a protena de 20 kDa bem aps o volume de citocromo c (11,2 kDa), mostrando que esta protena de 20 kDa  retardada de maneira anormal por interao com o Sephadex.</span>These results show that on both an ECU base and a total protein base, Peak II was more effective than any other peak or unfractionated concentrate. A mixture of Peaks I and II containing 70 ECU each / g of denim was also tested. This resulted in an L (right) value of 7.3 and b (inside out) of 2.5. Thus, this mixture was more effective than any peak alone. The purification procedure was scaled to obtain homogeneous samples of some of the desired proteins at these peaks. Concentrated ALK04237 development medium (4.5 liters) was fractionated with ammonium sulfate. Proteins that precipitated between 17 g and 42 g of ammonium sulfate per 100 ml of concentrate were suspended in 0.9 liter of 25 mM Tris / HCl, pH 7.2, containing 0.25 mM EDTA, and then diluted. with water to a conductivity of 4 mS / cm, and adjusted with 1 M NaOH to pH 8.0. The resulting solution (about 45 liters) was pumped at 150 ml / min through a 6.3 liter DEAE-Sepharose FF column at room temperature. Endoglycanase activity at Peak I did not bind under these conditions. Bound proteins were eluted at 110 ml / min with a linear 0.0 to 0.5 M NaCl gradient in 20 liters of 25 mM Tris / HCl, pH 7.7, containing 0.25 mM EDTA. Endoglycanase at Peak II eluted at around 14 mS / cm. Instead of separate Peaks III and IV, seen with small-scale DEAE preparations in cold space, a single peak, called Peak III / IV, eluted around 25 mS / cm.   &gt;    | -5 k    8 | - - V)    *  2 I 5  3 2  |   ca   c   5 (/) C &gt; (1) )    '8,' 0-0 0  . _ 3 - W 3  S (0    SIS   ^ 32 /    kcc  4 =  xj  ' - &lt;  3 * c 2  - @    I rv:    -- c -C  3   Cl -  J c&gt;  (  &amp; II  LLI   D - 5 8 I  I g  ? 2   !  8 g 2 8    : 8 '&amp;  5 co  2 a 2   I g  g C .   F XJ   ^  _   &lt;3 F   S ms 1 s * ":  - c r5 tj    ^ )  2  VS 3 ~  '0 8 Q m?  % L-  J =  .      8&gt;,  -S 2.  C ( ^ V- | s ^  2   2 -  br G3 C 31   k   Q- c    - 5 =    -D 3 i%       6 -,  C   m C , 5 -  2  &lt;2 '   '    2 3! 8 II '1&gt; -   ==  2 _ hd S    2  m    I |  ^ S w &lt;2  to -       1   Peak II proteins (3.5 liters) were precipitated with ammonium sulfate (450 g / liter) and sus in 170 ml 25 mM PIPES / KOH pH 6.0 containing 1 mM EDTA Portions of this material were transferred to 25 mM sodium acetate pH 4.0 containing 1 mM EDTA by filtration. gel on a 5 x 29 cm column of G25 Sephadex (coarse), and then fractionated over SP-Sepharose. Figure 8 shows the result that was obtained when 11.7 g of these proteins were applied to a 4 m column. 5 x 31 cm SP-Sepharose in 25 mM sodium acetate, pH 4.0, containing 1 mM EDTA at 150 ml / hr, and the column was developed at 75 ml / hr with a linear NaCl gradient 0.0 to 0.4 M in 3.4 liters of the same buffer. Most endoglycanase eluted in 0.2 M NaCl. The modified assay described in Example 10 was used. When the active fractions were stored at 7  C, a crystalline precipitate appeared in them and contained almost all endoglycanase activity. Active fractions (15 ml) in which crystallization was slow were induced to form crystals by sowing with 30  suspension of fractions already containing the crystals. After 2 to 3 days, the crystals were collected by centrifugation, washed with 25 mM PIPES / KOH, pH 6.0, containing 1 mM EDTA, and dissolved in 25 mM Tris / HCI, pH 7.2, containing EDTA. at 0.25 mM. SDS-PAGE analysis showed that the washed crystals contained a virtually homogeneous protein with an apparent molecular mass close to 20 kDa (the error in molecular weight SDS-PAGE estimates is at least  10%, and may be much larger). for unusual proteins). This protein is called 20K cellulase. Contamination protein could also be removed by gel filtration over Sephadex G50 in 50 mM PIPES / KOH, pH 6.0, containing 1 mM EDTA. An example of this is shown in Figure 9, where unwashed crystals were purified by gel filtration. Endoglycanase activity co-eluted with the 20 kDa protein well after cytochrome c volume (11.2 kDa), showing that this 20 kDa protein is abnormally retarded by interaction with Sephadex.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As protenas no Pico lll/IV foram precipitadas com sulfato de amnio e transferidas para acetato de sdio a 25 mM, pH 4,0, contendo EDTA  1 mM, na mesma forma que a descrita para as protenas no Pico II. Com a transferncia para o acetato de sdio a 25 mM, pH 4,0, um grande precipitado formou-se e foi descartado. O sobrenadante ativo foi fracionado sobre SP-Sepharose. Na baixa carga de protena (por exemplo, 200 mg de protena para uma coluna de 2,5 x 11 cm conforme mostrado na Figura 10, a maior parte da atividade de endoglicanase ligou-se  coluna e foi eluda com um gradiente de NaCI em torno de NaCI a 50 mM. Este pico ativo foi seguido por um segundo pico de protena inativa. A anlise por SDS-PAGE mostrou que os picos ativos e inativos ambos continham diversas protenas, incluindo as protenas com massas moleculares aparentes prximas a 50 kDa, que poderam no ser distinguidas umas das outras por SDS-PAGE. Ambos os picos foram adicionalmente purificados por cromatografia sobre Phenyl Sepharose, As fraes ativas (fraes 15 a 18 na Figura 10) foram combinadas, ajustadas para PIPES/KOH a 50 mM, pH 6,0 (por adio de PIPES/KOH a 0,25 M,pH 6,0) e 15 g % de sulfato de amnio (por adio de sulfato de amnio slido), e aplicadas a uma coluna de 1,5 x 8,5 cm de Phenyl Sepharose equilibrada com PIPES/KOH a 25 mM, pH 6,0, contendo EDTA a 1 mM e 15 g % de sulfato de amnio. A coluna foi desenvolvida com um gradiente linear de 15 a 0 g % de sulfato de amnio em 104 ml de PIPES/KOH a 25 mM, pH 6,0. Aps o final do gradiente, a coluna foi adicionalmente lavada com PIPES/KOH a 25 mM pH 6,0. Dois picos de protenas eluram sobre o gradiente, primeiramente um pequeno pico de protena inativa, e ento um pico maior contendo a maior parte da atividade de endoglicanase. A anlise por SDS-PAGE (Figuras 11A e B) mostrou que ambos os picos continham essencialmente protenas homogneas, com massas moleculares aparentes prximas  50 kDa (isto , elas migraram ligeiramente mais devagar do que o padro de ovalbumina pr-tingido da BioRad, que tem uma massa molecular aparente de 47 kDa). Estas duas protenas no puderam ser distinguidas pelas anlises por SDS-PAGE dos inventores, mesmo quando elas foram corridas juntas como misturas. A protena no pico ativo foi chamada celulase de 50K e a protena no pico inativo foi chamada de protena B de 50K, Maiores quantidades de celulase B de 50K foram obtidas por fracionamento do segundo (e inativo) pico eludo a partir de SP-Sepharose (fraes 19 a 23 na Figura 10) sobre Phenyl Sepharose exatamente na mesma forma que a descrita acima para as fraes ativas. A produo de quantidades ainda maiores de celulase de 50K e de celulase B de 50K foi facilitada pela sobrecarga da coluna de SP-Sepharose Por exemplo, quando 15 g de protena foram aplicados a uma coluna de 4,5 x 31 cm de SP-Sepharose, em vez de ligar-se  coluna, a celulase de 50K foi aparentemente deslocada por protenas mais fortemente ligadas, e eluiu antes do gradiente de NaCI. Este material j estava altamente purificado, e a celulase de 50K homognea foi isolada dele por cromatografia sobre Phenyl Sepharose conforme descrito acima. A fim de acelerar a purificao de maiores quantidades de celulase de 50K, as colunas de SP-Sepharose e Phenyl Sepharose foram invertidas. Aps ajuste da concentrao de sulfato de amnio para cerca de 15g%, as protenas precipitadas no Pico lll/IV foram aplicadas na Phenyl Sepharose conforme descrito antes. Com a alta sobrecarga (por exemplo, 17 g de protena aplicados a uma coluna de 3,2 x 25 cm de Phenyl Sepharose), a maior parte da protena total correu atravs da coluna, porm a celulase de 50K (contendo a maioria da atividade de endoglicanase) foi ligada e eluda no final do gradiente linear de 15 a 0 g% de sulfato de amnio em PIPES/KOH a 25 mM, pH 6,0. A anlise de Western com um anti-soro de coelho identificando a celulase B de 50K mostrou que a celulase B de 50K eluiu exatamente antes da celulase de 50K. A purificao adicional foi obtida por fracionamento sobre SP-Sepharose, conforme descrito anteriormente. Nesta ordem invertida de SP-Sepharose e Phenyl Sepharose, as protenas no Pico lll/IV precipitadas com o sulfato de amnio puderam ser aplicadas diretamente  etapa de purificao seguinte sem a remoo do sal. O grande precipitado de protenas, o qual apareceu com a transferncia das protenas concentradas no Pico lll/IV diretamente para o acetato de sdio a 25 mM, pH 4,0, para a SP-Sepharose, pode tambm ser evitado desta forma. Uma vez que a celulase de 50K somente liga-se exatamente  SP-Sepharose, o fracionamento precedente sobre a Phenyl Sepharose reduziu de maneira acentuada a carga de protena total aparentemente interferindo sobre a SP-Sepharose. A celulase de 50K e a celulase B de 50K foram, cada uma, testadas no Launder-Ometer para ver se elas so responsveis pelos efeitos benficos do Pico IV descrito no Exemplo 10. Ambas as protenas foram verificadas ter efeitos benficos (Tabela VI). Nas baixas concentraes usadas nesta experincia, elas prprias no aumentaram a liberao do corante ndigo da face externa do brim (isto , Ldir0ito no aumentou), porm elas efetivamente diminuram a colorao de volta do corante para a face interna do brim (UveSS0 tornou-se mais positivo e bavesso tornou-se menor), especialmente quando usadas juntamente com a celulase de20K. A celulase de 20K funcionou bem nos testes no Launder-Ometer em pH 5, bem como no pH 7. No pH 5, 0,2 mg de celulase de 20K por g de brim diminuiu o Ldlreito de 3,2 para 5,2. A adio de celulase de 50K a 0,1 mg por grama de brim juntamente com a celulase de 20K tambm diminuiu a colorao de volta no pH 5 (Lavesso e bavesso alteraram de 0,0 e 2,6 com a celulase de 20K sozinha para 1,3 e 1,5, respectivamente, com a mistura de celulases de 20K e de 50K).</span>The proteins at Peak 11 / IV were precipitated with ammonium sulfate and transferred to 25 mM sodium acetate pH 4.0 containing 1 mM EDTA in the same manner as described for the proteins at Peak II. Upon transfer to 25 mM sodium acetate, pH 4.0, a large precipitate formed and was discarded. The active supernatant was fractionated over SP-Sepharose. At the low protein load (eg 200 mg protein for a 2.5 x 11 cm column as shown in Figure 10) most endoglycanase activity bound to the column and was eluted with a NaCl gradient in around 50 mM NaCI This active peak was followed by a second inactive protein peak SDS-PAGE analysis showed that the active and inactive peaks both contained several proteins, including proteins with apparent molecular masses close to 50 kDa, which could not be distinguished from each other by SDS-PAGE. Both peaks were further purified by Phenyl Sepharose chromatography. The active fractions (fractions 15 to 18 in Figure 10) were combined, adjusted for 50 mM PIPES / KOH, pH 6.0 (by addition of 0.25 M PIPES / KOH, pH 6.0) and 15 g% of ammonium sulfate (by addition of solid ammonium sulfate), and applied to a 1.5 x column. 8.5 cm Phenyl Sepharose equilibrated with 25 mM PIPES / KOH pH 6.0 with having 1 mM EDTA and 15 g% ammonium sulfate. The column was developed with a linear gradient of 15 to 0 g% ammonium sulfate in 104 ml 25 mM PIPES / KOH, pH 6.0. After the end of the gradient, the column was further washed with 25 mM PIPES / KOH pH 6.0. Two protein peaks eluted over the gradient, first a small inactive protein peak, and then a larger peak containing most of the endoglycanase activity. SDS-PAGE analysis (Figures 11A and B) showed that both peaks contained essentially homogeneous proteins with apparent molecular masses close to 50 kDa (ie, they migrated slightly slower than BioRad's pre-dyed ovalbumin pattern). , which has an apparent molecular mass of 47 kDa). These two proteins could not be distinguished by the inventors' SDS-PAGE analyzes even when they were run together as mixtures. The active peak protein was called 50K cellulase and the inactive peak protein was called 50K protein B. Larger amounts of 50K cellulase B were obtained by fractionation of the second (and inactive) peak eluted from SP-Sepharose. (fractions 19 to 23 in Figure 10) on Phenyl Sepharose in exactly the same form as described above for active fractions. Production of even greater amounts of 50K cellulase and 50K cellulase B was facilitated by overloading the SP-Sepharose column. For example, when 15 g of protein was applied to a 4.5 x 31 cm SP-column. Instead of binding to the column Sepharose, the 50K cellulase was apparently displaced by more tightly bound proteins, and eluted before the NaCl gradient. This material was already highly purified, and homogeneous 50K cellulase was isolated from it by Phenyl Sepharose chromatography as described above. In order to accelerate the purification of larger amounts of 50K cellulase, the SP-Sepharose and Phenyl Sepharose columns were inverted. After adjusting the ammonium sulfate concentration to about 15g%, the proteins precipitated at Pico III / IV were applied to Phenyl Sepharose as described above. With the high overload (eg 17 g of protein applied to a 3.2 x 25 cm Phenyl Sepharose column) most of the total protein flowed through the column but 50K cellulase (containing most of the activity). endoglycanase) was bound and eluted at the end of the linear gradient of 15 to 0 g% ammonium sulfate in 25 mM PIPES / KOH, pH 6.0. Western analysis with a rabbit antiserum identifying 50K cellulase B showed that 50K cellulase B eluted just before 50K cellulase. Further purification was obtained by fractionation over SP-Sepharose as described above. In this inverted order of SP-Sepharose and Phenyl Sepharose, the proteins in Pico III / IV precipitated with ammonium sulfate could be applied directly to the next purification step without salt removal. The large protein precipitate, which appeared with the transfer of proteins concentrated in Pico III / IV directly to 25 mM sodium acetate, pH 4.0, to SP-Sepharose, can also be avoided in this way. Since 50K cellulase only binds exactly to SP-Sepharose, the previous fractionation over Phenyl Sepharose markedly reduced the total protein load apparently interfering with SP-Sepharose. 50K cellulase and 50K cellulase B were each tested on Launder-Ometer to see if they are responsible for the beneficial effects of Peak IV described in Example 10. Both proteins were found to have beneficial effects (Table VI). At the low concentrations used in this experiment, they themselves did not increase the indigo dye release from the outer face of the denim (ie, Ldir0ito did not increase), but they did effectively decrease the back dye stain to the inner face of the denim (UveSS0 became more positive and bavesso became smaller), especially when used together with the 20K cellulase. The 20K cellulase worked well in the Launder-Ometer tests at pH 5 as well as at pH 7. At pH 5, 0.2 mg of 20K cellulase per g of denim reduced the Ldite from 3.2 to 5.2. Addition of 50 mg cellulase at 0.1 mg per gram of denim together with 20K cellulase also decreased back coloration at pH 5 (Lavesso and besso changed from 0.0 and 2.6 with 20K cellulase alone to 1.3 and 1.5, respectively, with the mixture of 20K and 50K cellulases).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela VI. Liberao do Corante ndigo pela celulase de 20K, pela celulase de 50K e pela celulase B de 50K</span>Table VI. Indigo Dye Release by 20K Cellulase, 50K Cellulase and 50K Cellulase B</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As condies eram as mesmas que na Tabela V. A dose  mostrada como mg de protena por grama de brim.</span>The conditions were the same as in Table V. The dose is shown as mg protein per gram of denim.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Amostra Doss (mQ/Q) Ldireito Lavesso baVesso Tampo sozinho - 2,8 -0,6 1,6 Celulase de 20K 0,18 5,6 -1,0 4,0 0,09 4,8 -1,5 3,3 Celulase de 50K 0,15 2,6 -0,3 1,0 0,075 3,0 0,4 1,3 Celulase B de 50K 0,31 2,8 1,3 0,8 0,15 2,7 1,5 0,5 Celulase de 20K+ 0,18 + 0,075 5,6 0,3 2,5 Celulase de 50K 0,09 + 0,075 5,1 0,3 2,1 Celulase de 20K+ 0,18 + 0,15 4,7 0,0 3,0 Celulase B de 50K Exemplo 10 Propriedades da celulase de 20K</span>Sample Doss (mQ / Q) Right Lavesso baVesso Buffer alone - 2.8 -0.6 1.6 20K Cellulase 0.18 5.6 -1.0 4.0 0.09 4.8 -1.5 3 50K Cellulase 0.15 2.6 -0.3 1.0 0.075 3.0 0.4 1.3 50K Cellulase B 0.31 2.8 1.3 0.8 0.15 2.7 1.5 0.5 20K Cellulase + 0.18 + 0.075 5.6 0.3 2.5 50K Cellulase 0.09 + 0.075 5.1 0.3 2.1 20K Cellulase + 0.18 + 0.15 4.7 0.0 3.0 50K Cellulase B Example 10 Properties of 20K Cellulase</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Embora os anticorpos policlonais preparados contra as celulases purificadas a partir de Trchoderma reesei (designados anticorpos anti-EGI, anti-CBHI e anti-CBHII) identificassem as protenas no meio de desenvolvimento de ALK04237, houve somente uma reao cruzada muito fraca com a celulase de 20K pura sob as mesmas condies da anlise de Western blot.</span>Although polyclonal antibodies prepared against Trichoderma reesei purified cellulases (designated anti-EGI, anti-CBHI, and anti-CBHII antibodies) identified proteins in the ALK04237 developmental medium, there was only a very weak cross-reaction with cellulase. Pure 20K under the same conditions as Western blot analysis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Quando o meio de desenvolvimento a partir de ALKQ4237 foi sondado na anlise de Western com o anti-soro produzido nos coelhos contra a celulase de 20K pura, uma forte banda em torno de 35 kDa foi observada, alm da banda  20 kDa. Nenhuma atividade de endoglicanase aparente pode ser detectada para esta protena de 35 kDa. Tambm, uma banda mais fraca foi vista imediatamente  frente da banda a 20 kDa (Figura 14). O ALK04124 proporcionou um padro quase idntico ao ALK04237, indicando que este e outros fungos provavelmente contm celulases muito similares  celulase de 20K da presente inveno.</span>When the growth medium from ALKQ4237 was probed in Western analysis with the rabbit antiserum against pure 20K cellulase, a strong band around 35 kDa was observed in addition to the band at 20 kDa. No apparent endoglycanase activity can be detected for this 35 kDa protein. Also, a weaker band was seen immediately ahead of the band at 20 kDa (Figure 14). ALK04124 provided an almost identical pattern to ALK04237, indicating that this and other fungi probably contain cellulases very similar to the 20K cellulase of the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As sequncias de aminocidos de peptdeos trpticos derivados das celulases de 20K so mostradas na Figura 17. A celulase de 20K purificada funcionou bem no biotratamento com pedras em pH neutro sem a adio de outras atividades de enzima, conforme mostrado na Tabela VII.</span>The amino acid sequences of tryptic peptides derived from the 20K cellulases are shown in Figure 17. Purified 20K cellulase worked well in biotreatment with neutral pH stones without the addition of other enzyme activities, as shown in Table VII.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela VII. Biotratamento com Pedras pela Celulase de 20K Purificada As condies foram como na experincia mostrada na Tabela V. A dosagem  mostrada como mg de protena/g de tecido de brim. "Meio completo" indica o meio de desenvolvimento concentrado de ALK04237 no-fracionado.</span>Table VII. Purified 20K Cellulase Stone Biotreatment The conditions were as in the experiment shown in Table V. The dosage is shown as mg protein / g denim tissue. "Complete medium" indicates concentrated unfractionated developmental medium of ALK04237.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Comparada ao meio no-fracionado, a celulase de 20K resultou no mesmo grau de branqueamento (U* = 6,0-6,1) em 1/80 da dosagem da protena. Ademais, houve menos colorao de volta sobre a face do avesso do tecido (LaVoSSo = -0,5 em comparao com -2,9, e bavesso = 3,6 comparado  5,5). O tecido tratado com a celulase de 20K tinha uma textura macia aceitvel.</span>Compared to the unfractionated medium, the 20K cellulase resulted in the same degree of bleaching (1/4 = 6.0-6.1) in 1/80 of the protein dosage. In addition, there was less back staining on the wrong side of the tissue (LaVoSSo = -0.5 compared to -2.9, and bavesso = 3.6 compared to 5.5). The 20K cellulase treated fabric had an acceptable soft texture.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Embora a celulase de 20K funcionasse surpreendentemente bem sem outras adies, um aspecto e uma textura do tecido ainda melhores resultaram quando a 20K foi usada juntamente com as combinaes de DEAE-Sepharose I, III ou IV (Tabela VIII): Tabela VIII. Sinergia no Biotratamento com Pedras Entre a Celulase de 20K e as Combinaes de Endoglicanase Eludas de DEAE-Sepharose As condies foram como na Tabela V.</span>Although 20K cellulase worked surprisingly well without further additions, an even better appearance and tissue texture resulted when 20K was used in conjunction with DEAE-Sepharose I, III or IV combinations (Table VIII): Table VIII. Stone Biotreatment Synergy Between 20K Cellulase and DEAE-Sepharose Eluted Endoglycan Combinations The conditions were as in Table V.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As misturas de celulase de 20K com as Combinaes I, III e IV causaram mais branqueamento ((.^ aumentado) do que qualquer componente sozinho. Pelo menos para a combinao da celulase de 20K com a Combinao IV, est claro que isto  por causa da sinergia e no meramente um efeito aditivo. Ademais, a colorao de volta com todas as misturas foi realmente menor (LavesSo mais positivo, bavesso menor) do que a colorao de volta observada com a celulase de 20K sozinha. A combinao da 20K com a Combinao IV foi particularmente efetiva. A Combinao IV contm muitas protenas, uma das quais (um polipeptdeo de 50 kDa) co-purifica-se com a atividade de endoglicanase durante a cromatografia da Combinao IV sobre Sephadex G100 e S-Sefarose. Embora um bom biotratamento com pedras seja obtido com a celulase de 20K sozinha, melhores resultados so possveis com a celulase de 20K mais uma ou mais protenas purificadas a partir da Combinao IV. O biotratamento com pedras com as misturas da celulase de 20K e a celulase de 50K e a celulase B de 50K purificadas da Combinao lll/IV j foi apresentado (Tabela VI no Exemplo 9). Portanto, a presente inveno no est limitada ao uso de somente a celulase de 20K. Outras protenas no meio de ALK04237 so teis sozinhas ou em combinaes adequadas.</span>Mixtures of 20K cellulase with Combinations I, III and IV caused more bleaching ((increased)) than any component alone. At least for the combination of 20K cellulase with Combination IV, it is clear that this is by synergism and not merely an additive effect. In addition, the backstain with all mixtures was actually lower (LavesSo more positive, lower side) than the backstain observed with 20K cellulase alone. Combination IV was particularly effective Combination IV contains many proteins, one of which (a 50 kDa polypeptide) co-purifies with endoglycanase activity during Combination IV chromatography on Sephadex G100 and S-Sepharose. If good stone biotreatment is obtained with 20K cellulase alone, better results are possible with 20K cellulase plus one or more proteins purified from Combination IV. Stones with mixtures of 20K cellulase and 50K cellulase and purified 50K cellulase B from Combination 11 / IV have already been shown (Table VI in Example 9). Therefore, the present invention is not limited to the use of only 20K cellulase. Other proteins in the ALK04237 medium are useful alone or in suitable combinations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">No ensaio padro de endoglicanase descrito por Baiiey e col. (1981, loc. cit), a quantidade de enzima  escolhida de modo que produza, em 10 min. e pH 4,8 (tampo de citrato de Na a 0,05 M), cerca de 0,6 mM equivalentes de reduo a partir da hdroxietilcelulose a 1%, resultando em uma alterao de absorbncia (540) de entre 0,2 e 0,25. Isto de longe excede a faixa na qual a 540  proporcional  quantidade de celulase de 20K.</span>In the standard endoglycanase assay described by Baiiey et al. (1981, loc. Cit), the amount of enzyme is chosen so that it yields in 10 min. and pH 4.8 (0.05 M Na citrate buffer), about 0.6 mM equivalent reduction from 1% hydroxyethylcellulose, resulting in an absorbance change (540) of between 0.2 and 0.25. This far exceeds the range in which 540 is proportional to the amount of 20K cellulase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Portanto, o procedimento foi modificado como se segue. Enzima suficiente foi usada para produzir cerca de 0,2 mM equivalentes de reduo em 10 min. em um tampo HEPES a 0,05 M (pH 7,0). Para atingir a concentrao de incio de equivalentes de reduo acima da qual a cor  formada no sistema de DNS, a glicose a 0,12 mM foi recentemente adicionada ao reagente de DNS de estoque. Este mtodo (chamado 0 mtodo "modificado") foi usado quando caracterizando a atividade de endoglicanase da celulase de 20K e tambm da celulase de 50K. Com a hdroxietilcelulose a 1 % como substrato, a faixa na qual a 540  proporcional  quantidade de celulase de 20 e de 50K  relativamente estreita, e assim a carboximetilcelulose a 2% foi tomada como um substrato alternativo. Com a carboximetilcelulose a 2%, a faixa de correlao linear entre a 540 e a quantidade de celulase de 20K e de 50K foi mais ampla do que com a hdroxietilcelulose a 1%. A atividade de endoglicanase determinada com a carboximetilcelulose a 2% era cerca de 8-10 vezes para a celulase de 20K e cerca de 50 vezes para a celulase de 50K em comparao com aquela determinada com a hdroxietilcelulose a 1 %.</span>Therefore, the procedure was modified as follows. Sufficient enzyme was used to produce about 0.2 mM equivalent reduction in 10 min. in a 0.05 M HEPES buffer (pH 7.0). To achieve the start concentration of reduction equivalents above which color is formed in the DNS system, the 0.12 mM glucose was recently added to the stock DNS reagent. This method (called the "modified" method) was used when characterizing the endoglycanase activity of 20K cellulase and also 50K cellulase. With 1% hydroxyethylcellulose as substrate, the range in which 540 is proportional to the amount of 20 and 50K cellulase is relatively narrow, and thus 2% carboxymethylcellulose was taken as an alternative substrate. With 2% carboxymethylcellulose, the linear correlation range between 540 and the amount of 20K and 50K cellulase was wider than with 1% hydroxyethylcellulose. The endoglycanase activity determined with 2% carboxymethylcellulose was about 8-10 times for 20K cellulase and about 50 times for 50K cellulase compared with that determined with 1% hydroxyethylcellulose.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nenhuma atividade de celulase de 20K foi detectvel para o 4-metilumbeliferil-p-D-lactosdeo, um substrato caracterstico de celobiohidrolases. A atividade em relao ao papel de filtro foi tambm muito baixa, porm detectvel. A celulase de 20K era relativamente estvel ao calor. Ela foi incubada a 7 pg/ml e 100C em Tris-HCI a 25 mM, EDTA a 0,2 mM, por 30 ou 60 min., e ento testada em pH 7,0 e 50C. 52% e 35%, respectivamente, da atividade de endoglicanase permaneceram no pH 7,2. 40% e 22%, respectivamente, permaneceram no pH 8,8. (Estes valores de pH foram medidos  temperatura ambiente; o pH real  100C  algo menor.)  80C, pH 7,2, 70% da atividade permaneceram por 60 min.</span>No 20K cellulase activity was detectable for 4-methylumbeliferyl--D-lactoside, a characteristic substrate of cellobiohydrolases. The activity relative to the filter paper was also very low but detectable. The 20K cellulase was relatively heat stable. It was incubated at 7 pg / ml and 100  C in 25 mM Tris-HCl, 0.2 mM EDTA for 30 or 60 min., And then tested at pH 7.0 and 50  C. 52% and 35%, respectively, of endoglycanase activity remained at pH 7.2. 40% and 22%, respectively, remained at pH 8.8. (These pH values were measured at room temperature; actual pH at 100  C is somewhat lower.) At 80  C, pH 7.2, 70% of activity remained for 60 min.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estes resultados indicam que a enzima  adequada para aplicaes em que ela possa ser (por exemplo, acidentalmente) exposta a temperaturas elevadas. Assim como era resistente  inativao reversvel em altas temperaturas, a enzima exibiu uma temperatura tima de 70C durante 10 min. testada em pH 7,0 (Figura 15). A atividade diminuda observada acima de 70C foi principalmente devida a uma alterao reversvel na conformao da enzima: a enzima recuperou a maior parte de sua atividade quando retornou para 50C. A 5QC, a celulase de 20K exibiu 80% ou mais de sua atividade mxima por toda a faixa de pH de 4 a 9, e aproximadamente 50% em pH 10. Este foi o caso em ambos os ensaios por 10 min. (Figura 16A) e por 60 min. (Figura 16B). Estas figuras tambm mostram a dependncia do pH da enzima a 70C. Com os ensaios por 10 min., a enzima era mais ativa  70C do que ela era a 50C sobre a faixa de pH 4,5 a 8, e cerca de igualmente ativa em pH 10 (Figura 16A). Com os ensaios por 60 min. (isto , as condies comerciais de abordagem), a enzima era mais ativa a 70C do que ela era a 50C entre o pH 5,5 e 7,5. Entretanto, ela era somente ligeiramente menos ativa a 70C do que a 50C at o pH 10. Na prtica, isto significa que a enzima pode ser usada igualmente bem sobre uma ampla faixa de pH e em temperaturas at pelo menos 70C.</span>These results indicate that the enzyme is suitable for applications where it may be (for example, accidentally) exposed to elevated temperatures. As well as being resistant to reversible inactivation at high temperatures, the enzyme exhibited an optimum temperature of 70  C for 10 min. tested at pH 7.0 (Figure 15). The decreased activity observed above 70  C was mainly due to a reversible change in enzyme conformation: the enzyme recovered most of its activity when it returned to 50  C. At 50  C, the 20K cellulase exhibited 80% or more of its maximum activity over the pH range from 4 to 9, and approximately 50% at pH 10. This was the case in both trials for 10 min. (Figure 16A) and for 60 min. (Figure 16B). These figures also show the pH dependence of the enzyme at 70  C. With the 10 min assays, the enzyme was more active at 70  C than it was at 50  C over the pH range 4.5 to 8, and about equally active at pH 10 (Figure 16A). With trials for 60 min. (ie commercial approach conditions), the enzyme was more active at 70  C than it was at 50  C between pH 5.5 and 7.5. However, it was only slightly less active at 70  C than at 50  C until pH 10. In practice this means that the enzyme can be used equally well over a wide pH range and at temperatures up to at least 70  C. .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 11 Propriedades da celulase de SOK A celulase de SOK pura tinha tanto a atividade de endoglicanase (contra a hidroxietilcelulose), quanto a atividade de celobiohidrolase (contra o 4-metiiumbeliferil-p-D-laetosdeo, testada essencialmente conforme descrito por van Tilbeurgh e col., em Methods in Enzymology [1988] vol. 160, pginas 45-59). Uma amostra da enzima pura com uma A2eo de 1,8 continha 2030 ECU/ml e 300 PCU/ml em pH 7,0 e 50C (uma PCU  a quantidade de atividade que libera 1 nmol de metilumbeliferona por segundo).</span>Example 11 Properties of SOK Cellulase Pure SOK cellulase had both endoglycanase activity (against hydroxyethylcellulose) and cellobiohydrolase activity (against 4-methiiumbeliferyl-pD-laetoside, tested essentially as described by van Tilbeurgh et al. , in Methods in Enzymology [1988] vol. 160, pages 45-59). A sample of the pure enzyme with an A2eo of 1.8 contained 2030 ECU / ml and 300 PCU / ml at pH 7.0 and 50  C (one PCU is the amount of activity that releases 1 nmol methylumbeliferone per second).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nas anlises de Western, a celulase de 50K foi fortemente identificada pelo anti-soro (KH 1057) produzido contra a endoglicanase I de T. reesei, porm somente fracamente pelos anti-soros (KH 1050 e KH 1053, respectivamente) contra as celobiohidrolases I e II de T. reesei. Ela no foi identificada pelo anti-soro produzido contra a celulase de 20K (Figura 14). Quando o meio de desenvolvimento de ALK04237 foi sondado nas anlises de Western com o anti-soro de coelho produzido contra a prpria celulase de 50K, somente uma banda bvia (que tinha uma massa molecular entre 33 e 47 kDa) foi vista alm da banda muito forte  cerca de 50 kDa. A massa molecular aparente da celulase de 50K por SDS-PAGE diminuiu em cerca de 2 a 5 kDa quando a protena foi tratada com a endoglicosidase Hf, indicando que a enzima contm carboidrato removvel por esta endoglicosidase. A celulase de 50K era extraordinariamente resistente  digesto trptica, indicando que ela tem uma estrutura extraordinariamente estvel. Entretanto, ela foi clivada por tratamento com o brometo de cianognio, e os fragmentos resultantes puderam ento ser digeridos com a tripsina ou com a lisilendopeptidase C. As sequncias de alguns dos peptdeos assim obtidos so mostradas na Tabela IX.</span>In Western analysis, 50K cellulase was strongly identified by antiserum (KH 1057) produced against T. reesei endoglycanase I, but only weakly by antisera (KH 1050 and KH 1053, respectively) against cellobiohydrolases I and II by T. reesei. It was not identified by the antiserum produced against 20K cellulase (Figure 14). When the ALK04237 development medium was probed in Western analyzes with the rabbit antiserum produced against the 50K cellulase itself, only one obvious band (which had a molecular mass between 33 and 47 kDa) was seen beyond the very band. strong at about 50 kDa. The apparent molecular mass of 50K cellulase by SDS-PAGE decreased by about 2 to 5 kDa when the protein was treated with endoglycosidase Hf, indicating that the enzyme contains carbohydrate removable by this endoglycosidase. The 50K cellulase was remarkably resistant to tryptic digestion, indicating that it has an extraordinarily stable structure. However, it was cleaved by treatment with cyanogen bromide, and the resulting fragments could then be digested with trypsin or lysylendopeptidase C. The sequences of some of the peptides thus obtained are shown in Table IX.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela IX</span>Table IX</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Seqncias de peptdeos isolados da celulase de 50K (resduos incertos na ocorrncia menor) n2 507 VYLLDETEHR</span>Peptide sequences isolated from 50K cellulase (minor occurrence uncertain residues) n2 507 VYLLDETEHR</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n2 509 XXLNPGGAYYGT</span>n 509 XXLNPGGAYYGT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n2 563 MsEGAECEYDGVCDKDG</span>562 MsEGAECEYDGVCDKDG</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n2 565 NPYRVXITDYYGNS</span>n2 565 NPYRVXITDYYGNS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n2 603 DPTGARSELNPGGAYYGTGYXDAQ ne 605 XXVPDYhQHGVda n2610 NEMDIXEANSRA</span>602 DPTGARSELNPGGAYYGTGYXDAQ n  605 XXVPDYhQHGVda n2610 NEMDIXEANSRA</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ne 611 LPXGMNSALYLSEMDPTGARSELNP</span>ne 611 LPXGMNSALYLSEMDPTGARSELNP</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n5 612 VEPSPEVTYSNLRXGEIXgXF</span>n5 612 VEPSPEVTYSNLRXGEIXgXF</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n- 619 DGCGWNPYRVvITtDYYnN</span>n- 619 DGCGWNPYRVvITtDYYnN</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ns 620 LPCGMXSALY</span>ns 620 LPCGMXSALY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ns 621 ADGCQPRTNYlVLDdLIHPXXQ A celulase de 50K  uma enzima estvel que exibe atividade de endoglicanase sobre uma ampla faixa de valores de pH e em altas temperaturas, assim ela pode ser adequada para uso em muitas condies industriais. Em pH 7,0 e com tempos de reao de 60 min., ela tem uma temperatura tima entre 65 e 70C, e mesmo com este longo tempo de reao ainda exibe, a 75C, 50% da atividade observada a 50C (Figura 12).</span>ns 621 ADGCQPRTNYlVLDdLIHPXXQ 50K cellulase is a stable enzyme that exhibits endoglycanase activity over a wide range of pH values and at high temperatures, so it may be suitable for use in many industrial conditions. At pH 7.0 and 60 min. Reaction time, it has an optimum temperature between 65 and 70  C, and even with this long reaction time it still exhibits at 75  C 50% of the activity observed at 50  C.  C (Figure 12).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Com tempos de reao de 60 min., o pH timo era muito amplo a 50C, com atividade essencialmente constante entre pH 4,4 e 7,0, e atividades em pH 9 e 10 iguais a 50% e 30%, respectivamente, daquela em pH 7,0. A 70C, houve um timo ntido em pH 6, e, entre pH 5 e 7, a atividade (com tempos de reao de 60 min.) era 3 vezes, ou mais, maior do que aquela a 50C. Entretanto, em pH 4,4 e em valores de pH acima de 8, a atividade era maior a 50C do que a 70C (em ensaios por 60 min ), sugerindo que a estabilidade da enzima diminui a 70C, lado direito, a faixa de pH 5 a 7,5. A dependncia do pH  ilustrada na Figura 13.</span>With reaction times of 60 min., The optimal pH was very broad at 50  C, with essentially constant activity between pH 4.4 and 7.0, and activities at pH 9 and 10 equal to 50% and 30%, respectively. , that at pH 7.0. At 70  C there was a clear optimum at pH 6, and between pH 5 and 7 the activity (with reaction times of 60 min.) Was 3 times or more greater than that at 50  C. However, at pH 4.4 and at pH values above 8, activity was greater at 50  C than at 70  C (in 60 min trials), suggesting that enzyme stability decreases at 70  C, right side, the pH range 5 to 7.5. The pH dependence is illustrated in Figure 13.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 12 Propriedades da celulase B de S0K</span>Example 12 Properties of S0K Cellulase B</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nenhuma atividade de endoglicanase detectvel pode ser medida para a celulase B de 50k (anteriormente chamada protena B de 50K) com a hidroxietilcelulose ou com a carboximetilcelulose. No pH acdico, a celulase B de 50K tinha uma atividade de celobiohidrolase baixa, a qual (medida com 4-metilumbeliferil-3-D-lactosdeo), em pH 5, era menos do que 0,1% daquela da celulase de 50K. Ademais, a celulase B de 50K tinha uma atividade detectvel com relao ao papel de filtro em pH 4,8 e celulose Solca Floc amrfica, entumecida, cida, em pH 5 e 7, usada nas determinaes da atividade de enzima.</span>No detectable endoglycanase activity can be measured for 50k cellulase B (formerly called 50K protein B) with hydroxyethylcellulose or carboxymethylcellulose. At acidic pH, 50K cellulase B had a low cellobiohydrolase activity which (measured with 4-methylumbelliferyl-3-D-lactoside) at pH 5 was less than 0.1% of that of 50K cellulase. In addition, 50K cellulase B had detectable activity with respect to filter paper at pH 4.8 and amorphous, swollen, acidic Solca Floc cellulose at pH 5 and 7, used in the determination of enzyme activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nas anlises de Western, a celulase B de 50K foi fortemente identificada pelo anti-soro (KH1Q50) produzido contra a celobiohidrolase I de T. reesei, porm somente fracamente pelos anti-soros contra a celobiohidrolase II ou a endoglicanase I de T. reesei, ou contra a celulase de 50K. Ela no foi identificada pelo anti-soro produzido contra a celulase de 20K (Figura 14). A Tabela X mostra as sequncias de peptdeos isolados da celulase B de 50K.</span>In Western analysis, 50K cellulase B was strongly identified by the antiserum (KH1Q50) produced against T. reesei cellobiohydrolase I, but only weakly by the T. reesei cellobiohydrolase II or endoglycanase I antisera. or against 50K cellulase. It was not identified by the antiserum produced against 20K cellulase (Figure 14). Table X shows the peptide sequences isolated from 50K cellulase B.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela IX</span>Table IX</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Seqncias de peptdeos isolados da celulase de 50K (resduos incertos na ocorrncia menor) n 534 vGNPDFYGK</span>Peptide sequences isolated from 50K cellulase (minor occurrence uncertain residues) n 534 vGNPDFYGK</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ns 535 FGPIGSTY</span>ns 535 FGPIGSTY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n 631 LSQYFIQDGeRK</span>n 631 LSQYFIQDGeRK</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n 632 FTWSRFEENK</span>n 632 FTWSRFEENK</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">n 636 HEYGTNVGSRFYLMNGPDK</span>n 636 HEYGTNVGSRFYLMNGPDK</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 13 Estabilidade das celulases neutras em diferentes detergentes A estabilidade das preparaes de celulases neutras foi testada em trs solues detergentes diferentes. As solues detergentes eram 0M0 Total (ou OMO Neste, Lever UK), OMO Color (Lever S.A.)  Lquido Detergente de Cor (Unilever, Os Pases Baixos). As preparaes de celulases testadas foram os filtrados da cultura concentrados de ALK04125, ALK04179, ALK04237 e ALK04265 (Exemplo 1) e as celulases de 20K e de 50K purificadas da cepa ALK04237 (Exemplo 9).</span>Example 13 Stability of neutral cellulases in different detergents The stability of neutral cellulases preparations was tested on three different detergent solutions. The detergent solutions were 0M0 Total (or OMO Estes, Lever UK), OMO Color (Lever S.A.) is Color Detergent Liquid (Unilever, The Netherlands). The cellulase preparations tested were the culture filtrates concentrated from ALK04125, ALK04179, ALK04237 and ALK04265 (Example 1) and the purified 20K and 50K cellulases from the ALK04237 strain (Example 9).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de celulases foram incubadas a 40C em solues detergentes a 0,25 %. A atividade contra a hidroxietilcelulose (ECU/ml, Exemplo 1) foi medida (pH 7, 50C) a partir das amostras tiradas aps 5-30 minutos de incubao.</span>Cellulase preparations were incubated at 40  C in 0.25% detergent solutions. The activity against hydroxyethylcellulose (ECU / ml, Example 1) was measured (pH 7.50  C) from samples taken after 5-30 minutes of incubation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes testadas eram como se segue: Filtrados da cultura: ALK04125: 780 ECU/ml (pH 7, 50C) ALK04179: 830 ECU/m! ALK04265: 760 ECU/ml ALK04237: 650 ECU/ml Protenas purificadas: celulase de 20K: 9423 ECU/ml celulase de 50K: 10100 ECU/ml Os resultados so mostrados nas Tabelas XI - XIII</span>The preparations tested were as follows: Culture filtrates: ALK04125: 780 ECU / ml (pH 7.50  C) ALK04179: 830 ECU / m 2! ALK04265: 760 ECU / ml ALK04237: 650 ECU / ml Purified Proteins: 20K Cellulase: 9423 ECU / ml 50K Cellulase: 10100 ECU / ml Results are shown in Tables XI - XIII</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de celulases de ALK04179, ALK04265 e ALK04237 e as celulases de 20K e de 50K permaneceram quase 100 % estveis por 30 minutos  40C em todos os trs detergentes testados. O ALK04125 permanece estvel por 30 minutos  40C no Lquido Detergente de Cor e no OMO Neste, Tabela XI. Estabilidade de diferentes celulases no Lquido Detergente de Cor  0,25% (pH 7,5 - 7,9).</span>The cellulose preparations of ALK04179, ALK04265 and ALK04237 and the 20K and 50K cellulases remained almost 100% stable for 30 minutes at 40  C in all three detergents tested. ALK04125 remains stable for 30 minutes at 40  C in Color Detergent Liquid and OMO in this Table XI. Stability of different cellulases in 0.25% Color Detergent Liquid (pH 7.5 - 7.9).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preparao % de dosagem pH* % de atividade deixada de enzima (ml) 0' 5' 10' 20' 30' Filtrados da cultura: ALK04125 6 7,3 100 97 98 98 99 ALK04179 6 7,1 100 99 100 100 10 ALK04265 6 7,2 100 100 100 100 100 ALK04237 6 7,1 100 100 82 95 100 Protenas purificadas de ALK04237: Celulase de 20K 1 7,8 100 98 99 97 100 Celulase de 50K 1 7,6 100 100 100 100 100 * = pH do detergente a 0,25 % + soluo de enzima aps 30' de incubao) Tabela XII. Estabilidade de diferentes celulases no OMO Total a 0,25% (ou OMO Neste, pH 8,5).</span>Preparation% Dosage pH *% Enzyme Activity Left (ml) 0 '5' 10 '20' 30 'Culture Filtered: ALK04125 6 7.3 100 97 98 98 99 ALK04179 6 7.1 100 99 100 100 10 ALK04265 6 7.2 100 100 100 100 100 ALK04237 6 7.1 100 100 82 95 100 Purified ALK04237 Proteins: 20K Cellulase 1 7.8 100 98 99 97 100 50K Cellulase 1 7.6 100 100 100 100 100 * = 0.25% detergent pH + enzyme solution after 30 'incubation) Table XII. Stability of different cellulases in 0.25% Total OMO (or OMO Estes, pH 8.5).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preparao % de dosagem pH* % de atividade deixada de enzima (ml) 0' 5' 10' 20' 30' Filtrados da cultura: ALK04125 6 7,8 100 98 96 86 87 ALK04179 6 7,3 100 98 96 96 99 ALK04265 6 7,1 100 100 100 100 100 ALK04265 4 7,8 100 99 97 100 100 ALK04237 4 7,8 100 100 100 99 100 ALK04237 2 7,3 100 99 97 99 99 Protenas purificadas de ALK04237: Celulase de 20K 1 8,2 100 100 99 93 100 Celulase de 50K 1 7,8 100 95 92 95 94 * = pH do detergente a 0,25 % + soluo de enzima aps 30' de incubao) Tabela XIII. Estabilidade de diferentes celulases no OMO Color  0,25% (pH 9,6-10).</span>Preparation% Dosage pH *% Enzyme Activity Left (ml) 0 '5' 10 '20' 30 'Culture Filtered: ALK04125 6 7.8 100 98 96 86 87 ALK04179 6 7.3 100 98 96 96 99 ALK04265 6 7.1 100 100 100 100 100 ALK04265 4 7.8 100 99 97 100 100 ALK04237 4 7.8 100 100 100 99 100 ALK04237 2 7.3 100 99 97 99 99 Purified proteins from ALK04237: 20K 18 Cellulase, 2 100 100 99 93 100 50K Cellulase 1 7.8 100 95 92 95 94 * = 0.25% detergent pH + enzyme solution after 30 'incubation) Table XIII. Stability of different cellulases in 0.25% OMO Color (pH 9.6-10).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preparao % de dosagem pH* % de atividade deixada de enzima (ml) 0' 5' 10' 20' 30' Filtrados da cultura: ALK04125 6 9,6 100 (15) (15) (13) (14) ALK04179 6 8,3 100 97 100 97 99 ALK04265 6 9,1 100 100 100 100 100 ALK04265 4 8,5 100 93 95 99 98 ALK04237 4 8,5 100 98 96 96 99 ALK04237 2 9,1 100 93 95 99 98 Tabela XIII - continuao Preparao % de dosagem pH* % de atividade deixada de enzima (ml) 0' 5' 10' 20' 30' protenas purificadas de ALK04237: Celulase de 20K 1 9,8 100 99 100 100 100 Celulase de 50K 1 8,9 100 100 100 100 100 * = pH do detergente a 0,25 % + soluo de enzima aps 30' de incubao) Exemplo 14 Funo das celulases neutras nos detergentes em substrato de HEC A funo de diferentes celulases neutras nos detergentes foi determinada utilizando-se a hidroxietilcelulose (HEC) como um substrato. As preparaes de celulases testadas eram os filtrados da cultura concentrados de ALK04265 e ALK04237 e as celulases de 20K e de 50K purificadas a partir da cepa ALK04237. Os substratos de HEC foram preparados dissolvendo-se a HEC a 1 % em solues detergentes a 0,25 %. Pela utilizao destes substratos, a atividade contra a HEC (ECU/ml) foi medida a 40C a partir de cada preparao de celulase, conforme descrito no Exemplo 1. Os detergentes e as preparaes de celulases usados nestas experincias so descritos no Exemplo 13. pH dos substratos: HEC/tampo pH 7 HEC/Lquido Detergente de Cor pH 7,5 HEC/OMO Total pH 7,8 HEC/OMO Color pH 9,7 Tabela XIV. ECU das preparaes de celulase em diferentes detergentes (comparada como % a partir da atividade de ECU medida em tampo de pH 7) % de Atividade ECU/lquido ECU/OMO ECU/OMO Preparao ECU/tampo det. de cor Total Color filtrados da cultura: ALK04265 100 89 96 59 ALK04237 100 97 95 40 protenas purificadas: celulase de 20K 100 100 93 81 celulase de 50K 100 92 79 46 As preparaes de celulase de ALK04237 e ALK04265 e as celulases de 20K e de 50K funcionam em todos os trs detergentes testados quando utiliza-se a HEC como um substrato.</span>Preparation% Dosage pH *% Enzyme Activity Left (ml) 0 '5' 10 '20' 30 'Culture Filtered: ALK04125 6 9.6 100 (15) (15) (13) (14) ALK04179 6 8 100 100 100 100 99 99 ALK04265 6 9.1 100 100 100 100 100 100 ALK04265 4 8.5 100 93 95 99 98 ALK04237 4 8.5 100 98 96 96 99 ALK04237 2 9.1 100 93 95 99 98 Table XIII - continued Preparation% Dosage pH *% Enzyme Activity Left (ml) 0 '5' 10 '20' 30 'purified proteins from ALK04237: 20K Cellulase 1 9.8 100 99 100 100 100 50K Cellulase 1 8.9 100 100 100 100 100 * = 0.25% detergent pH + enzyme solution after 30 'incubation) Example 14 Function of neutral cellulases in HEC substrate detergents The function of different neutral cellulases in detergents was determined using hydroxyethylcellulose (HEC) as a substrate. The cellulase preparations tested were the concentrated culture filtrates of ALK04265 and ALK04237 and the 20K and 50K cellulases purified from the ALK04237 strain. HEC substrates were prepared by dissolving 1% HEC in 0.25% detergent solutions. By using these substrates, activity against HEC (ECU / ml) was measured at 40  C from each cellulase preparation as described in Example 1. The detergents and cellulase preparations used in these experiments are described in Example 13. Substrate pH: HEC / buffer pH 7 HEC / Color Detergent Liquid pH 7.5 HEC / OMO Total pH 7.8 HEC / OMO Color pH 9.7 Table XIV. ECU of cellulase preparations in different detergents (compared as% from ECU activity measured in pH 7 buffer)% ECU Activity / liquid ECU / OMO ECU / OMO ECU Preparation / buffer det. Total Color Filtered from Culture: ALK04265 100 89 96 59 ALK04237 100 97 95 40 Purified Proteins: 20K Cellulase 100 100 93 81 50K Cellulase 100 92 79 46 The cellulose preparations of ALK04237 and ALK04265 and the cellulases of 20K and 50K works on all three detergents tested when using HEC as a substrate.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 15 Uso de celulases neutras em detergentes sobre tecidos urdidos de algodo Nesta experincia  descrita a capacidade das celulases neutras de funcionar como agentes amaciantes de tecido e de impedir a formao de felpo, e assim, reduzir a tendncia  formao de bolas do tecido de algodo aps lavagens de roupas repetidas nos detergentes. As preparaes de celulases testadas eram o filtrado da cultura concentrado de ALK04237 e as celulases de 20K e de 50K purificadas a partir da cepa ALK04237 (Exemplos 1 e 9). A experincia de lavagem foi efetuada com um Launder-0 meter LP-2 (Atlas, Illinois, EUA). Cerca de 10 g de amostra de tecido urdido de algodo pr-alvejado foram carregados para um recipiente de 1,2 litros que continha 150 ml de soluo detergente a 0,25% com ou sem celulase. As dosagens de celulases foram baseadas nas quantidades de protenas. As solues detergentes eram o OMO Total (Lever, UK) e o Lquido Detergente de Cor (Unilever, Os Pases Baixos). Uma quantidade de esferas de ao foi adicionada em cada recipiente para aumentar a ao mecnica. 0 Launder-Ometer foi corrido a 42 rpm por 0,5 ou 1 hora a 40C. 0 material foi lavado 4 vezes com enxaguadura e secagem intermedirias. A perda de peso (ver o Exemplo 6) foi usada para descrever a quantidade de felpo removido da superfcie dos tecidos.</span>Example 15 Use of Neutral Cellulases in Detergents on Cotton Woven Fabrics In this experiment the ability of neutral cellulases to function as fabric softening agents and to prevent the formation of wool is described, and thus to reduce the tendency for the formation of cotton balls. cotton after repeated laundry washes in detergents. The cellulase preparations tested were the concentrated culture filtrate of ALK04237 and the purified 20K and 50K cellulases from the ALK04237 strain (Examples 1 and 9). The wash experiment was performed with a Launder-0 meter LP-2 (Atlas, Illinois, USA). About 10 g of pre-bleached cotton woven sample was loaded into a 1.2 liter container containing 150 ml of 0.25% detergent solution with or without cellulase. Cellulase dosages were based on protein amounts. Detergent solutions were OMO Total (Lever, UK) and Color Detergent Liquid (Unilever, The Netherlands). A quantity of steel balls was added to each container to increase mechanical action. Launder-Ometer was run at 42 rpm for 0.5 or 1 hour at 40  C. The material was washed 4 times with intermediate rinsing and drying. Weight loss (see Example 6) was used to describe the amount of fluff removed from the tissue surface.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela XV. Perda de peso dos tecidos aps o tempo da primeira lavagem com celulases neutras nos detergentes. ns da preparao dosagem de en- tempo h % de perda amostra zima como pro- de peso tena/g de tecido No Lquido Detergente de Cor 1 - 1 0,5 2 ALK04237 11 1 0,3 3 ALK04237 22 1 0,7 4 celulase de 20K 2 1 0,1 5 celulase de 20K 5 1 0,5 6 celulase de 20K 8 1 1,0 7 celulase de 50K 2 1 0,1 8 celulase de 50K 5 1 0,2 9 - 0,5 0,2 10 celulase de 20K 8 0,5 0,5 No OMO Total: 11 - - 1 0,03 12 celulase de 20K 8 1 1,1 13 - - 0,5 0,1 14 celulase de 20K 8 0,5 0,7 Na Tabela XV  mostrado que aps a primeira lavagem no Launder-Ometer, a perda de peso dos tecidos foi aumentada claramente mais com os tecidos tratados com celulase do que com os tecidos tratados com o detergente nico. Tambm a perda de peso foi aumentada como uma funo da dosagem de celuiase e, adicionaimente, com a celulase de 20K, a perda de peso foi aumentada quando o tempo de lavagem foi aumentado de 0,5 para 1 hora. A celulase de 20K funcionou igualmente bem no Lquido Detergente de Cor e no OMO Total. Estes resultados indicam que particularmente a celulase de 20K e a preparao de celulase de ALK04237 funcionam nos detergentes como agentes removedores de felpos aps j um tempo de lavagem.</span>Table XV. Tissue weight loss after first wash time with neutral cellulases in detergents. ns of preparation time dosing h% loss sample zyme as weight pro- tein / g tissue No Color Detergent Liquid 1 - 1 0.5 2 ALK04237 11 1 0.3 3 ALK04237 22 1 0.7 4 20K cellulase 2 1 0.1 5 20K cellulase 5 1 0.5 6 20K cellulase 8 1 1.0 7 50K cellulase 2 1 0.1 8 50K cellulase 5 1 0.2 9 - 0.5 0 , 20 10 20K cellulase 8 0.5 0.5 No OMO Total: 11 - - 1 0.03 12 20K cellulase 8 1 1.1 13 - - 0.5 0.1 14 20K 80 cellulase, 0.7 In Table XV it is shown that after the first Launder-Ometer wash, tissue weight loss was increased significantly more with cellulase treated than single detergent treated fabrics. Also weight loss was increased as a function of cellulase dosage and, additionally, with 20K cellulase, weight loss was increased when the wash time was increased from 0.5 to 1 hour. The 20K cellulase worked equally well in Color Detergent Liquid and Total OMO. These results indicate that particularly the 20K cellulase and the ALK04237 cellulase preparation function in detergents as fluff removers after a wash time.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aps trs tempos de lavagem adicionais com as amostras 1,2, 4 e 7 (Tabela XV), a avaliao dos tecidos foi efetuada por um jri consistindo em trs pessoas. Os jurados foram solicitados a avaliar a maciez e o aspecto visual dos tecidos tratados como se segue. A maciez dos tecidos: A. o tecido tratado com a celulase  mais macio do que o tecido tratado sem a celulase. B. o tecido tratado com a celulase  to macio quanto o tecido tratado sem a celulase. C. O tecido tratado com a celulase  mais spero do que o tecido tratado sem a celulase.</span>After three additional wash times with samples 1,2, 4 and 7 (Table XV), tissue evaluation was performed by a jury consisting of three people. Judges were asked to evaluate the softness and visual appearance of the treated tissues as follows. The softness of the tissues: A. Cellulase treated tissue is softer than cellulase treated tissue. B. Cellulase treated tissue is as soft as cellulase treated tissue. C. Tissue treated with cellulase is rougher than tissue treated without cellulase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os resultados so mostrados na Tabela XVI. O aspecto visual dos tecidos foi avaliado por classificao dos tecidos em uma contagem de 1 a 5. A contagem de 5 no proporcionou nenhum felpo ou bola e a textura do tecido tornou-se mais aparente. A contagem de 1 proporcionou muitas bolas e felpo. A contagem total para cada tecido foi calculada e dividida pelo nmero dos jurados. A contagem mdia do aspecto visual de cada tecido  mostrada na Tabela XVI.</span>Results are shown in Table XVI. The visual appearance of the fabrics was assessed by grading the fabrics to a count of 1 to 5. The count of 5 provided no fuzz or ball and the texture of the fabric became more apparent. Counting 1 provided many balls and fuzz. The total count for each tissue was calculated and divided by the number of judges. The average count of the visual appearance of each fabric is shown in Table XVI.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela XVI. Maciez e aspecto visual dos tecidos aps 4 tempos de lavagem repetidos com celulases neutras nos detergentes. preparao dosagem de enzi- Tempo maciez aspecto zima como pro- h visual tena/g de tecido No Lquido Detergente de Cor: 1 1 ALK04237 11 1 100%: mais macios com 3,2 a celulase celulase de 20K 2 1 100%: mais macios com 3,7 a celulase celulase de 5K 2 1 100%: sem diferena 1,7 Aps os 4 tratamentos, os tecidos tratados com a celulase tinham claramente um melhor aspecto visual do que os tecidos que foram tratados com o detergente nico. Assim, os tecidos tratados com estas celulases mantiveram o bom aspecto, e a formao de felpo foi evitada aps as lavagens repetidas, em comparao com o tecido tratado sem as celulases. Tambm aps 4 tempos de lavagem, os tecidos tratados com ALK04237 e com celulase de 20K eram mais macios do que o tecido tratado com o detergente nico.</span>Table XVI Softness and visual appearance of fabrics after 4 repeated wash times with neutral cellulases in detergents. preparation enzyme dosage Time softness zym aspect as visual pro- tein / g tissue No Liquid Detergent Color: 1 1 ALK04237 11 1 100%: softer with 3.2 to 20K cellulase cellulase 2 1 100%: more soft with 3.7 cellulase 5K 2 1 100% cellulase: no difference 1.7 After the 4 treatments, tissues treated with cellulase clearly had a better visual appearance than fabrics that were treated with single detergent. Thus, tissues treated with these cellulases maintained good appearance, and the formation of fuzz was prevented after repeated washes compared to tissue treated without cellulases. Also after 4 wash times, ALK04237 and 20K cellulase treated fabrics were softer than single detergent treated fabric.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 16 Uso de celulases neutras nos detergentes sobre malhas felpudas de algodo Nesta experincia  descrita a capacidade das celulases neutras de funcionarem como agente amaciante de tecido e evitar a formao de felpo e, assim, reduzir a tendncia  formao de bolas da malha felpuda de algodo colorida aps lavagens de roupas repetidas nos detergentes. As preparaes de celulases testadas eram o filtrado da cultura concentrado de ALK04237 e a celulase de 20K purificada a partir da cepa ALK04237 (Exemplos 1 e 9).</span>Example 16 Use of Neutral Cellulases in Cotton Wool Knit Detergents In this experiment the ability of neutral cellulases to function as a fabric softener and to prevent the formation of fuzz and thus reduce the tendency to ball formation of the fuzzy mesh is described. colored cotton after repeated laundry washes in detergents. The cellulase preparations tested were the concentrated culture filtrate of ALK04237 and the 20K cellulase purified from the ALK04237 strain (Examples 1 and 9).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As amostras de malha felpuda de algodo verde foram lavadas no Launder-Ometer, no Detergente Lquido de Cor ou no OMO Total, por 1 h, 3 ou 10 vezes, com ou sem as celulases, conforme descrito no Exemplo 15. A avaliao das malhas foi efetuada por um jri consistindo em trs pessoas. Os jurados foram solicitados a avaliar a maciez e o aspecto visual (tanto o lado direito quanto o avesso) das malhas tratadas, conforme descrito no Exemplo 15. A perda de peso das malhas foi determinada como descrito no Exemplo 15. Os resultados so mostrados na Tabela XVII.</span>Fuzzy green cotton knit samples were washed in Launder-Ometer, Liquid Color Detergent or Total OMO for 1 h, 3 or 10 times with or without cellulases as described in Example 15. The mesh was made by a jury consisting of three people. Judges were asked to evaluate the softness and visual appearance (both right and wrong side) of the treated meshes as described in Example 15. The weight loss of the meshes was determined as described in Example 15. Results are shown in Table XVII.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aps 3 tempos de lavagem, as malhas tratadas com celulase de 20K tinham um melhor aspecto visual, tanto no lado direito quanto no avesso, do que as malhas tratadas com o detergente nico. As malhas tratadas 10 vezes com a preparao de celulase de ALK04237 tinham claramente um melhor aspecto visual e uma cor verde mais viva do que as malhas tratadas somente com o detergente. O melhor aspecto visual das malhas tratadas com a celulase foi detectado j aps 1 tempo de lavagem (especialmente sobre o avesso), e ele foi adicionalmente desenvolvido durante as lavagens adicionais. As malhas tratadas com a celulase eram tambm mais macias do que as malhas tratadas com o detergente nico.   3 h-T   .  2 2   8&gt; *  lo &gt; CNI 5 "  (0  _ (0        Q-  Q-  ET? -  f".     t  t   )  c ?  " " -* cm" " -~ -  3   3  Q  - 2  F - % ' g ro   I</span>After 3 wash times, the 20K cellulase treated meshes had a better visual appearance on both the right and inside side than the single detergent treated meshes. Meshes treated 10 times with the ALK04237 cellulase preparation clearly had a better visual appearance and brighter green color than meshes treated with detergent alone. The best visual appearance of the cellulase treated meshes was detected after 1 wash time (especially on the reverse side), and it was further developed during the additional washings. The cellulase-treated meshes were also softer than the single detergent-treated meshes.   3 h-  .  2 2   8&gt; *  lo&gt; CNI 5  " (0  _ (0        Q-  Q- ET? -  f ".     t  t   )  c ?  "  "- * cm"  "- ~ -  3   3 Q  - 2  F -% 'ro g ro   I</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">$  &gt; )    COCN TS W . iS  (C 00'  00 " 3 (0 .  3   -   SZ *5  S c  C  3 ( ^ m C ( t0   45 &gt;  &gt; 13 Jto c* C0 1  g    3 j JS (  - - - - .W "Q</span>$  &gt; )    COCN TS W . iS  (C 00 ' 00  "3 (0 .  3    -   SZ * 5  S c  C 3 ( ^ m C ( t0   45&gt;  &gt; 13 Jto c * C0 1  g    3 j JS ( - - - - .W" Q</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">&gt; OT  3 &gt; c  &lt; Q- .    sP F (0  ' g  c w '   S c -S     13 $ 2 co n   - 3   3    -g 5  " | 5&gt; s  &gt; S !   . (   S I  C0  w 3       . -SilOiCM iCM |   g  _  c   &lt; !&gt; m  ,S  " 3   *8. Q   ? 5 | 3 * &lt;  &amp;   00 2   Sn 5 t   .  i cn  &lt;c  . &lt;C  h- CO CO  T- CN T~ oi T- cm" t o L.  &gt;  co o TJ _ro ro  CO &gt; o 5  g- LO u&gt; co CO t~ t T- CM T- CM    (O (O to O o .2 J3 jo 2!    o o     co 'S.  5  e co  E o o ZJ T3 O O O .2   to to ^ -p  .&lt;S .5 o   ~  U &lt;N   2 Pi 2  i I Cu P I p T3 = | E .2     1 I o : &lt;M-g e r. t  3 (0^0 co o  II t- E -J co t-O T- * Exemplo 17 Uso de celulases neutras nos detergentes sobre malhas felpudas de algodo envelhecidas Nesta experincia  descrita a capacidade das celulases neutras de funcionar em como agente renovador e amaciante de tecido. A malha felpuda de algodo verde foi lavada 10 vezes, com secagem intermediria, na mquina de lavar roupas da Cylinda com programa 3 a 60C, 10 ml de OMO Color (Lever, UK). Isto era para estimular as lavagens da malha na prtica.</span>&gt; OT  3 &gt; c  &lt;Q-.   sP F (0   'g  cw'   S c -S    13 $ 2 co n   - 3  3    -g 5   "| 5&gt; s  &gt; S! . (   SI  C0  w 3      . -SilOiCM iCM |   g  _ - c -  &lt;!&gt; M , S  " 3   * 8. Q  ? 5 | 3 * &lt;  &amp;   00 2 Sn  Sn 5 t   .  i cn  &lt;c . &lt;C  h- CO CO  T - CN T ~ oi T- cm "tio L. &gt;  with TJ _ro ro  CO &gt; o 5 g LO u&gt; co CO t ~ t T-CM T-CM    (O (O to O o .2 J3 jo 2!    oo     co 'S. 5  e co  E oo ZJ T3 OOO .2   to to ^ -p . &lt;S .5 o Pi  ~  U &lt;N  2 Pi 2  i I Cu P I p T3 = | E. 2    1 I o: &lt; Mg e r. T  3 (0 ^ 0 Example 17 Using Neutral Cellulases in Detergents on Aged Cotton Knitwear In this experiment the ability of neutral cellulases to function as a fabric softener and renewer is described. Green cotton wool was washed 10 times, with intermediate drying, in the Cylinda washing machine with program 3 at 60  C, 10 ml of OMO Color (Lever, UK). This was to stimulate mesh washes in practice.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aps 10 tratamentos, esta malha envelhecida tinha um aspecto sem atrativo e desbotado com muitos felpos na superfcie.</span>After 10 treatments, this aged mesh looked unattractive and faded with many fluff on the surface.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aps estas 10 lavagens repetidas, a malha felpuda foi usada para as experincias de lavagem com ou sem celulase. As amostras de malha foram lavadas no Launder-Ometer, no Detergente Lquido de Cor, por 1 h, 1 a 3 vezes, conforme descrito no exemplo 15, com enxaguadura e secagem intermedirias. As preparaes de celulases usadas eram o filtrado da cultura concentrado de ALK04237 e as celulases de 20K e de 50K de ALK04237 (Exemplo 9). A avaliao das malhas foi efetuada por um jri consistindo em trs pessoas. Os jurados foram solicitados a avaliar a maciez e o aspecto visual (tanto o lado direito quanto o avesso) das malhas tratadas, conforme descrito no Exemplo 15. A perda de peso das malhas foi determinada como descrito no Exemplo 15. Os resultados so mostrados na Tabela XVIII.</span>After these 10 repeated washes, the fuzzy mesh was used for the washing experiments with or without cellulase. The mesh samples were washed in Launder-Ometer in the Liquid Color Detergent for 1 h, 1 to 3 times as described in Example 15 with intermediate rinsing and drying. The cellulase preparations used were the ALK04237 concentrate culture filtrate and the ALK04237 20K and 50K cellulases (Example 9). The evaluation of the meshes was carried out by a jury consisting of three people. Judges were asked to evaluate the softness and visual appearance (both right and wrong side) of the treated meshes as described in Example 15. The weight loss of the meshes was determined as described in Example 15. Results are shown in Table XVIII.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aps um tempo de lavagem, as malhas tratadas com ALK04237 e com a celulase de 20K tinham um aspecto visual ligeiramente melhor do que a malha tratada com o detergente nico. O bom aspecto visual e o aspecto mais atrativo foram adicionalmente desenvolvidos para as malhas tratadas com a celulase de 20K aps 2 e 3 tempos de lavagem. O aspecto visual foi tambm aperfeioado aps dois tempos de lavagem sobre as malhas tratadas com a celulase de 50K em comparao com a malha tratada com o detergente nico. Em geral, as malhas tratadas com as celulases tinham um aspecto claramente aperfeioado e atrativo, ao passo que as malhas tratadas sem a celulase tinham um aspecto ainda sem atrativo e desbotado.  #  8 3  ~  - W. 3  C0  .     &gt; +m *"*     ?  -  $   Q.  10  m  * Q  cx -  cd   *-  -    - t   ro  SP 3  C0  .  3 2   0)  *  ^ (0 &gt; -'   c  '0   " 05   &gt; QQQCDh-h-COQO</span>After a wash time, the ALK04237 and 20K cellulase treated meshes had a slightly better visual appearance than the single detergent treated meshes. Good visual appearance and more attractive appearance were further developed for 20K cellulase treated meshes after 2 and 3 wash times. The visual appearance was also improved after two wash times on the 50K cellulase treated meshes compared to the single detergent treated meshes. In general, cellulase-treated meshes had a clearly improved and attractive appearance, whereas cellulase-treated meshes had a still unattractive and faded appearance.  #  8 3  ~  - W. 3  C0  .     &gt; + me  * " *     ?  -  $  Q.   10  m  *  Q cx -  cd    * -   -    -  t  ro  SP 3  C0 .  3 2   0)  *  ^ (0&gt; - '  c ' 0    "05    &gt; QQQCDh-h-COQO</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">-g  .     rC |sT C iC Z Z 3 ffi  o) &amp; 5     x: 2 5 D     p co   m  -p S ) ^ &lt; E f   I S it-t-CMCMCMCMCOOO</span>-g  .     rC | sT iC ZZ 3 ffi   o) &amp; 5    - x: 22 5 D      p co   m  -p S ) ^ &lt;E f   IS it-t-CMCMCMCMCOOO</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> B &gt; c 5 oi 5  Q.  o  TJ C CO r o o  O o o c o co co  "   ~  Cl     -S S ~  -i  "D g  ? o&gt; | s | 1 E ro B N  co   o) o ir o lo _ OCX i CM IO i    , IO</span> B &gt; c 5 hi 5  Q.  o  TJ C CO r oo  Ooc o co co "    ~ Cl    -SS ~   -i  "D  g  ? o&gt; | s | 1 E ro B N o co o o o o o o o o o o o o o o o o o</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">* I = o _ T   fs. 6  S co X o  ffl CM  tj &gt;_ E ^  t n 5 O  * * * JQ g. m g- * ic *!:* * ,ro g- 2 2 -j o ooo o l- C  CL I &lt; CM i CM LO  I CM  tn (  &gt; C0 -   CN ( CO (  (| I    ro _ 3 tn "&gt;  *   g*    CO r r r - " - r r (   /   ro ^ 3 3 S^      m .8 co      13 5    D 5 coco   "5 .  * MJ * ' MS V  CC rj C C ra .r o 2 E '0 2 2 s    a f  | | |    3 3   " fc  73 = r- r- WCC m "D  &gt; E E m   m I (   2 2 Oco ^ tn tn tz tn tn t ico-= CO N .... ........ c 2. - sP sP v^psP sO   Cl) TT O^* li O Sm OO O O O O rs 7, co OO ooo o 9 11 | C t T r -r-* T- Z * Exemplo 18 Isolamento do DNA cromossmico de ALK04237 e construo da biblioteca genmica 0 Melanocarpus albomyces ALK04237 foi desenvolvido em culturas de frascos com agitao, em meio de dextrose da batata (PD; Difco, EUA), a 42C, 250 rpm, por 3 dias. O DNA cromossmico foi isolado de acordo com Raeder e Broda, Lett. Appl. Microbiol. 1:17-20 (1985). Resumidamente, o miclio foi lavado com EDTA a 20 mM e lisado em tampo de extrao (Tris-HCI  200 mM (pH 8,5), NaCI a 250 mM, EDTA a 25 mM, SDS a 0,5%). O DNA foi extrado com fenol e uma mistura de clorofrmio:lcool isoamlico (24:1 v/v). O RNAfoi digerido com RNase. O DNA cromossmico foi parcialmente digerido com Sai/3A (Boehringer Mannheim, Alemanha) e tratado com fosfatase alcalina do intestino do bezerro. O DNA variando de 5 - 15 kb foi isolado a partir de um gel de agarose usando a beta-agarase (Boehringer Mannheim, Alemanha), e usado para construir a biblioteca genmica de ALK04237. O Kit de Vetor SamHI Lambda DASHII pr-digerido (Stratagene, EUA) foi usado para construir a biblioteca e as instrues do fabricante foram seguidas em todas as etapas subseqentes. Resumidamente, cerca de 200 ng do DNA fracionado no tamanho foram ligados em 1 pg de braos preparados com DASHII, e acondicionados usando o extrato de acondicionamento Gigapack II (Stratagene, EUA). O ttulo da biblioteca foi determinado infectando-se as clulas de XL 1-Blue MRA (P2) de E. coli com diluies em srie do fago acondicionado e preparando-se sobre placas de NZY. A biblioteca foi armazenada  4C em tampo SM, com clorofrmio a 4% (v/v). Ela foi usada para exame sem amplificao.</span>* I = o _    fs. 6 S co X o  ffl CM  tj &gt; _ E ^  t n 5 O * * * JQ g. m g- * ic *!: * *, ro g- 2 2 -jo ooo ol  - C  CL I &lt;CM i CM LO  I CM  tn ( &gt; C0 -   CN ( CO (   ( | I    ro _ 3 tn "&gt;  *     g *    CO rrr - " - rr (    /    ro ^ 3 3 S ^      m .8 co      13 5    D 5 coconut   "5  .   * MJ  *  'MS V   CC rj CC ra  ction 2 E '0 2 2 s    af  | | |   - 3 3' "  fc  73 = r- r-WCC m "D &gt; EE m  m I (   2 2 Hollow ^ tn tn tz tn tn tico- = CO N .... ........ c 2. - sP sP v ^ psP sO  Cl) TT O ^ * li O  Sm OO OOOO rs 7, with "OO ooo o 9 11" Example 18 Isolation of the chromosomal DNA from ALK04237 and construction of the genomic library Melanocarpus albomyces ALK04237 was developed in Shake flask cultures in potato dextrose medium (PD; Difco, USA) at 42  C, 250 rpm for 3 days Chromosomal DNA was isolated according to Raeder and Broda, Lett. Appl. Microbiol 1: 17-20 (1985) Briefly, the mycelium was washed with 20 mM EDTA and lysed in extraction buffer (200 mM Tris-HCl (pH 8.5)). , 250 mM NaCl, 25 mM EDTA, 0.5% SDS). The DNA was extracted with phenol and a mixture of chloroform: isoamyl alcohol (24: 1 v / v). RNA was digested with RNase. Chromosomal DNA was partially digested with Sai / 3A (Boehringer Mannheim, Germany) and treated with calf intestinal alkaline phosphatase. DNA ranging from 5 - 15 kb was isolated from an agarose gel using beta agarase (Boehringer Mannheim, Germany), and used to construct the ALK04237 genomic library. The pre-digested SamHI Lambda DASHII Vector Kit (Stratagene, USA) was used to build the library and the manufacturer's instructions were followed in all subsequent steps. Briefly, about 200 ng of size fractionated DNA was ligated into 1 pg of DASHII-prepared arms, and packaged using Gigapack II wrapping extract (Stratagene, USA). The titer of the library was determined by infecting E. coli XL 1-Blue MRA (P2) cells with serial dilutions of the packed phage and preparing on NZY plates. The library was stored at 4  C in SM buffer with 4% (v / v) chloroform. It was used for examination without amplification.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 19 Amplificao, clonagem e seqenciamento do DNA de celulase de 20K com os primers degenerados Para amplificar o gene de celulase de 20K por reao em cadeia por polimerase (PCR), um par de primers degenerados, com base nas seqncias de peptdeos (Figura 17), foi sintetizado. 0 primer 1 (429-32) foi derivado a partir dos aminocidos n- 8-14 do peptdeo com N terminal n 429 (Figura 17), e o primer 2 (fr28-16) foi projetado como a fita sem sentido para os aminocidos n- 2 - 8 do peptdeo fr28 (Figura 17). Os stios de restrio de EcoR1 adicionais foram adicionados nas extremidades 5' para facilitar a clonagem do fragmento amplificado.</span>Example 19 Amplification, cloning and sequencing of 20K cellulase DNA with degenerate primers To amplify the 20K cellulase gene by polymerase chain reaction (PCR), a pair of degenerate primers based on peptide sequences (Figure 17 ) has been synthesized. Primer 1 (429-32) was derived from amino acids # 8-14 of N-terminal peptide # 429 (Figure 17), and primer 2 (fr28-16) was designed as the meaningless ribbon for amino acids # 2-8 of peptide fr28 (Figure 17). Additional EcoR1 restriction sites were added at the 5 'ends to facilitate cloning of the amplified fragment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primer 1 (429-32) EcoRI</span>Primer 1 (429-32) EcoRI</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5'- ATA GAATTC TA (C/T) TGG GA (C/T) TG (C/T) AA (A/G) CC Y W D C K P</span>5'- ATA GAATTC TA (C / T) TGG GA (C / T) TG (C / T) AA (A / G) CC Y W D C K P</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primer 2(fr28-16) EcoRi 5'- ATA GAATTC TT (A/G) TC (A/C/G/T) GC (A/G) TT (C/T TG (A/G) AA</span>Primer 2 (fr28-16) EcoRi 5'- ATA GAATTC TT (A / G) TC (A / C / G / T) GC (A / G) TT (C / T TG (A / G) AA</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">N D A N Q F</span>N D A N Q F</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CCA</span>CCA</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">W</span>W</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Na reao por PCR, 1 pg do DNA genmico de ALK04237 purificado (Exemplo 18) foi usado como o molde. A DNA polimerase Dynazyme (Finnzymes Ltd, Finlndia) foi usada de acordo com as instrues do fornecedor. DNA de molde (0,7pg/pl) 1,4  Primer 1 (0,5 pg/pi) 1  Primer 2 (0,5pg/pi) 1  dNTPs (2 nM) 5  10 tampo de PCR 10  dH20 82  Dynamize (2U/pI) 1  Total 101,4  A reao por PCR foi efetuada sob as seguintes condies: Etapa 1 95C 5 min Etapa 2 95C 1 min Etapa 3 56C 1 min Etapa 4 72C 1 min Etapa 5 ir para a "etapa 2" 29 vezes mais Etapa 6 72C 8 min Etapa 7 4C sustentar Dez  de mistura de reao foram analisados por eletroforese em gel de agarose, e uma banda nica correspondendo a cerca de 600 bp no comprimento foi detectada. O restante do produto de PCR foi digerido com a endoglicanase de restrio de EcoR1, e corrido por eletroforese em agarose. A seo de agarose contendo o fragmento de DNA foi excisada, e purificada pelo mtodo de Magic PCR Preps (Promega, EUA) de acordo com as instrues do fornecedor. O fragmento isolado foi ligado com o plasmdio pBluescript II SK+ (Stratagene, EUA), o qual foi cortado similarmente com coR1. As clulas de XL-Blue de Escherichia coli adequadas (Stratagene, EUA) foram transformadas com a mistura de ligao. O DNA do plasmdio a partir de algumas das colnias resultantes foi isolado pelo mtodo de Magic Minipreps (Promega, EUA) de acordo com as instrues do fornecedor. O DNA do plasmdio foi analisado por eletroforese em agarose, e um clone com caractersticas esperadas foi designado pALK549. O DNA de Melanocarpus a partir de pALK549 foi seqenciado utilizando-se os kits ABI (Applied Biosystems, EUA) com base nos primers T3 e T7 marcados com fluorescente, ou nos primers especficos para seqncia com didesoxinucleotdeos marcados com fluorescente, pelo protocolo de seqnciamento com ciclo de primer com corante de Taq, de acordo com as instrues do fornecedor. Por causa do alto teor de GC do DNA de Melanocarpus, as reaes de seqnciamento foram efetuadas na temperatura de recozimento de 58C, com DMSO  5% (v/v). As reaes de seqnciamento foram analisadas no seqnciador ABI 373A (Applied Biosystems, EUA), e as seqncias obtidas foram caracterizadas pela utilizao do Pacote de Software de Anlise de Seqncia de Grupo para Computador da Genetics, verso 7.2. O inserto (594 bp) no pALK549 foi verificado codificar a maior parte dos peptdeos derivados da celulase de 20K (Figura 17). O DNA amplificado por PCR (alm dos primers) corresponde aos nucleotdeos 175-716 na Figura 19. O DNA cromossmico a partir de Myriococcum sp. ALK04124 foi isolado conforme descrito no Exemplo 18. Uma reao por PCR com os primers 429-32 e fr28-16 e com o DNA cromossmico de ALK04124 como o molde produziu um fragmento de mesmo tamanho que o DNA de ALK04237. Este fragmento foi parcialmente seqnciado, e era quase idntico  seqncia de ALK04237.  concludo que o Myriococcum sp. ALK04124 tem uma protena, a qual  quase idntica  celulase de 20K de Melanocarpus albomyces ALK04237. Este resultado est tambm em concordncia com a observao de que os anticorpos especficos para a celulase de 20K de ALK04237 tambm identificam uma banda da protena de 20K a partir do meio de desenvolvimento de ALK04124 na anlise de Western (Figura 14). As enzimas de ambas as cepas proporcionaram bons resultados similares nas experincias de biotratamento com pedras (Exemplos 3 e 4).</span>In the PCR reaction, 1 pg of purified ALK04237 genomic DNA (Example 18) was used as the template. Dynazyme DNA polymerase (Finnzymes Ltd, Finland) was used according to the supplier's instructions. Template DNA (0.7pg / pl) 1.4  Primer 1 (0.5 pg / pi) 1  Primer 2 (0.5pg / pi) 1  dNTPs (2 nM) 5  10 PCR Buffer 10  dH20 82  Dynamize (2U / pI) 1  Total 101.4  The PCR reaction was performed under the following conditions: Step 1 95  C 5 min Step 2 95  C 1 min Step 3 56  C 1 min Step 4 72  C 1 min Step 5 go to "step 2" 29 times longer Step 6 72  C 8 min Step 7 4  C sustain Ten  reaction mixture was analyzed by agarose gel electrophoresis, and a single band corresponding at about 600 bp in length was detected. The remainder of the PCR product was digested with EcoR1 restriction endoglycanase, and run by agarose electrophoresis. The agarose section containing the DNA fragment was excised, and purified by the Magic PCR Preps method (Promega, USA) according to the supplier's instructions. The isolated fragment was ligated with plasmid pBluescript II SK + (Stratagene, USA), which was cut similarly with? CoR1. Suitable Escherichia coli XL-Blue cells (Stratagene, USA) were transformed with the ligation mixture. Plasmid DNA from some of the resulting colonies was isolated by the Magic Minipreps method (Promega, USA) according to the supplier's instructions. Plasmid DNA was analyzed by agarose electrophoresis, and a clone with expected characteristics was designated pALK549. Melanocarpus DNA from pALK549 was sequenced using the ABI kits (Applied Biosystems, USA) based on the fluorescently labeled T3 and T7 primers, or the fluorescently labeled dideoxynucleotide sequence-specific primers, using the DNA sequencing protocol. Taq dye primer cycle according to the supplier's instructions. Because of the high GC content of Melanocarpus DNA, sequencing reactions were performed at annealing temperature of 58  C, with 5% (v / v) DMSO. Sequencing reactions were analyzed on the ABI 373A sequencer (Applied Biosystems, USA), and the sequences obtained were characterized by the use of the Genetics Computer Group Sequence Analysis Software Package, version 7.2. The insert (594 bp) in pALK549 was found to encode most 20K cellulase-derived peptides (Figure 17). PCR amplified DNA (in addition to primers) corresponds to nucleotides 175-716 in Figure 19. Chromosomal DNA from Myriococcum sp. ALK04124 was isolated as described in Example 18. A PCR reaction with primers 429-32 and fr28-16 and chromosomal DNA from ALK04124 as the template produced a fragment of the same size as ALK04237 DNA. This fragment was partially sequenced, and was almost identical to the sequence of ALK04237. It is concluded that Myriococcum sp. ALK04124 has a protein which is almost identical to Melanocarpus albomyces 20K cellulase ALK04237. This result is also in line with the observation that ALK04237 20K cellulase specific antibodies also identify a 20K protein band from the ALK04124 development medium in Western analysis (Figure 14). Enzymes from both strains provided similar good results in stone biotreatment experiments (Examples 3 and 4).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 20 Clonagem e seqnciamento do gene de celulase de 20K de Melanocarpus albomyces ALK04237 As clulas de XL1-Blue MRA (P2) de E. coli (Stratagene, EUA) foram desenvolvidas em LB + maltose a 0,2% + MgS04  10 mM, e diludas para ODeoo = 0,5. As clulas foram infectadas com a biblioteca genmica de Melanocarpus albomyces ALK04237 (Exemplo 18) por 15 min., a 37C, e preparadas com gar sobre a parte de cima de NZY em placas de NZY. As placas foram incubadas a 37C durante a noite. As placas foram transferidas para um filtro de nilon (Hybond, Amersham, UK) de acordo com as instrues da Stratagene. 0 fragmento de PCR purificado (Exemplo 19) foi marcado com digoxigenina de acordo com a Boehringer, DIG DNA Labeling and Detection Nonradioactive, Manual de Aplicao. A hibridao foi efetuada a 68C. Os clones positivos foram selecionados em tampo SM/clorofrmio, e purificados com um segundo ciclo de exame.</span>Example 20 Cloning and Sequencing of the Melanocarpus albomyces 20K Cellulase Gene ALK04237 E. coli XL1-Blue MRA (P2) cells (Stratagene, USA) were grown in LB + 0.2% maltose + 10 mM MgSO4 , and diluted to ODeoo = 0.5. Cells were infected with the Melanocarpus albomyces ALK04237 genomic library (Example 18) for 15 min. At 37  C and prepared with agar on the top of NZY in NZY plates. The plates were incubated at 37  C overnight. The plates were transferred to a nylon filter (Hybond, Amersham, UK) according to Stratagene instructions. The purified PCR fragment (Example 19) was labeled with digoxigenin according to Boehringer, DIG DNA Labeling and Detection Nonradioactive, Application Manual. Hybridization was performed at 68  C. Positive clones were selected in SM / chloroform buffer, and purified with a second round of examination.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foram encontrados 4 clones positivos sob estas condies. O isolamento do DNA de bacterifago lambda em grande escala, a partir dos clones, foi feito de acordo com Sambrook e col., em Molecular Cloning: A Laboratory Manual, 2~ edio, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, Nova York, 1989. Os DNAs do fago foram analisados por digesto do DNA com diversas enzimas de restrio, e o DNA digerido foi hibridizado com a sonda de PCR. Trs fragmentos de hibridao foram isolados: fragmento de EcoR1-XftoI de cerca de 2,6 kb, fragmento de Xho\ de cerca de 4,9 kb e fragmento de Saci de cerca de 3 kb. Estes foram inseridos no vetor de pBluescript II SK+ similarmente cortado (Stratagene, EUA), criando os plasmdios pALK1221, pALK1222 e pALK1223, respectivamente (Figura 18). O DNA de Melanocarpus albomyces no pALK1221 foi seqnciado conforme descrito no Exemplo 19. A sequncia de DNA codificando a celulase de 20K de Melanocarpus albomyces  mostrada na Figura 19. A sequncia  936 bp de comprimento, e tem um quadro de leitura aberto (OFR) codificando para 235 aminocidos; o gene tem dois ntrons. O stio de processamento de peptdeo de sinal putativo est aps a alanina 21, e a extremidade com N da protena madura comea na alanina 22, conforme sugerido pelos resultados do seqnciamento do peptdeo (Figura 17, peptdeo ns 429). O OFR prediz uma protena com um peso molecular de 25,0 kDa para a pr-protena de tamanho natural, e 22,9 kDa para a protena madura. Isto est em boa concordncia com os resultados obtidos a partir do trabalho de purificao da protena (Exemplo 10). Estes resultados tambm verificam que a protena de cerca de 35 kDa, detectada anteriormente com o anti-soro de celulase de 20K (Exemplo 10),  um produto de gene diferente do que a celulase de 20K. A celulase de 20K de Meianocarpus albomyces parece pertencer  famlia K das celulases e  famlia 45 das glicosi! hidrolases (Henrissat e Bairoch, Biochem. J. 293:781-788 (1993)). A celulase de 20K mostra homologia (cerca de 76% de identidade na sobreposio dos 235 aminocidos) em relao  endoglicanase V de Humicola insolens (embl:a23635), porm a celulase de 20K tem a caracterstica surpreendente de que ela no abriga o domnio de ligao  celulose (CBD) e o seu ligador, que so caractersticas da endoglicanase V de Humicola insolens e de outras endoglicanases relacionadas (Schlein e col., 1993, Em: Suominen &amp; Renikanen (eds), Foundation for Biotechnical and Industrial Fermentation Research, Helsinki, vol. 8, 109,; Saloheimo e col., 1994, Mol. Microbiol. 13, 219). Esta caracterstica da celulase de 20K pode ser responsvel pelo excelente desempenho da enzima nas experincias de biotratamento com pedras (Exemplo 10).</span>Four positive clones were found under these conditions. Isolation of large-scale lambda bacteriophage DNA from clones was done according to Sambrook et al. In Molecular Cloning: A Laboratory Manual, 2 nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York , 1989. Phage DNAs were analyzed by DNA digestion with various restriction enzymes, and the digested DNA was hybridized with the PCR probe. Three hybridization fragments were isolated: about 2.6 kb EcoR1-XftoI fragment, about 4.9 kb Xho? Fragment and about 3 kb Saci fragment. These were inserted into the similarly cut pBluescript II SK + vector (Stratagene, USA), creating plasmids pALK1221, pALK1222 and pALK1223, respectively (Figure 18). Melanocarpus albomyces DNA in pALK1221 was sequenced as described in Example 19. The DNA sequence encoding Melanocarpus albomyces 20K cellulase is shown in Figure 19. The sequence is 936 bp in length, and has an open reading frame (OFR) ) coding for 235 amino acids; The gene has two introns. The putative signal peptide processing site is after alanine 21, and the N-terminus of the mature protein begins at alanine 22, as suggested by the results of peptide sequencing (Figure 17, peptide # 429). OFR predicts a protein with a molecular weight of 25.0 kDa for the life-size preprotein, and 22.9 kDa for the mature protein. This is in good agreement with the results obtained from the protein purification work (Example 10). These results also verify that the about 35 kDa protein previously detected with the 20K cellulase antiserum (Example 10) is a different gene product than the 20K cellulase. Meianocarpus albomyces 20K cellulase appears to belong to the K cellulose family and the glycosyl family 45. hydrolases (Henrissat and Bairoch, Biochem. J. 293: 781-788 (1993)). The 20K cellulase shows homology (about 76% identity at 235 amino acid overlap) to Humicola insolens endoglycanase V (embl: a23635), but the 20K cellulase has the surprising feature that it does not harbor the cellulose binding (CBD) and its linker, which are characteristic of Humicola insolens endoglycanase V and other related endoglycases (Schlein et al., 1993, In: Suominen &amp; Renikanen (eds), Foundation for Biotechnical and Industrial Fermentation Research, Helsinki, vol. 8, 109; Saloheimo et al., 1994, Mol. Microbiol., 13, 219). This characteristic of 20K cellulase may be responsible for the enzyme's excellent performance in stone biotreatment experiments (Example 10).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 21 Amplificao, clonagem e seqiinciamento do DNA de celulase de SOK com os prmers degenerados Os peptdeos derivados a partir da celulase de SOK (Tabela IX) compartilham alguma homologia em relao  endoglicanase I de Humicola grisea (DDBJ:D63516). Para amplificar o gene de celulase de SOK por reao em cadeia por polimerase (PCR), um par dos primers degenerados, baseados nas sequncias de peptdeos (Tabela IX), foi sintetizado. O primer 1 (507-128) foi derivado dos aminocidos n~ 5-10 do peptdeo ns 507 (Tabela IX), e o primer 2 (509-rev) foi projetado como a fita sem sentido para os aminocidos n- 4 - 9 do peptdeo 509 (Tabela IX). A ordem dos dois peptdeos na protena - e a natureza de sentido-sem sentido correspondente - foi deduzida a partir de comparao com a endoglicanase I de Humicola grisea.</span>Example 21 Amplification, Cloning, and Sequencing of SOK Cellulase DNA with Degenerate Primers Peptides derived from SOK cellulase (Table IX) share some homology to Humicola grisea endoglycanase I (DDBJ: D63516). To amplify the SOK cellulase gene by polymerase chain reaction (PCR), a pair of degenerate primers based on the peptide sequences (Table IX) were synthesized. Primer 1 (507-128) was derived from amino acids # 5-10 of peptide ns 507 (Table IX), and primer 2 (509-rev) was designed as the meaningless ribbon for amino acids # 4-9. of peptide 509 (Table IX). The order of the two peptides in the protein - and the corresponding sense-nonsense nature - was deduced from comparison with Humicola grisea endoglycanase I.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primer 1 (507/128) 5- GA (C/T) GA (A/G) AC (A/C/G/T) GA (A/G) CA (C/T) A/C) G D E T E H R</span>Primer 1 (507/128) 5'-GA (C / T) GA (A / G) AC (A / C / G / T) GA (A / G) CA (C / T) A / C) G D E T E H R</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primer 2 (509/rev) 5' - TA (A/C)G/T) GC (A/C/G/T) CC (A/CG/T) CC (A/C/G/T) GG (A/G) TT Y A G G P N</span>Primer 2 (509 / rev) 5 '- TA (A / C) G / T) GC (A / C / G / T) CC (A / CG / T) CC (A / C / G / T) GG ( A / G) TT YAGGPN</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Na reao por PCR, 1,5 g do D NA genmico de ALK04237 purificado (Exemplo 18) foram usados como o molde. A DNA polimerase Dynazyme (Finnzymes Ltd, Finlndia) foi usada de acordo com as instrues do fornecedor. DNA de molde (0,3 pg/) 5  Primer 1 (0,5 pg/) 1  Primer 2 (0,5 pg/) 1  dNTPs (2 nM) 5  10 tampo de PCR 10  dH20 79  Dynamize (2/) 1  Total 102 A reao por PCR foi efetuada sob as seguintes condies: Etapa 1 95C 5 min Etapa 2 95C 1 min Etapa 3 56C 1 min Etapa 4 72C 1 min Etapa 5 ir para a "etapa 2" 29 vezes mais Etapa 6 72C 8 min Etapa 7 4C sustentar Dez  de mistura de reao foram analisados por eletroforese em gel de agarose, e uma banda nica correspondendo a cerca de 160 bp no comprimento foi detectada. O restante do produto de PCR foi carregado em um gel de agarose que sofreu eletroforese, e a seo de agarose contendo o fragmento de DNA foi excisada, e purificada pelo mtodo de Magic PCR Preps (Promega, EUA) de acordo com as instrues do fornecedor. O fragmento isolado foi ligado com o plasmdio pBluescript II SK+ (Stratagene, EUA), o qual tinha sido digerido com a endonuclease de EcoRV, e preso na extremidade por ddT, conforme descrito em Holton e Graham (1990) Nucl. cids. Res. 19, 1156. As clulas de XL-Blue de Escherichia coli adequadas (Stratagene, EUA) foram transformadas com a mistura de ligao. O DNA do plasmdio, a partir de algumas das colnias resultantes, foi isolado pelo mtodo de Magic Minipreps (Promega, EUA) de acordo com as instrues do fornecedor. O DNA do plasmdio foi analisado por eletroforese em agarose, e um clone com caractersticas esperadas foi designado pALK1064. O inserto (161 bp) em pALK1G64 foi seqnciado conforme descrito no Exemplo 19, e foi verificado conter um ORF, o qual predisse um peptdeo homlogo  endoglicanase I de Humicola grisea (DDBJ:D63516). O ORF tambm codificou o peptdeo n 612 (Tabela IX) a partir da celulase de 50K purificada. O DNA amplificado por PCR (alm dos primers) corresponde aos nucleotdeos 404-530 na Figura 21. A PCR com os primers 507 e 590-rev com o DNA cromossmico de ALK04124 como molde (Exemplo 19) produziu um fragmento de mesmo tamanho que a partir do DNA de ALK04237. Isto sugere que o Myrococcum sp. ALK04124 tem uma protena muito similar  celulase de 50K de Melanocarpus albomyces ALK04237. Isto  tambm suportado pelo fato de que as enzimas de ambas as cepas proporcionaram bons resultados nas experincias de biotratamento com pedras.</span>In the PCR reaction, 1.5 g of the purified ALK04237 genomic DNA NA (Example 18) was used as the template. Dynazyme DNA polymerase (Finnzymes Ltd, Finland) was used according to the supplier's instructions. Template DNA (0.3 pg / ) 5  Primer 1 (0.5 pg / ) 1  Primer 2 (0.5 pg / ) 1  dNTPs (2 nM) 5  10 PCR Buffer 10  dH20 79  Dynamize (2 / ) 1  Total 102 The PCR reaction was performed under the following conditions: Step 1 95  C 5 min Step 2 95  C 1 min Step 3 56  C 1 min Step 4 72  C 1 min Step 5 go to "step 2" 29 times longer Step 6 72  C 8 min Step 7 4  C sustain Ten  reaction mixture was analyzed by agarose gel electrophoresis, and a single band corresponding to about 160 bp in length was detected. The remainder of the PCR product was loaded onto an electrophoresed agarose gel, and the agarose section containing the DNA fragment was excised, and purified by the Magic PCR Preps method (Promega, USA) according to the supplier's instructions. . The isolated fragment was ligated with plasmid pBluescript II SK + (Stratagene, USA), which had been digested with EcoRV endonuclease, and end-capped by ddT, as described in Holton and Graham (1990) Nucl. Acids Res. 19, 1156. Suitable Escherichia coli XL-Blue cells (Stratagene, USA) were transformed with the ligation mixture. Plasmid DNA from some of the resulting colonies was isolated by the Magic Minipreps method (Promega, USA) according to the supplier's instructions. Plasmid DNA was analyzed by agarose electrophoresis, and one clone with expected characteristics was designated pALK1064. The insert (161 bp) in pALK1G64 was sequenced as described in Example 19, and found to contain an ORF which predicted a homologue peptide to Humicola grisea endoglycanase I (DDBJ: D63516). ORF also encoded peptide # 612 (Table IX) from purified 50K cellulase. PCR amplified DNA (in addition to primers) corresponds to nucleotides 404-530 in Figure 21. PCR with 507 and 590-rev primers with ALK04124 chromosomal DNA as template (Example 19) produced a fragment of the same size as from the DNA of ALK04237. This suggests that Myrococcum sp. ALK04124 has a protein very similar to the 50K cellulase of Melanocarpus albomyces ALK04237. This is also supported by the fact that the enzymes of both strains provided good results in stone biotreatment experiments.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 22 Clonagem e seqnciamento do gene de celulase de 50K de Melanocarpus albomyces ALK04237 O banco genmico de Melanocarpus albomyces ALK04237 foi preparado por hibridao conforme descrito no Exemplo 20. O fragmento de PCR purificado, carregando parte do gene de celulase de 50K (Exemplo 21), foi marcado com digoxigenina de acordo com Boehringer, DIG DNA Labeling and Detection Nonradioactive, Manual de Aplicao. A hibridao foi efetuada a 68C. Os clones positivos foram selecionados em tampo SM/clorofrmio, e purificados com um segundo ciclo de exame.</span>Example 22 Cloning and Sequencing of the Melanocarpus albomyces ALK04237 50K Cellulase Gene The Melanocarpus albomyces ALK04237 genomic library was prepared by hybridization as described in Example 20. The purified PCR fragment carrying part of the 50K cellulase gene (Example 21) , was labeled with digoxigenin according to Boehringer, DIG DNA Labeling and Nonradioactive Detection, Application Manual. Hybridization was performed at 68  C. Positive clones were selected in SM / chloroform buffer, and purified with a second round of examination.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foram encontrados 10 clones positivos sob estas condies. O isolamento do DNA de bacterifago lambda em grande escala, a partir dos clones, foi feito de acordo com Sambrook e coi., 1989. Os DNAs do fago foram analisados por digesto do DNA com diversas enzimas de restrio, e o DNA digerido foi hibridizado com a sonda de PCR especfica para celulase de 50K. Quatro fragmentos de hibridao foram isolados: fragmento de Sac\-Xho\ de cerca de 2,8 kb, fragmento de Saci de cerca de 5 kb, fragmento de Xho\ de cerca de 3,2 kb, e fragmento de EcoR1 de cerca de 2 kb. Estes foram inseridos no vetor de pBluescript II SK+ similarmente cortado (Stratagene, EUA), criando os plasmdios pALK1234, pALK1233, pALK1226 e pALK1227, respectivamente (Figura 20). O DNA do Melanocarpus albomyces ALK04327 foi seqenciado a partir dos plasmdios especficos de 50K-celulase mencionados acima. O protocolo seqencivel foi descrito no exemplo 19. O DNA de Melanocarpus albomyces ALK04237foi seqnciado a partir dos plasmdios especficos para celulase de 50K mencionados acima. A sequncia revela um ORF de cerca de 1363 bp de comprimento, interrompido por um ntron. O OFR codifica para 428 aminocdos. A protena predita tem um peso molecular de 46,8 kDa e divagem de peptdeo de sinal posterior de 44,8 kDa. Todos os peptdeos na Tabela IX so encontrados na sequncia de protena predita (Figura 2), embora alguns aminocidos identificados com incerteza durante o seqnciamento de peptdeos provaram estar incorretos. A protena mostra homologia  endoglicanase I de Humicola grsea (DDBJ:D63516).</span>10 positive clones were found under these conditions. Isolation of large-scale lambda bacteriophage DNA from clones was done according to Sambrook et al., 1989. Phage DNAs were analyzed by digestion of DNA with various restriction enzymes, and digested DNA was hybridized. with the 50K cellulase specific PCR probe. Four hybridization fragments were isolated: about 2.8 kb Sac \ - Xho fragment, about 5 kb Saci fragment, about 3.2 kb Xho \ fragment, and about Eco K1 EcoR1 fragment. 2 kb. These were inserted into the similarly cut pBluescript II SK + vector (Stratagene, USA), creating the plasmids pALK1234, pALK1233, pALK1226 and pALK1227, respectively (Figure 20). Melanocarpus albomyces ALK04327 DNA was sequenced from the 50K-cellulase specific plasmids mentioned above. The sequencing protocol was described in example 19. Melanocarpus albomyces ALK04237 DNA was sequenced from the above 50K cellulase specific plasmids. The sequence reveals an ORF of about 1363 bp in length, interrupted by an intron. OFR codes for 428 amino acids. The predicted protein has a molecular weight of 46.8 kDa and a posterior signal peptide split of 44.8 kDa. All peptides in Table IX are found in the predicted protein sequence (Figure 2), although some amino acids identified with uncertainty during peptide sequencing proved to be incorrect. The protein shows homology to Humicola grisea endoglycanase I (DDBJ: D63516).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 23 Amplificao, clonagem e seqnciamento do DNA de celulase B de 50K com os primers degenerados Os peptdeos derivados a partir da celulase B de 50K (Tabela X) compartilham alguma homologia em relao  celobiohidrolase I (DDBJ:D63515). Para amplificar o gene de celulase B de 50K por reao em cadeia por polimerase (PCR), um par dos primers degenerados com base nas seqncias de peptdeos (Tabela X) foi sintetizado. O primer 1 (636) foi derivado a partir dos aminocidos n- 1 - 5 do peptdeo n9 636 (Tabela X) (o primeiro aminocido foi imaginado ser a lisina, porque este peptdeo foi isolado aps a digesto com uma protease clivando depois as lisinas), e o primer 2 (534-rev) foi projetado como a fita sem sentido para os aminocidos n~ 3 - 8 do peptdeo ns 534 (Tabela X). A ordem dos dois peptdeos na protena - e a correspondente natureza sentido-anti-sentido dos iniciadores foi deduzida a partir de comparao com a celobiohidrolase I de Humicola grisea.</span>Example 23 Amplification, Cloning, and Sequencing of 50K Cellulase B DNA with Degenerate Primers Peptides derived from 50K cellulase B (Table X) share some homology to cellobiohydrolase I (DDBJ: D63515). To amplify the 50K cellulase B gene by polymerase chain reaction (PCR), a pair of degenerate primers based on peptide sequences (Table X) were synthesized. Primer 1 (636) was derived from amino acids # 1-5 of peptide # 636 (Table X) (the first amino acid was thought to be lysine because this peptide was isolated after digestion with a protease cleaving then lysines ), and primer 2 (534-rev) was designed as the nonsense strand for amino acids # 3-8 of peptide # 534 (Table X). The order of the two peptides in the protein - and the corresponding sense-antisense nature of the primers was deduced from comparison with Humicola grisea cellobiohydrolase I.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primer 1 (636) 5- AA (A/G) CA (C/T) GA(A/G) TA (C/T) GG (A/C/G7T) AC</span>Primer 1 (636) 5-AA (A / G) AC (C / T) GA (A / G) TA (C / T) GG (A / C / G7T) AC</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">K  E Y G T</span>K  E Y G T</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primer 2 (534-ver) 5 -CC (A/G) TA (A/G) AA (A/G) TC (A/C/G/T) GG (A/G) TT</span>Primer 2 (534-ver) 5'-CC (A / G) TA (A / G) AA (A / G) TC (A / C / G / T) GG (A / G) TT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">G Y F D P N</span>G Y F D P N</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Na reao por PCR, 1,5 pg do DNA genmico de ALK04237 purificado (Exemplo 18) foram usados como o molde. A DNA polimerase Dynazyme (Finnzymes Ltd, Finlndia) foi usada de acordo com as instrues do fornecedor.</span>In the PCR reaction, 1.5 pg of the purified ALK04237 genomic DNA (Example 18) was used as the template. Dynazyme DNA polymerase (Finnzymes Ltd, Finland) was used according to the supplier's instructions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Molde de DNA (0,3 pg/) 5  Primer 1 (Q,5g/l) 1,7  Primer 2 (0,3\) 1,7  dNTPs (2 nM) 5  10x tampo de PCR 10  dH20 80 | Dynamize (2/) 1  Total 104,4  A reao por PCR foi efetuada sob as seguintes condies: Etapa 1 95C 5 min Etapa 2 95C 1 min Etapa 3 48C 1 min Etapa 4 72C 2 min Etapa 5 ir para a "etapa 2" 34 vezes mais Etapa 6 72C 8 min Etapa 7 4C sustentar Vinte  de mistura de reao foram analisados por eletroforese em gel de agarose, e algumas bandas foram detectadas. Uma das bandas tinha um tamanho aparente de 700 bp, tamanho este que estava em concordncia com o tamanho que se esperaria, quando comparando com o gene de celobiohidrolase de Humicola grsea, particularmente, se o fragmento contivesse um ou mais ntrons. Os produtos de PCR foram . purificados pelo mtodo de Magc PCR Preps (Promega, EUA) de acordo com as instrues do fornecedor. O fragmento isolado foi ligado com o plasmdio pBluescript II SK+ (Stratagene, EUA), o qual tinha sido digerido com a endonuclease de EcoRV, e preso na extremidade por ddT, conforme descrito em Holton e Graham, Nucl, Acids. Res. 19, 1156 (1990). As clulas de XL-Blue de Escherchia coli adequadas (Stratagene, EUA) foram transformadas com a mistura de ligao. O DNA do plasmdio, a partir de algumas das colnias resultantes, foi isolado pelo mtodo de Magic Minipreps (Promega, EUA) de acordo com as instrues do fornecedor. O DNA do plasmdio foi analisado por eletroforese em agarose, e um clone com um inserto de cerca de 700 bp foi designado pALK1224. O inserto em pALK1224 foi seqnciado conforme descrito no Exemplo 19, e foi verificado conter um ORF codificando todo o peptdeo r\ 636 a partir da celulase B de 50K (Tabela X). O ORF predisse um peptdeo homlogo  celobiohidrolase I de Humicola grisea (DDBJ:D63515). O DNA amplificado por PCR (alm dos primers) corresponde aos nucleotdeos 371-1023 na Figura 23.</span>DNA template (0.3 pg / ) 5  Primer 1 (Q, 5g / l) 1.7  Primer 2 (0.3 \) 1.7  dNTPs (2 nM) 5  10x buffer PCR 10  dH20 80  | Dynamize (2 / ) 1  Total 104,4  The PCR reaction was performed under the following conditions: Step 1 95  C 5 min Step 2 95  C 1 min Step 3 48  C 1 min Step 4 72  C 2 min Step 5 go to "step 2" 34 times more Step 6 72  C 8 min Step 7 4  C sustain Twenty  of reaction mixture was analyzed by agarose gel electrophoresis, and some bands were detected. One of the bands had an apparent size of 700 bp, which was in line with the expected size when compared to the large humicola cellobiohydrolase gene, particularly if the fragment contained one or more introns. The PCR products were. purified by the Magc PCR Preps method (Promega, USA) according to the supplier's instructions. The isolated fragment was ligated with plasmid pBluescript II SK + (Stratagene, USA), which had been digested with EcoRV endonuclease, and end-capped by ddT, as described in Holton and Graham, Nucl, Acids. Res. 19, 1156 (1990). Appropriate Escherchia coli XL-Blue cells (Stratagene, USA) were transformed with the ligation mixture. Plasmid DNA from some of the resulting colonies was isolated by the Magic Minipreps method (Promega, USA) according to the supplier's instructions. Plasmid DNA was analyzed by agarose electrophoresis, and a clone with an insert of about 700 bp was designated pALK1224. The insert in pALK1224 was sequenced as described in Example 19, and was found to contain an ORF encoding the entire peptide r636 from 50K cellulase B (Table X). The ORF predicted a homologous peptide to Humicola grisea cellobiohydrolase I (DDBJ: D63515). PCR amplified DNA (in addition to primers) corresponds to nucleotides 371-1023 in Figure 23.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 24 Clonagem e seqnciamento do gene de celulase B de 50K de Melanocarpus albomyces ALK04237 0 banco genmico de Melanocarpus albomyces ALK04237 foi preparado por hibridao conforme descrito no Exemplo 20. O inserto em pALK1224 foi removido por digesto do plasmdio com as endoglicanases de restrio EcoRI e HindUl O DNA do plasmdio digerido foi corrido por eletroforese em agarose. A seo de agarose contendo o fragmento de DNA de cerca de 700 bp foi excisada, e purificada pelo mtodo de Magic PCR Preps (Promega, EUA) de acordo com as instrues do fornecedor. O fragmento de PCR purificado a partir de pALK1224, carregando parte do gene de celulase B de 50K (Exemplo 23), foi marcado com digoxigenina de acordo com Boehringer, DIG DNA Labeling and Detection Noradioactive, Manual de Aplicao. A hibridao foi efetuada a 68C. Os clones positivos foram selecionados em tampo SM/clorofrmio, e purificados com um segundo ciclo de exame.</span>Example 24 Cloning and Sequencing of the Melanocarpus albomyces ALK04237 50K Cellulase B Gene The Melanocarpus albomyces ALK04237 genomic library was prepared by hybridization as described in Example 20. The insert in pALK1224 was removed by digestion of the plasmid with EcoRI restriction endoglycases and HindUl Digested plasmid DNA was run by agarose electrophoresis. The agarose section containing the approximately 700 bp DNA fragment was excised, and purified by the Magic PCR Preps method (Promega, USA) according to the supplier's instructions. The PCR fragment purified from pALK1224, carrying part of the 50K cellulase B gene (Example 23), was labeled with digoxigenin according to Boehringer, DIG DNA Labeling and Detection Noradioactive, Application Manual. Hybridization was performed at 68  C. Positive clones were selected in SM / chloroform buffer, and purified with a second round of examination.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foram encontrados 3 clones positivos sob estas condies. O isolamento do DNA de bacterifago lambda em grande escala, a partir dos clones, foi feito de acordo com Sambrook e col., em Molecular Cloning: A Laboratory Manual, 2a edio, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, Nova York, 1989. Os DNAs do fago foram analisados por digesto do DNA com diversas enzimas de restrio, e o DNA digerido foi hibridizado com a sonda de PCR especfica para celulase B de 50K. Um fragmento de Not\ de 3,5 kb de hibridao foi isolado, e inserido no vetor de pBluescript II SK+ similarmente cortado (Stratagene, EUA), criando o plasmdio pALK1229 (Figura 22). A extremidade 5' extrema do gene foi encontrada por hibridao dos DNAs do fago com o fragmento de Not\-Pst\ de 0,2 kb a partir de pALK1229. Um fragmento de Psfl de 2,4 kb de hibridao foi isolado e inserido no vetor de pBluescript II SK+ similarmente cortado (Stratagene, EUA), criando o plasmdio pALK1236 (Figura 22).</span>3 positive clones were found under these conditions. Isolation of large-scale lambda bacteriophage DNA from clones was done according to Sambrook et al. In Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Phage DNAs were analyzed by DNA digestion with various restriction enzymes, and the digested DNA was hybridized with the 50K cellulase B-specific PCR probe. A hybridization 3.5 kb Not I fragment was isolated, and inserted into the similarly cut pBluescript II SK + vector (Stratagene, USA), creating plasmid pALK1229 (Figure 22). The extreme 5 'end of the gene was found by hybridizing the phage DNAs to the 0.2 kb Not \ -Pst \ fragment from pALK1229. A 2.4 kb hybridization Psfl fragment was isolated and inserted into the similarly cut pBluescript II SK + vector (Stratagene, USA), creating plasmid pALK1236 (Figure 22).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Parte dos insertos em pALK1229 e pALK1236 foram seqnciados conforme descrito no Exemplo 19. O DNA codificando a celulase B de 50K de Melanocarpus albomyces  mostrado na Figura 23 (A e B). A sequncia revela um ORF de 1734 bp de comprimento interrompido por cinco ntrons. O ORF codifica para 452 aminocidos. A protena predita tem um peso molecular de 49,9 kDa e uma divagem de peptdeo de sinal posterior de 47,6 kDa. Todos os peptdeos na Tabela X so encontrados na sequncia de protena predita (Figura 23A e B), embora alguns dos aminocidos identificados com incerteza durante o seqnciamento do peptdeo provaram estar incorretos. A protena predita mostra homologia para a celobiohidrolase I de Humicola grisea (DDBJ:D63515) e outras celobiohidrolases. Entretanto, a celulase B de 50K tem uma caracterstica surpreendente de que ela no abriga o domnio de ligao  celulose (CBD) e o seu ligador, que  caracterstico  celobiohidrolase I de Humicola grisea e  muitas outras celobiohidrolases.</span>Part of the inserts in pALK1229 and pALK1236 were sequenced as described in Example 19. DNA encoding Melanocarpus albomyces 50K cellulase B is shown in Figure 23 (A and B). The sequence reveals a 1734 bp ORF interrupted by five introns. ORF codes for 452 amino acids. The predicted protein has a molecular weight of 49.9 kDa and a posterior signal peptide split of 47.6 kDa. All peptides in Table X are found in the predicted protein sequence (Figure 23A and B), although some of the amino acids identified with uncertainty during peptide sequencing proved to be incorrect. The predicted protein shows homology to Humicola grisea cellobiohydrolase I (DDBJ: D63515) and other cellobiohydrolases. However, 50K cellulase B has a surprising feature that it does not harbor the cellulose binding domain (CBD) and its linker, which is characteristic of Humicola grisea cellobiohydrolase I and many other cellobiohydrolases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 25 Exame da biblioteca genmica de Melanocarpus albomyces ALK04237 com os genes de celulases de Trichoderma reesei O banco genmico de Melanocarpus albomyces ALK04237 foi preparado por hibridao conforme descrito no Exemplo 20. O fragmento de DNA carregando o DNA especfico para cbh1 de Trichoderma reesei foi isolado por corte do plasmdio pTTcOl (Figura 24) com a endonuclease de restrio HincM, e isolamento do fragmento de cerca de 1,6 kb do gel de agarose aps eletroforese. O fragmento de DNA carregando o DNA especfico para eg!2 de Trichoderma reesei foi isolado por corte do plasmdio pMS2 (Figura 25) com as endonucleases de restrio SamHi e EcoRl, e isolamento do fragmento de cerca de 1,5 kb do gel de agarose aps a eletroforese. A clonagem do gene de cbh1  descrita em Teeri e col., Bio/Technology 1: 691-696 (1983). O gene de egl2 (originalmente chamado "eg/3")  descrito por Saloheimo e col., Gene 63:11-21 (1988).</span>Example 25 Examination of the Melanocarpus albomyces ALK04237 genomic library with the Trichoderma reesei cellulase genes The Melanocarpus albomyces ALK04237 genomic library was prepared by hybridization as described in Example 20. The DNA fragment carrying Trichoderma reesei cbh1-specific DNA was isolated by cutting the plasmid pTTcO1 (Figure 24) with the HincM restriction endonuclease, and isolating the about 1.6 kb agarose gel fragment after electrophoresis. The DNA fragment carrying Trichoderma reesei eg 2 -specific DNA was isolated by cutting plasmid pMS2 (Figure 25) with restriction endonucleases SamHi and EcoR1, and isolating the approximately 1.5 kb fragment from the agarose gel after electrophoresis. Cloning of the cbh1 gene is described in Teeri et al., Bio / Technology 1: 691-696 (1983). The egl2 gene (originally called "eg / 3") is described by Saloheimo et al., Gene 63: 11-21 (1988).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os fragmentos foram marcados com digoxigenina de acordo com Boehringer, DIG DNA Labeling and Detection Nonradioactive, Manual de Aplicao. A hibridao foi efetuada a 68C com a sonda de cbh1, e a 60C com a sonda de egl2. Os clones positivos foram selecionados em tampo SM/clorofrmio, e purificados com um segundo ciclo de exame.</span>The fragments were labeled with digoxigenin according to Boehringer, DIG DNA Labeling and Nonradioactive Detection, Application Manual. Hybridization was performed at 68  C with the cbh1 probe, and at 60  C with the egl2 probe. Positive clones were selected in SM / chloroform buffer, and purified with a second round of examination.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foram encontrados 13 clones positivos de cbh1 e 6 positivos de egl2 sob estas condies. Um clone hibridizou para ambas as sondas. O DNA de lambda foi isolado dos clones conforme descrito acima. Os DNAs do fago foram analisados por digesto do DNA com diversas enzimas de restrio, e o DNA digerido foi hibridizado com as sondas de cbh1 e egl2. Os clones foram tambm hibridizados com o fragmento de PCR especfico para celulase de 20K (Exemplo 19). Um clone (lambda-16) era claramente positivo, e dois outros clones (lambda-8/1 e lambda-5/2) eram fracamente positivos; todos estes clones foram originalmente selecionados com a sonda de cbh1.</span>Thirteen cbh1 positive and six egl2 positive clones were found under these conditions. One clone hybridized to both probes. Lambda DNA was isolated from the clones as described above. Phage DNAs were analyzed by digesting DNA with various restriction enzymes, and digested DNA was hybridized with the cbh1 and egl2 probes. Clones were also hybridized to the 20K cellulase specific PCR fragment (Example 19). One clone (lambda-16) was clearly positive, and two other clones (lambda-8/1 and lambda-5/2) were poorly positive; All of these clones were originally selected with the cbh1 probe.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Um fragmento de *coRI de cerca de 4 kb do lambda-16, o qual hibridizou tanto para a sonda de cbh1 de Trichoderma reesei quanto para o fragmento de PCR especfico para celulase de 20K, foi isolado de gel de agarose aps a eletroforese, e inserido no pBluescript II SK+ similarmente cortado. O plasmdio resultante foi chamado pALK1230 (Figura 26).</span>A about 4 kb CoRI fragment from lambda-16, which hybridized to both the Trichoderma reesei cbh1 probe and the 20K cellulase-specific PCR fragment, was isolated from agarose gel after electrophoresis. and inserted into the similarly cut pBluescript II SK +. The resulting plasmid was called pALK1230 (Figure 26).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Parte do inserto em pALK1230 foi seqnciado conforme descrito no Exemplo 19. O DNA parece no codificar a celulase de 20K, porm codifica para uma protena homloga s diversas celulases, particularmente na rea do domnio de ligao  celulose (CBD). Assim, o produto de gene muito provavelmente tem alta afinidade em relao ao material celulsico, e, portanto, este gene foi designado como protena com CBD. A seqncia  mostrada na Figura 27.</span>Part of the insert in pALK1230 was sequenced as described in Example 19. DNA does not appear to encode 20K cellulase but encodes a protein homologous to the various cellulases, particularly in the area of cellulose binding domain (CBD). Thus, the gene product most likely has high affinity for cellulosic material, and therefore this gene was designated as protein with CBD. The sequence is shown in Figure 27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As reaes por PCR com os primers 636 e 534-rev (Exemplo 23) foram efetuadas com o DNA dos 19 clones de lambda como moldes. Um clone de lambda, iambda-3, proporcionou uma banda de cerca de 700 bp de tamanho, similar quele no Exemplo 23 quando o DNA cromossmico de ALK04237 foi usado como um molde. Este clone tinha sido originalmente selecionado pela sonda de cbh1 de Trchoderma. O DNA de lambda foi digerido com diversas endonucleases de restrio, e hibridizado com a sonda especfica para a celulase B de 50K. O clone mostrou um padro de enzima de restrio similar aos 3 clones no Exemplo 24.  concludo que o lambda-3 tambm carrega o gene de celulase B de 50K.</span>PCR reactions with 636 and 534-rev primers (Example 23) were performed with DNA from 19 lambda clones as templates. A lambda clone, iambda-3, provided a band of about 700 bp in size, similar to that in Example 23 when the ALK04237 chromosomal DNA was used as a template. This clone had originally been selected by the Trchoderma cbh1 probe. Lambda DNA was digested with several restriction endonucleases, and hybridized to the 50K cellulase B specific probe. The clone showed a restriction enzyme pattern similar to the 3 clones in Example 24. It is concluded that lambda-3 also carries the 50K cellulase B gene.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 26 Protenas de fuso Um vetor recombinante codificando a celulase de 20K, a celulase de 50K ou a celulase B de 50K,  preparado fundindo-se a seqncia de codificao da celulase com a sequncia de celulase ou de hemicelulase de Trchoderma reesei, ou pelo menos um domnio funcional das ditas celulase ou hemicelulase, conforme descrito na US 5.298.405, no WO 93/24621 e na submisso de Genbank L25310, incorporados aqui por referncia. Especialmente, a enzima  selecionada do grupo consistindo em CBHI, CBHII, EGI, EGII, XYLI, XYLII e MANI, ou um seu domnio, tal como o sinal de secreo ou a seqncia de ncleo.</span>Example 26 Fusion Proteins A recombinant vector encoding 20K cellulase, 50K cellulase or 50K cellulase B is prepared by fusing the cellulase coding sequence with the Trchoderma reesei cellulase or hemicellulase sequence, or at least at least one functional domain of said cellulase or hemicellulase as described in US 5,298,405, WO 93/24621 and Genbank submission L25310, incorporated herein by reference. Especially, the enzyme is selected from the group consisting of CBHI, CBHII, EGI, EGII, XYLI, XYLII and MANI, or a domain thereof, such as the secretion signal or nucleus sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As protenas de fuso podem ser construdas de modo que contenham um domnio de ncleo de manase, ou de celobiohidrolase, ou de endoglicanase com N terminal ou o ncleo e os domnios de articulao a partir das mesmas, fundido a uma das sequncias de celulase de Melanocarpus. O resultado  uma protena que contm um ncleo de manase, ou de celobiohidrolase, ou de endoglicanase com N terminal ou ncleo e regies de articulao, e uma celulase de Melanocarpus com C terminal. A protena de fuso contm tanto a mananase ou a celobiohidrolase ou a endoglicanase de Trchoderma, quanto as atividades de celulases dos diversos domnios conforme proporcionados na construo de fuso. Alternativamente, as mutaes que modificam as atividades da manase, ou da celobiohidrolase, ou da endoglicanase de Trchoderma, ou as atividades de celulases de Melanocarpus, podem ser includas nas construes. Neste caso, as protenas de fuso contm tanto a atividade de enzima de Trchoderma quanto a atividade de celulase de Melanocarpus dos diversos domnios conforme proporcionados na construo de fuso.</span>Fusion proteins may be constructed such that they contain a mannase, or cellobiohydrolase, or N-terminal endoglycanase nucleus domain, or nucleus and hinge domains thereof, fused to one of the Melanocarpus cellulase sequences . The result is a protein that contains a mannase, or cellobiohydrolase, or endoglycanase nucleus with N-terminal or nucleus and hinge regions, and a C-terminal Melanocarpus cellulase. The fusion protein contains both Trichoderma's mannanase or cellobiohydrolase or endoglycanase, as well as the cellulase activities of the various domains as provided in the fusion construct. Alternatively, mutations that modify the activities of Trichoderma's mannase, or cellobiohydrolase, or endoglycanase, or the activities of Melanocarpus cellulases, may be included in the constructs. In this case, the fusion proteins contain both Trichoderma enzyme activity and Melanocarpus cellulase activity of the various domains as provided in the fusion construct.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As protenas de fuso podem tambm ser construdas de modo tal que a extremidade de mananase, ou de celobiohidrolase, ou de endoglicanase, ou um seu fragmento desejado, seja colocada antes de uma das seqncias de ceiulase de Melanocarpus, especialmente de modo a permitir o uso de um stio no-especfico de protease na extremidade como um stio de protease, para a recuperao da parte de ceiulase de Melanocarpus a partir da protena de fuso expressa. Alternativamente, as protenas de fuso podem ser construdas de modo que proporcionem um stio de protease em um ligador sinttico que seja colocado antes das celulases de Melanocarpus, com ou sem as seqncias da extremidade. Exemplo 27 Hospedeiros A construo recombinante, codificando as protenas de fuso ou as protenas de Melanocarpus desejadas,  preparada conforme acima descrito, e transformada em um fungo filamentoso, tal como o Aspergillus spp., preferivelmente o Trichoderma spp.</span>Fusion proteins may also be constructed such that the end of mannanase, or cellobiohydrolase, or endoglycanase, or a desired fragment thereof, is placed before one of the Melanocarpus cellulase sequences, especially so as to permit use. of a non-specific endpoint protease site as a protease site, for the recovery of the Melanocarpus cellulase moiety from the expressed fusion protein. Alternatively, fusion proteins may be constructed such that they provide a protease site on a synthetic linker that is placed before Melanocarpus cellulases, with or without end sequences. Example 27 Hosts The recombinant construct encoding the desired melanocarpus fusion proteins or proteins is prepared as described above and transformed into a filamentous fungus such as Aspergillus spp., Preferably Trichoderma spp.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 28 Meio de Trichoderma para a produo de ceiulase de 20K</span>Example 28 Trichoderma Medium for 20K Cellulase Production</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Neste exemplo so descritas experincias de lavagem com pedras para determinar o meio mais adequado de celulases de Trichoderma para a produo de ceiulase de 20K. O propsito destas experincias foi determinar quais celulases de Trichoderma causariam a colorao de volta, na lavagem com pedras, em condies neutras. A cepa de Trichoderma reesei ALK03620 (o gene de endoglicanase 2  deletado) foi escolhida como o hospedeiro para estas experincias. Nos estudos anteriores, a enzima de EGII (endoglicanase II) de Trichoderma mostrou causar efeitos prejudiciais s estruturas de fibras de algodo, e assim enfraquecer as propriedades de resistncia dos tecidos contendo algodo (Em: Miettinen-Oinonen e col.: Effects of cellulases on cotton fiber and fabrics. Em: Proceedings of the TIWC96 Conference, 1996, Vol. 1 (2), pginas 197.).</span>In this example stone washing experiments are described to determine the most suitable Trichoderma cellulases medium for the production of 20K cellulase. The purpose of these experiments was to determine which Trichoderma cellulases would cause back staining in stone washing under neutral conditions. The Trichoderma reesei strain ALK03620 (the endoglycanase 2 gene is deleted) was chosen as the host for these experiments. In previous studies, Trichoderma's EGII (endoglycanase II) enzyme has been shown to have detrimental effects on cotton fiber structures, thereby weakening the strength properties of cotton-containing fabrics (Em: Miettinen-Oinonen et al .: Effects of cellulases on cotton fiber and fabrics In: Proceedings of the TIWC96 Conference, 1996, Vol. 1 (2), pages 197.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Algumas experincias de lavagem com pedras foram efetuadas em pH 6,5 e 7, conforme descrito no Exemplo 3, exceto que nenhum Berol foi usado.</span>Some stone washing experiments were performed at pH 6.5 and 7 as described in Example 3, except that no Berol was used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As preparaes de celulase de Trchoderma testadas eram: ALK03133 (eg/2 e cbh2 deletados) ALK03269 (egl2 e egi 1 deletados) ALK03268 (eg/2 e cb/?1 deletados) A dosagem de preparaes de Trchoderma foi cerca de 2,5 mg (= dosagem baixa, L) ou cerca de 5 mg (= dosagem alta, H) da protena total por g de tecido. 0,4 mg de celulase de 20K purificada por g de tecido foi usado quando necessitado.</span>Trichoderma cellulase preparations tested were: ALK03133 (eg / 2 and cbh2 deleted) ALK03269 (egl2 and egi 1 deleted) ALK03268 (eg / 2 and cb /? 1 deleted) The dosage of Trchoderma preparations was about 2.5 mg (= low dosage, L) or about 5 mg (= high dosage, H) of total protein per g of tissue. 0.4 mg of 20K cellulase purified per g of tissue was used when required.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os resultados das medies de cor dos tecidos de brim testados so mostrados na Tabela XIX.</span>The results of the color measurements of the tested denim fabrics are shown in Table XIX.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os resultados da lavagem com pedras mostram que o meio de ALK03269 (eg/2 e egl 1 deletados) causa menos colorao de volta nas condies neutras do que o meio de ALK03268 (eg/2 e cbh 1 deletados) ou de ALK03133 (eg/2 e cbh2 deletados). Assim, o hospedeiro preferido para a produo de celulase de 20K para o biotratamento com pedras  uma cepa similar ao ALK03269, Embora com concentraes maiores de celulase de 20K, o meio de Trchoderma tem provavelmente somente uma importncia muito pequena. Um meio similar ao ALK03269  provavelmente to bom para a produo de celulase de 50K e de celulase B de 50K, para o biotratamento com pedras, quanto ele  para a produo de celulase de 20 K.</span>Stone wash results show that ALK03269 (eg / 2 and egl 1 deleted) medium causes less staining back under neutral conditions than ALK03268 (eg / 2 and cbh 1 deleted) or ALK03133 (eg / 2 and cbh2 deleted). Thus, the preferred host for producing 20K cellulase for stone biotreatment is a strain similar to ALK03269. Although with higher concentrations of 20K cellulase, Trchoderma medium is probably only of very minor importance. A medium similar to ALK03269 is probably as good for producing 50K cellulase and 50K cellulase B for stone biotreatment as it is for producing 20K cellulase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela XIX. Medies de cor de tecidos de brim tratados com diferentes preparaes de celulase de Trchoderma com (+) ou sem (-) celulase de 20 K.</span>Table XIX Color measurements of denim tissues treated with different preparations of Trchoderma cellulase with (+) or without (-) 20 K cellulase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">preparao/ 20k pH Lado direito Avesso deltaE dosagem +/- L b deltaE L b -  6^5 2^2  3/ J 0,1 1,4 ALKO3620/L - 6,5 2,2 2,6 3,0 -0,7 2,6 2,9 ALKO3620/L + 6,5 5,5 4,0 7,7 -1,3 5,0 5,5 ALK03133/L - 6,5 1,9 2,2 3,7 0,2 1,6 2,3 ALK03133/H - 6,5 4,2 1,9 4,5 -1,5 3,3 4,8 ALK03133/L + 6,5 5,7 4,3 7,8 0,3 4,5 5,0 ALK03133/H + 6,5 8,5 4,0 9,4 -1,4 5,9 7,8 ALK03269/L - 6,5 2,9 1,9 4,4 0,8 0,8 1,6 ALK03269/H - 6,5 4,3 1,5 4,5 0,6 1,3 2,6 ALK03269/L + 6,5 6,6 4,2 8,7 1,1 4,0 4,3 ALK03269/H + 6,5 7,9 3,9 8,5 0,7 3,7 5,1 ALK03268/L - 6,5 2,9 1,7 3,7 0,1 1,8 3,0 ALK03268/H - 6,5 4,2 2,0 4,3 -0,7 3,4 5,0 ALK03268/L + 6,5 5,9 3,2 7,7 -1,2 4,5 6,0 ALK03268/H + 6,5 7,1 3,7 7,7 -2,0 5,8 7,3 7,0 2,9 0,8 2,6 0,7 0,5 1,5 ALKO3620/L - 7,0 3,3 1,2 1,9 1,7 0,3 1,1 ALKO3620/L + 7,0 6,7 3,4 5,6 1,1 3,2 2,9 ALK03133/L - 7,0 3,2 1,0 1,4 0,6 0,6 0,9 ALK03133/L + 7,0 5,9 3,7 5,5 0,1 4,3 3,1 ALK03369/L - 7,0 3,6 1,2 2,2 1,3 -0,3 1,3 ALK03269/L + 7,0 6,4 3,4 5,9 1,2 3,2 2,8 ALK03268L - 7,0 2,9 1,4 3,9 0,5 0,4 2,5 ALK03268/L + 7,0 8,4 3,1 9,6 1,1 3,5 4,6 Exemplo 29 Produo de celulase de 20K de Melanocarpus albomyces ALK04237 em T. reesei As cepas de Trchoderma reesei foram construdas para a produo de celulase de 20K de Melanocarpus albomyces ALK04237. As cepas produzem a celulase de 20K de Melanocarpus e so inadequadas para produzir a endoglicanase II e a celobiohidrolase I ou a endoglicanase I de T. reesei. Tais preparaes deficientes em atividade ceiuloltica de Trichoderma, e a fabricao das mesmas por mtodos de DNA recombinante, so descritas na US 5.298.405 ou em Suominen e col. (1993) High frequency one-step gene replacement in Trichoderma reesei. II. Effects of deletions of individual cellulase genes. Mol. Gen. Genet. 241: 523, incorporados aqui por referncia.</span>preparation / 20k pH Right side Inside out deltaE dosage +/- L b deltaE L b - 6 ^ 5 2 ^ 2  3 / J 0.1 1.4 ALKO3620 / L - 6.5 2.2 2.6 3 .0 -0.7 2.6 2.9 ALKO3620 / L + 6.5 5.5 4.0 7.7 -1.3 5.0 5.5 ALK03133 / L - 6.5 1.9 2, 2 3.7 0.2 1.6 2.3 ALK03133 / H - 6.5 4.2 1.9 4.5 -1.5 3.3 4.8 ALK03133 / L + 6.5 5.7 4 , 3 7.8 0.3 4.5 5.0 ALK03133 / H + 6.5 8.5 4.0 9.4 -1.4 5.9 7.8 ALK03269 / L - 6.5 2.9 1.9 4.4 0.8 0.8 1.6 ALK03269 / H - 6.5 4.3 1.5 4.5 0.6 1.3 2.6 ALK03269 / L + 6.5 6.6 4.2 8.7 1.1 4.0 4.3 ALK03269 / H + 6.5 7.9 3.9 8.5 0.7 3.7 5.1 ALK03268 / L - 6.5 2.9 1.7 3.7 0.1 1.8 3.0 ALK03268 / H - 6.5 4.2 2.0 4.3 -0.7 3.4 5.0 ALK03268 / L + 6.5 5, 9 3.2 7.7 -1.2 4.5 6.0 ALK03268 / H + 6.5 7.1 3.7 7.7 -2.0 5.8 7.3 7.0 2.9 0 .8 2.6 0.7 0.5 1.5 ALKO3620 / L - 7.0 3.3 1.2 1.9 1.7 0.3 1.1 ALKO3620 / L + 7.0 6.7 3 , 4 5.6 1.1 3.2 2.9 ALK03133 / L - 7.0 3.2 1.0 1.4 0.6 0.6 0.6 0.9 ALK03133 / L + 7.0 5.9 3 .7 5.5 0.1 4.3 4.3 ALK03369 / L - 7.0 3.6 1.2 2.2 1.3 -0.3 1.3 ALK03269 / L + 7.0 6.4 3.4 5.9 1.2 3.2 2.8 ALK03268L - 7.0 2.9 1.4 3.9 0.5 0 .4 2.5 ALK03268 / L + 7.0 8.4 3.1 9.6 1.1 3.5 4.6 Example 29 Production of 20K cellulase from Melanocarpus albomyces ALK04237 in T. reesei Trchoderma reesei strains were constructed for the production of 20K cellulase from Melanocarpus albomyces ALK04237. The strains produce Melanocarpus 20K cellulase and are unsuitable for producing endoglycanase II and cellobiohydrolase I or T. reesei endoglycanase I. Such preparations that are deficient in Trichoderma cellulolytic activity, and their manufacture by recombinant DNA methods, are described in US 5,298,405 or in Suominen et al. (1993) High frequency one-step gene replacement in Trichoderma reesei. II. Effects of deletions of individual cellulase genes. Mol. Gen. Genet. 241: 523, incorporated herein by reference.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Na construo das cepas que produzem a celulase de 20K de Melanocarpus albomyces, a cepa de Trichoderma reesei ALKO3620 parental foi transformada com os cassetes de expresso a partir do plasmdio pALK1231 ou pALK1235 (Figuras 28 e 29). Nos cassetes, a celulase de 20K  expressa a partir de um promotor de cbh1 forte. A integrao dos cassetes de expresso resultou nas substituies dos genes de cbh 1 (pALK1231) parental ou eg!1 (pALK1235).</span>In the construction of the strains producing Melanocarpus albomyces 20K cellulase, the parental Trichoderma reesei strain ALKO3620 was transformed with expression cassettes from plasmid pALK1231 or pALK1235 (Figures 28 and 29). In cassettes, 20K cellulase is expressed from a strong cbh1 promoter. Integration of expression cassettes resulted in the substitution of the parental or eg1 cbh 1 (pALK1231) genes (pALK1235).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Na cepa hospedeira ALK03620, o gene de egl2 foi substitudo pelo fragmento de Xba\-Bgl\l de 3,3 kb do gene de ble a partir de Streptoalloteichus hindustanus (Mattern e col. (1988) A vector of Aspergillus transformation conferring phleomycin resistance. Fungai Genet Newslett. 35: 25.; Drocourt e col. (1990) Cassettes of the Streptoalloteichus hindustanus ble gene for transformation of lower and higher eukaryotes to phleomycin resistance. Nucl. Acids Res. 18: 4009) usando os mtodos de DNA recombinante descritos na US 5.298.405, incorporada aqui por referncia.</span>In the host strain ALK03620, the egl2 gene was replaced by the 3.3 kb Xba \ -Bgl \ l fragment of the ble gene from Streptoalloteichus hindustanus (Mattern et al. (1988). The vector of Aspergillus transformation conferring phleomycin resistance Fungai Genet Newslett 35: 25 Drocourt et al (1990) Cassettes of the Streptoalloteichus hindustanus ble gene for transformation of lower and higher eukaryotes to phleomycin resistance (Nucl. Acids Res. 18: 4009) using recombinant DNA methods described in US 5,298,405, incorporated herein by reference.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os plasmdios pALK1231 e pALK1235, que foram usados na construo das cepas de produo de celulase de Melanocarpus, so idnticos um ao outro com relao ao promotor de cbh1, ao gene de celulase de 20K e ao terminador de cbh1, os quais so descritos abaixo: * promotor de cbh1 (celobiohidrolase 1) de 7. reesei: O promotor  de VTT-D-80133 de Trichoderma reesei (Teeri e col. (1983) The molecular cloning of the major cellulase gene from Trichoderma reesei. Bio/Technology 1: 696.). O fragmento de EcoRI - Sacll de 2,2 kb (Karhunen e col. (1993) High frequency one-step gene replacement in Trichoderma reesei. I. Endogiucanas I overproduction. Mol. Gen. Genet. 241: 515.) foi usado na construo. A sequncia da rea do promotor precedendo o ATG foi publicada por Shoemaker e col. (1983) Molecular cloning of exo-celobiohydrolase from Trichoderma reesei strain L27. Bio/Technology 1. 691.). Os ltimos 15 nucleotdeos do promotor de cbh1 de T. reesei L27 (o stio de Sacll est sublinhado) so CCGCGGACTGGCATC (Shoemaker e col. 1983). O promotor de cbh1, a partir da cepa de T. reesei VTT-D-80133, foi seqnciado no Alko Research Laboratories, e uma diferena de um nucleotdeo na sequncia de DNA foi observada dentro da regio acima mencionada. Na cepa de T. reesei VTT-D-80133, a sequncia precedendo o ATG  CCGCGGACTG/C/GCATC (o stio de Sacll est sublinhado, a citosina adicional na sequncia de DNA est entre os cortes).</span>Plasmids pALK1231 and pALK1235, which were used in the construction of the Melanocarpus cellulase producing strains, are identical with respect to the cbh1 promoter, 20K cellulase gene and cbh1 terminator, which are described below: * 7. reesei cbh1 (cellobiohydrolase 1) promoter: The promoter is from Trichoderma reesei VTT-D-80133 (Teeri et al. (1983). The molecular cloning of the major cellulase gene from Trichoderma reesei. Bio / Technology 1: 696.). The 2.2 kb EcoRI - Sac11 fragment (Karhunen et al. (1993) High frequency one-step gene replacement in Trichoderma reesei. I. Endogiucanase I overproduction. Mol. Gen. Genet. 241: 515.) construction. The promoter area sequence preceding the ATG was published by Shoemaker et al. (1983) Molecular cloning of exo-celiacobiohydrolase from Trichoderma reesei strain L27. Bio / Technology 1,691.). The last 15 nucleotides of the T. reesei L27 cbh1 promoter (Sacll site is underlined) are CCGCGGACTGGCATC (Shoemaker et al. 1983). The cbh1 promoter from the T. reesei strain VTT-D-80133 was sequenced at Alko Research Laboratories, and a one nucleotide difference in DNA sequence was observed within the aforementioned region. In the T. reesei VTT-D-80133 strain, the sequence preceding ATG is CCGCGGACTG / C / GCATC (Sac11 site is underlined, additional cytosine in the DNA sequence is between sections).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os nucleotdeos ausentes do promotor (10 pbs aps o Sacll at o ATG) foram adicionados e a fuso exata do promotor ao primeiro ATG da celulase de 20K de Melanocarpus (ver abaixo) foi feita utilizando-se o mtodo de PCR (reao em cadeia por polimerase). A fuso e o fragmento de PCR foram seqnciados para assegurar que nenhum erro tivesse ocorrido na reao. No pALK1231, a rea do promotor tambm est funcionando como um DNA homlogo (junto com o fragmento de cbh1 3'; ver abaixo) para objetivar a integrao do DNA de transformao ao local de cbh1. * gene de celulase de 20K de Melanocarpus albomyces: A seqncia de nucleotdeos e a sequncia de aminocidos deduzida do gene de celulase de 20K codificando na celulase de 20 kDa  apresentada no Exemplo 20 (Figura 19). Um fragmento de 0,9 kb comeando a partir do cdon de AT foi usado em ambos os plasmdios. * terminador de cbh1 de T. reesei: O fragmento de Avall de 739 bp (Karhunen e col. (1993) High frequency one-step gene replacement in Trichoderma reesei. I. Endogiucanas I overproduction. Mol. Gen. Genet. 241: 515.) comeando 113 bp antes do cdon de interrupo do gene de cbh1 foi adicionado aps o gene de celulase de 20K para assegurar a terminao da transcrio.</span>Nucleotides absent from the promoter (10 bp after Sacll to ATG) were added and the exact fusion of the promoter to the first Melanocarpus 20K cellulase ATG (see below) was done using the PCR (chain reaction) method. polymerase). The fusion and PCR fragment were sequenced to ensure that no errors had occurred in the reaction. In pALK1231, the promoter area is also functioning as a homologous DNA (along with the 3 'cbh1 fragment; see below) to target integration of the transformation DNA into the cbh1 site. Melanocarpus albomyces 20K cellulase gene: The nucleotide sequence and deduced amino acid sequence of the 20K cellulase gene encoding the 20kDa cellulase is shown in Example 20 (Figure 19). A 0.9 kb fragment starting from the AT codon was used in both plasmids. * T. reesei cbh1 terminator: The 739 bp Avall fragment (Karhunen et al. (1993) High frequency one-step gene replacement in Trichoderma reesei I. Endogiucanase I overproduction Mol. Gen. Genet. 241: 515 .) starting 113 bp before the cbh1 gene disruption codon was added after the 20K cellulase gene to ensure transcription termination.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alm do material descrito acima, o plasmdio pALK1231 contm: * gene de amdS: O gene foi isolado do Aspergillus nidulans VH1-TRSX6 e ele est codificando para a acetamidase (Hynes e col. (1983) Isolation of genomic clones containing the amdS gene of Aspergillus nidulans and their use in the analysis of the structural and regulatory mutations. Mol. Cell. Biol. 3: 1430.). A acetamidase capacita a cepa de desenvolver-se utilizando-se a acetamida como a nica fonte de nitrognio e esta caracterstica tem sido usada para a seleo dos transformantes, O fragmento de 3,1 kb (Spel - Xbal), a partir do plasmdio p3SR2 (Kelly J. e Hynes M. (1985) Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans. EMBO J. 4: 475.),  usado nos plasmdios. O fragmento contm 1007 bps da rea do promotor, 1897 bps da regio de codificao (ntrons includos)  os 183 bps da rea de terminador do gene de amdS. * fragmento de cbh1 3': O fragmento foi isolado de T. reesei ALK02466 por utilizao de resgate de plasmdio (1,7 kb, BamHI - EcoRI, comeando 1,4 kb aps a INTERRUPO do gene, Suominen e col. (1993) High frequency one-step gene replacement in Trichoderma reesei. II. Effects of deletions of individual cellulase genes. Mol. Gen. Genet. 241: 523.). A cepa ALK02466 deriva-se da cepa ALK0233 (Harkki e col. (1991) Genetic engineering of Trichoderma to produce strains with novel cellulase profiles. Enzyme Microb. Technol. 13: 227.). O fragmento de 3'  usado juntamente com a rea de promotor para objetivar o gene de celulase de 20K ao local de cbh1 por recombinao homloga. O plasmdio pALK1235 contm: * gene de hph: O gene codificando a HmB fosfotransferase  originalmente isolado de JM109 de E. coli K-12 (Yanish-Perron e col. (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33: 103.) e ele confere resistncia  higromicina B (HmB). A resistncia  higromicina (inativada por fosforilao por HmB fosfotransferase) foi usada para a seleo dos transformantes. O gene de hph, juntamente com o promotor de pki e o terminador de cbh2 (ver abaixo),  isolado do plasmdio pRLMex30 (Mach e col. (1994) Transformation of Trichoderma reesei based on hygromycin B resistance using homologous expression signals. Curr. Genet. 25: 567.) como um fragmento de Not\-Pvu\\ de 2,2 kb. * promotor de pki: O promotor de pki (piruvato cinase) de 0,75 kb para a expresso de hph foi sintetizado por PCR usando o DNA de T. reesei QM 9414 como um molde (Schindler e col. (1993) Characterization of the pyruvate kinase-encoding gene (pkii) of Trichoderma reesei. Gene 1301271.). * terminador de cbh2: A sequncia de terminador de cbh2 comea imediatamente aps o cdon de INTERRUPO do gene de cbh2 (at o stio de PvuW 0,5 kb a partir do cdon de INTERRUPO; Mach e col. (1994) Transformation of Trichoderma reesei based on hygromycin B resistance using homologous expression signals. Curr. Genet. 25: 567.) e origina-se a partir do plasmdio pRLMex30. * fragmento de egi1 5': O fragmento de egH 5' de 1,8 kb (Seal -Stu\) foi isolado de T. reesei QM 6a (Mandeis e Reese (1957) Induction of cellulase in Trichoderma viridae as influenced by carbon sources and metais. J. Bacteriol. 73: 269.). Este fragmento est situado cerca de 1,35 kb a montante da regio de codificao de egH e ele foi usado para objetivar a integrao do DNA de transformao no local de egH. fragmento de eg!1 3': O fragmento de egH 3' de 1,6 kb (Seal -Xho\) foi, conforme o fragmento de 5', isolado de T. reesei QM 6a. O fragmento est situado 0,3 kb a jusante da extremidade do gene de eg!1 e  usado para a objetivao do DNA de transformao no local de eg!1.</span>In addition to the material described above, plasmid pALK1231 contains: * amdS gene: The gene has been isolated from Aspergillus nidulans VH1-TRSX6 and is coding for acetamidase (Hynes et al. (1983) Isolation of genomic clones containing the amdS gene of Aspergillus nidulans and their use in the analysis of structural and regulatory mutations (Mol. Cell. Biol. 3: 1430.). Acetamidase enables the strain to develop using acetamide as the sole nitrogen source and this feature has been used to select transformants. The 3.1 kb (Spel - Xbal) fragment from plasmid p3SR2 (Kelly J. and Hynes M. (1985) Transformation of Aspergillus niger by the AmdS gene of Aspergillus nidulans. EMBO J. 4: 475.), is used in plasmids. The fragment contains 1007 bps of promoter area, 1897 bps of coding region (introns included) and 183 bps of amdS gene terminator area. * 3 'cbh1 fragment: The fragment was isolated from T. reesei ALK02466 by use of plasmid rescue (1.7 kb, BamHI - EcoRI, starting 1.4 kb after Gene INTERRUPTION, Suominen et al. (1993) High frequency one-step gene replacement in Trichoderma reesei II Effects of deletions of individual cellulase genes Mol. Gen. Genet 241: 523.). The strain ALK02466 is derived from the strain ALK0233 (Harkki et al. (1991) Genetic engineering of Trichoderma to produce strains with novel cellulase profiles. Enzyme Microb. Technol. 13: 227.). The 3 'fragment is used in conjunction with the promoter area to target the 20K cellulase gene to the cbh1 site by homologous recombination. Plasmid pALK1235 contains: * hph gene: The gene encoding HmB phosphotransferase is originally isolated from E. coli K-12 JM109 (Yanish-Perron et al. (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors Gene 33: 103.) and it confers resistance to hygromycin B (HmB). Hygromycin resistance (inactivated by HmB phosphotransferase phosphorylation) was used for selection of transformants. The hph gene, together with the pki promoter and cbh2 terminator (see below), is isolated from plasmid pRLMex30 (Mach et al. (1994) Transformation of Trichoderma reesei based on hygromycin resistance using homologous expression signals. Genet. 25: 567.) as a 2.2 kb Not \ -Pvu \\ fragment. * pki promoter: The 0.75 kb pki (pyruvate kinase) promoter for hph expression was synthesized by PCR using T. reesei QM 9414 DNA as a template (Schindler et al. (1993) Characterization of the pyruvate kinase-encoding gene (pkii) of Trichoderma reesei. Gene 1301271.). * cbh2 terminator: The cbh2 terminator sequence begins immediately after the cbh2 gene STOP codon (to the PvuW site 0.5 kb from the STOP codon; Mach et al. (1994) Transformation of Trichoderma reesei based on hygromycin B resistance using homologous expression signals (Curr. Genet. 25: 567.) and originates from plasmid pRLMex30. * 5 'egi1 fragment: The 1.8 kb egH 5' fragment (Seal -Stu \) was isolated from T. reesei QM 6a (Mandeis and Reese (1957) Induction of cellulase in Trichoderma viridae as influenced by carbon sources and metals J. Bacteriol 73: 269). This fragment is located about 1.35 kb upstream of the egH coding region and was used to target the integration of the transforming DNA at the egH site. Eg 13 'fragment: The 1.6 kb egH 3' fragment (Seal-Xho \) was, according to the 5 'fragment, isolated from T. reesei QM 6a. The fragment is located 0.3 kb downstream of the eg11 gene endpoint and is used for objectification of the transforming DNA at the eg11 site.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os mtodos padres de DNA descritos por Sambrook e col. (1989) Em: Molecular cloning: a laboratory manual, 2~ ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., foram usados na construo dos vetores. As enzimas de restrio, T4 DNA ligase, fragmento de Klenow da DNA polimerase I, T4 DNA polimerase, polinucleotdeo cinase e Taq pofimerase, eram da Boehringer Mannheim, Alemanha) e da New England Biolabs (EUA). Cada enzima foi usada de acordo com as instrues do fabricante. O DNA do plasmdio foi isolado utilizando-se as colunas Qiagen (Qiagen GmbH, Alemanha) ou Promega Magic Minipreps (Promega, EUA) de acordo com os protocolos do fabricante. Os oligonucleotdeos usados nas reaes por PCR e nas reaes de seqnciamento foram sintetizados por um Sintetizador de DNA ABI (Applied Biosystems, EUA) 381 A. O seqnciamento de DNA foi feito conforme descrito no Exemplo 19.</span>The standard DNA methods described by Sambrook et al. (1989) In: Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., were used to construct the vectors. Restriction enzymes T4 DNA ligase, Klenow fragment of DNA polymerase I, T4 DNA polymerase, polynucleotide kinase and Taq pofimerase were from Boehringer Mannheim, Germany) and New England Biolabs (USA). Each enzyme was used according to the manufacturer's instructions. Plasmid DNA was isolated using Qiagen (Qiagen GmbH, Germany) or Promega Magic Minipreps (Promega, USA) columns according to the manufacturer's protocols. Oligonucleotides used in PCR reactions and sequencing reactions were synthesized by an ABI DNA Synthesizer (Applied Biosystems, USA) 381 A. DNA sequencing was performed as described in Example 19.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os fragmentos de DNA para a clonagem ou as transformaes foram isolados a partir de gis de agarose de baixo ponto de fuso (FMC Bioproducts, EUA) por tratamento com -agarose I (New England Biolabs, EUA) ou por utilizao do Kit de Extrao de Gel QIAEX (Qiagen GmbH, Alemanha) de acordo com as instrues do fornecedor. O T, reesei ALK0362Q foi transformado conforme descrito por Penttil e col. (1987) A versatile transformation system for the cellulolytic filamentous fungus Trichoderma reesei. Gene 61:155.) com as modificaes descritas em Karhunen e col. (1993) High frequency one-step gene replacement in Trichoderma reesei, I. Endoglucanase I overproduction. Mol. Gen. Genet. 241: 515.). Os transformantes de T. reesei foram transferidos em um meio seletivo e purificados atravs de condios. Os transformantes foram estabilizados por cultivo dos mesmos sobre inclinaes seletivas por duas geraes antes da esporulao sobre o gar de dextrose de batata. Exemplo 30 Caractersticas dos transformantes que produzem a celulase de 20K de Melanocarpus albomyces ALK04237 Os transformantes purificados foram desenvolvidos em frascos com agitao, em um meio contendo 4 % de soro de leite, 1,5 % de fonte de nitrognio complexa derivada de gro, 5 % de KH2P04 e 0,5 % de (NH4)2S04. As culturas foram desenvolvidas a 30C e 250 rpm por 7 dias.</span>DNA fragments for cloning or transformations were isolated from low melting agarose gels (FMC Bioproducts, USA) by treatment with -agarose I (New England Biolabs, USA) or by using the Extraction Kit QIAEX Gel (Qiagen GmbH, Germany) according to the supplier's instructions. T, reesei ALK0362Q was transformed as described by Penttil et al. (1987) The versatile transformation system for the cellulolytic filamentous fungus Trichoderma reesei. Gene 61: 155.) With the modifications described in Karhunen et al. (1993) High frequency one-step gene replacement in Trichoderma reesei, I. Endoglucanase I overproduction. Mol. Gen. Genet. 241: 515). T. reesei transformants were transferred in a selective medium and purified by conidia. Transformants were stabilized by cultivating them on selective slopes for two generations before sporulation on potato dextrose agar. Example 30 Characteristics of Melanocarpus albomyces 20K cellulase producing transformants ALK04237 Purified transformants were grown in shake flasks in medium containing 4% whey, 1.5% complex grain-derived nitrogen source, 5 % KH 2 PO 4 and 0.5% (NH 4) 2 SO 4. Cultures were grown at 30  C and 250 rpm for 7 days.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Os sobrenadantes da cultura foram manchados ("blotted") diretamente sobre os filtros de nitroceluiose por uma aparelhagem de manchar com um ponto ("dot-blot"). A CBHI foi detectada por imunotingimento usando um anticorpo monocionai especfico para,CBHI Cl-258, e a EGI peio anticorpo monocionai especfico EI-2 (Aho e cI. (1991) Monocionai antibodies against core and ceiluiose-binding domains of Trichoderma reesei cellobiohydrolases I e II and endoglucanase I. Eur. J. Biochem. 200: 643.), e o sistema AP de Western blot ProtoBlot (Promega, EUA) de acordo com as recomendaes do fabricante.</span>Culture supernatants were blotted directly onto the nitrocelluiosis filters by a dot-blot apparatus. CBHI was detected by immunostaining using a monoclonal antibody specific for, CBHI Cl-258, and EGI by specific monoclonal antibody EI-2 (Aho ec  I. (1991) Monoclonal antibodies against core and ceiluiose-binding domains of Trichoderma reesei cellobiohydrolases I and II and endoglucanase I. Eur. J. Biochem. 200: 643.), and the Western blot AP system ProtoBlot (Promega, USA) according to the manufacturer's recommendations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As cepas de T. reesei ALK03620/pALK1231/14, ALK03620/pALK1231/16, ALKO3620/pALK1231/20 e ALKO3620/pALK1231/59 no contm o gene de cbh1, O gene de cbh1  substitudo pelo gene marcador de amdS e pela construo de celulase de 20K no cassete de expresso de pALK1231. A substituio do gene de cbh1 foi verificada nas hibridaes Southern. As cepas de T. reesei SALK0362Q/pALK1235/40 e ALKO3620/pALK1235/49 no contm o gene de egl1. O gene de eg!1  substitudo pelo gene marcador de hph e pela construo de celulase de 20K nos cassetes de expresso de pALK1235. A substituio do gene de egH foi verificada nas hibridaes por Southern. A cepa hospedeira ALKO3620 usada nas transformaes  deficiente do gene de eg/2 (substitudo pelo gene de ble de Streptoalioteichus hindustanus (Mattern e col., 1988, Drocourt e col., 1990). Assim, as cepas no produzem os componentes de celulase de Trichoderm EGII e CBHI ou EGI.</span>T. reesei strains ALK03620 / pALK1231 / 14, ALK03620 / pALK1231 / 16, ALKO3620 / pALK1231 / 20 and ALKO3620 / pALK1231 / 59 do not contain the cbh1 gene. The cbh1 gene is replaced by the amdS marker gene and the construct. of 20K cellulase in the pALK1231 expression cassette. Cbh1 gene replacement was verified in Southern hybridizations. T. reesei strains SALK0362Q / pALK1235 / 40 and ALKO3620 / pALK1235 / 49 do not contain the egl1 gene. The eg1 gene is replaced by the hph marker gene and the 20K cellulase construct in the pALK1235 expression cassettes. The replacement of the egH gene was verified in the hybridizations by Southern. The host strain ALKO3620 used in the transformations is deficient in the eg / 2 gene (replaced by the Streptoalioteichus hindustanus ble gene (Mattern et al., 1988, Drocourt et al., 1990). Thus, the strains do not produce cellulase components). Trichoderm EGII and CBHI or EGI.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As amostras a partir dos sobrenadantes da cultura foram corridas sobre gis em lminas de poliacrilamida contendo 0,1% de SDS no sistema de eletroforese Mini Protean II da Bio-Rad (EUA). O anticorpo policlonal preparado contra a celulase de 20K purificada foi usado para detectar a protena produzida nos Western blots. Na deteco, o Sistema ProtoBlot AP da Promega foi usado. O resultado do Western  mostrado na Figura 30. Os transformantes ALKO3620/pALK1235/49, ALK03620/pALK1235/40, ALKO3620/pALK1231/14 e ALKO3620/pALK1231/16 (caminhos 1, 2, 4 e 5) produzem uma protena que reage com o anti-soro de celulase de 20K policlonal. O tamanho da protena produzida pelos transformantes  o mesmo do tamanho da celulase de 20K purificada (caminho 6). O ALK0362G (caminho 3) no produz a protena correspondente.</span>Samples from culture supernatants were run on gels on polyacrylamide slides containing 0.1% SDS on Bio-Rad (USA) Mini Protean II electrophoresis system. Polyclonal antibody prepared against purified 20K cellulase was used to detect protein produced in Western blots. In detection, Promega's ProtoBlot AP System was used. The Western result is shown in Figure 30. The ALKO3620 / pALK1235 / 49, ALK03620 / pALK1235 / 40, ALKO3620 / pALK1231 / 14 and ALKO3620 / pALK1231 / 16 transformants (lanes 1, 2, 4 and 5) produce a reacting protein. with polyclonal 20K cellulase antiserum. The size of the protein produced by the transformants is the same as the size of the purified 20K cellulase (lane 6). ALK0362G (lane 3) does not produce the corresponding protein.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">As atividades de endoglicanase dos transformantes foram determinadas conforme descrito no Exemplo 10. Quando 2% de carboximetilcelulose (CMC) foram usados como um substrato, a temperatura de reao foi alterada at 70 C, e assim, a atividade de endoglicanase de ALK03620 foi inativada por calor. Quando utiliza-se 1 % de hidroxietilcelulose como um substrato, a inativao por calor foi efetuada antes das medies da atividade enzimtica. As amostras do meio de desenvolvimento foram diludas para o tampo de HEPES  0,05 M, pH 7,0, e incubadas 20 min em 70 C. A inativao por calor da endoglicanase I (a principal endoglicanase deixada em ALK03620) era quase completa. A atividade dos transformantes negativos para egl1 caiu cerca de 30% na inativao por calor, o que indica a inativao por calor pequena da celulase de 20K. As atividades de endoglicanase so apresentadas na Tabela XX. Quando a HEC foi o substrato, a atividade de celulase de 20K foi extrapolada para a atividade antes do tratamento trmico dividindo-se a atividade obtida aps o tratamento trmico por 0,7.</span>The endoglycanase activities of the transformants were determined as described in Example 10. When 2% carboxymethylcellulose (CMC) was used as a substrate, the reaction temperature was changed to 70  C, and thus the ALK03620 endoglycanase activity was inactivated. by heat. When 1% hydroxyethylcellulose is used as a substrate, heat inactivation was performed prior to measurements of enzymatic activity. Samples from the development medium were diluted to 0.05 M HEPES buffer, pH 7.0, and incubated 20 min at 70  C. Heat inactivation of endoglycanase I (the main endoglycanase left in ALK03620) was almost complete. The activity of egl1 negative transformants fell by about 30% on heat inactivation, indicating the small heat inactivation of 20K cellulase. Endoglycanase activities are presented in Table XX. When HEC was the substrate, the 20K cellulase activity was extrapolated to the activity before heat treatment by dividing the activity obtained after heat treatment by 0.7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabela XX. As atividades de endoglicanase de transformantes de T. reesei que produzem a celulase de 20K de Melanocarpus albomyces.</span>Table XX The endoglycanase activities of T. reesei transformants producing Melanocarpus albomyces 20K cellulase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Atividade de celulase de 20K</span>20K cellulase activity</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Substrato CMC (unidades artificiais/ml) 70C, pH 7,0 HEC 50C, pH 7,0 _______ _ _____ ALKO3620 50*** 38*** ALKO3620/pALK1231/14 2400 350 ALKO3620/pALK1231/16 2600 350 AL KO3620/pAKL1231/20 6500 750 ALK03620/pALK1231/59 6800 750 ALK03620/pALK1231 /40 2400 325 ALKO3620/pALK1235/49 2100 350 * = no medida ** = no inativada por calor, contm tambm a celulase de 50K, a celulase B de 50K e outras atividades de celulase. *** = atividade devida s celulases de Trichoderma ) As atividades de endoglicanas da cepa hospedeira de T reesei ALK03620 so quase totalmente inativadas por calor a 70C. Os transformantes que produzem a celulase de 20K de Melanocarpus albomyces produzem quantidades substanciais de celulase de 20K relativamente estvel ao calor. O nvel de produo de endoglicanase dos transformantes  diversas vezes maior do que aquele da cepa parental de celulase de 20K ALK04237.</span>CMC Substrate (Artificial Units / ml) 70  C, pH 7.0 HEC 50  C, pH 7.0 _______ _ _____ ALKO3620 50 *** 38 *** ALKO3620 / pALK1231 / 14 2400 350 ALKO3620 / pALK1231 / 16 2600 350 AL KO3620 / pAKL1231 / 20 6500 750 ALK03620 / pALK1231 / 59 6800 750 ALK03620 / pALK1231 / 40 2400 325 ALKO3620 / pALK1235 / 49 2100 350 * = not measured ** = not heat inactivated, also contains 50K cellulase, 50K cellulase B and other cellulase activities. *** = activity due to Trichoderma cellulases) The endoglycan activities of the T reesei host strain ALK03620 are almost completely heat inactivated at 70  C. Transformants producing Melanocarpus albomyces 20K cellulase produce substantial amounts of relatively heat stable 20K cellulase. The endoglycanase production level of the transformants is several times higher than that of the 20K ALK04237 parental cellulase strain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Exemplo 31 Produo de celulase de 50K de Melanocarpus albomyces ALK04237 em T. reesei As cepas de Trichoderma reesei foram construdas para a produo de celulase de 50K de Melanocarpus albomyces ALK04237. As cepas produzem a celulase de 50K de Melanocarpus e so incapazes de produzir a endoglicanase II e a celobiohidrolase I ou a endoglicanase I de . reesei. Na construo das cepas que produzem a celulase de 50K de Melanocarpus albomyces, a cepa de Trichoderma reesei parental ALKO3620 foi transformada com os cassetes de expresso do plasmdio pALK1238 ou pALK1240 (Figuras 31 e 32). Nos cassetes, a celulase de 50K  expressa a partir do promotor de cbh1 forte. A integrao dos cassetes de expresso resulta nas substituies do gene de cbh1 parental (pALK1238) ou do egl1 (pALK1240). A clonagem e a transformao foram feitas conforme descritas no Exemplo 29, exceto que o gene de celulase de 20K foi substitudo pelo gene de celulase de 50K (fragmento de 1,7 kb comeando a partir do cdon de ATG) descrito no Exemplo 22. Os transformantes que produzem a celulase de 50K de Melanocarpus albomyces so ento caracterizados similares ao exemplo 30, com modificaes bvias para uma pessoa versada na tcnica. Os transformantes que produzem a celulase B de 50K de Melanocarpus albomyces e a protena com CBD podem ser criados similares aos Exemplos 29 e 30, com modificaes bvias para uma pessoa versada na tcnica.</span>Example 31 Production of 50K cellulase from Melanocarpus albomyces ALK04237 in T. reesei Trichoderma reesei strains were constructed for the production of 50K cellulase from Melanocarpus albomyces ALK04237. The strains produce Melanocarpus 50K cellulase and are unable to produce endoglycanase II and cellobiohydrolase I or  endoglycanase I. reesei. In the construction of the strains producing the Melanocarpus albomyces 50K cellulase, the parental Trichoderma reesei strain ALKO3620 was transformed with the plasmid expression cassettes pALK1238 or pALK1240 (Figures 31 and 32). In cassettes, 50K cellulase is expressed from the strong cbh1 promoter. Integration of expression cassettes results in substitutions of the parental cbh1 (pALK1238) or egl1 (pALK1240) gene. Cloning and transformation were as described in Example 29, except that the 20K cellulase gene was replaced by the 50K cellulase gene (1.7 kb fragment starting from the ATG codon) described in Example 22. Transformants producing Melanocarpus albomyces 50K cellulase are then characterized similar to Example 30, with obvious modifications to a person skilled in the art. Transformants producing Melanocarpus albomyces 50K cellulase B and CBD protein can be created similar to Examples 29 and 30, with obvious modifications to a person skilled in the art.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tendo agora completamente descrito a inveno, ser entendido por aqueles versados na tcnica que a inveno pode ser efetuada dentro de uma faixa ampla e equivalente de condies, parmetros e similares, sem afetar o esprito ou o escopo da inveno, ou de qualquer modalidade da mesma. Todas as referncias citadas aqui so completamente incorporadas por referncia.</span>Having now fully described the invention, it will be understood by those skilled in the art that the invention may be effected within a broad and equivalent range of conditions, parameters and the like without affecting the spirit or scope of the invention, or any embodiment thereof. . All references cited herein are fully incorporated by reference.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>PARTICULARS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis) Form PCT RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RECEBIMENTO NO CASO DE UM DEPSITO ORIGINAL expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>RECEIPT IN CASE OF AN ORIGINAL DEPOSIT Dispatched in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was gotten.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/4 (pgina nica) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 4 (single page) BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL ESTABELECIMENTO DA VIABILIDADE expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2 (a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel.</span>INTERNATIONAL FORM OF FEASIBILITY ISSUED pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITORY AUTHORITY identified at the bottom of this page 1 Indicate the date of the original deposit or, where a new deposit or transfer has been made, the most recent relevant date (date of new deposit or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 primeira pgina) * Preencher se a informao tiver sido requerida  se os resultados do teste forem negativos.</span>Form BP / 9 first page) * To be completed if information is required is if test results are negative.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 segunda e ltima pgina) INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13/'s) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 9 second and last page) INFORMATION ON A DEPOSITED MICROORGANISM (PCT Rule 13th / 's) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PROPOSALS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RECEBIMENTO NO CASO DE UM DEPSITO ORIGINAL expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina ' Onde a Regra 6.4 (d) aplicar-se, tal data   data na qual a situao legal da autoridade depositria internacional foi obtida.</span>RECEIPT IN CASE OF AN ORIGINAL DEPOSIT Dispatched in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 'Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was gotten.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/4 (pgina nica) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 4 (single page) BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL ' ESTABELECIMENTO DA VIABILIDADE expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2 (a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel.</span>INTERNATIONAL FORM 'FEASIBILITY ESTABLISHMENT issued in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITORY AUTHORITY identified at the bottom of this page 1 Indicate the date of the original deposit or, where a new deposit or transfer has been made, the most recent relevant date (date the new deposit or the date of the transfer). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 primeira pgina)  Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Form BP / 9 first page) Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 segunda e ltima pgina) INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 9, second and last page) Indications on a deposited micro-organism (PCT Rule 13bis) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE PURPOSES OF MICROORGANISM FOR PURPOSES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">" RECEBIMENTO NO CASO DE UM DEPSITO ORIGINAL expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina ' Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>"RECEIPT IN CASE OF AN ORIGINAL DEPOSIT Dispatched in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 'Where Rule 6.4 (d) applies, such date is the date on which the legal position of the depositary authority was obtained internationally.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/4 (pgina nica) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 4 (single page) BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">= ESTABELECIMENTO DA VIABILIDADE expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2 (a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel.</span>= ESTABLISHMENT OF FEASIBILITY issued in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITORY AUTHORITY identified at the bottom of this page 1 Indicate the date of the original deposit or, where a new deposit or transfer has been made, the most recent relevant date (date of new deposit or date of transfer). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 primeira pgina)  Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Form BP / 9 first page) 'Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 segunda e ltima pgina) INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 9, second and last page) Indications on a deposited micro-organism (PCT Rule 13bis) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE PURPOSES OF MICROORGANISM FOR PURPOSES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RECEBIMENTO NO CASO DE UM DEPSITO ORIGINAL expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>RECEIPT IN CASE OF AN ORIGINAL DEPOSIT Dispatched in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was gotten.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/4 (pgina nica) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 4 (single page) BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL ESTABELECIMENTO DA VIABILIDADE expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 11ndicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2 (a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel.</span>INTERNATIONAL FORM OF FEASIBILITY ISSUED pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITORY AUTHORITY identified at the bottom of this page 11 indicate the date of the original deposit or, where a new deposit or transfer has been made, the most recent relevant date (date of new deposit or date of transfer). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 primeira pgina) 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Form BP / 9 first page) 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 segunda e ltima pgina) INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT RO/184 (julho de 1992) ' ' TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 9 second and last page) INFORMATION ON A DEPOSITED MICROORGANISM (PCT Rule 13bis) PCT Form RO / 184 (July 1992) '' BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE PURPOSES OF PURPOSES FOR PURPOSES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RECEBIMENTO NO CASO DE UM DEPSITO ORIGINAL expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>RECEIPT IN CASE OF AN ORIGINAL DEPOSIT Dispatched in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was gotten.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/4 (pgina nica) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 4 (single page) BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL ESTABELECIMENTO DA VIABILIDADE expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2 (a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel.</span>INTERNATIONAL FORM OF FEASIBILITY ISSUED pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITORY AUTHORITY identified at the bottom of this page 1 Indicate the date of the original deposit or, where a new deposit or transfer has been made, the most recent relevant date (date of new deposit or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 primeira pgina)  Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Form BP / 9 first page) 'Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio BP/9 segunda e ltima pgina) INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form BP / 9, second and last page) Indications on a deposited micro-organism (PCT13bis Rule) Form PCT RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE MICROORGANISM DEPOSIT FOR PURPOSES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli FIN-05200 Rajamki RECEBIMENTO NO CASO DE UM DEPSITO ORIGINAL</span>Primalco Ltd. Biotec Valta-Akseli FIN-05200 Rajamki RECEIPT IN CASE OF ORIGINAL DEPOSIT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA</span>issued in accordance with Rule 7.1 by the DEPOSITORY AUTHORITY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">INTERNACIONAL identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>Where the Rule 6.4 (d) applies, that date is the date on which the legal position of the international depositary authority was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSMZ-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli FIN-05200 Rajamki ESTABELECIMENTO DA VIABILIDADE expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na Darte inferior desta Daina maicar a aaia ao aeposno originai ou, onae um novo aeposito ou uma transterencia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Primalco Ltd. Biotec Valta-Akseli FIN-05200 Rajamki FEASIBILITY ESTABLISHMENT issued in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified in the lower part of this Daina to piss off the original aeposno or, where a new deposit or transfer has been made, the most recent relevant date (new deposit date or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/9 (pgina nica) 0196 INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSMZ-BP / 9 (single page) 0196 PARTICULARS RELATING TO A DEPOSITED MICROORGANISM (PCT 13bis Rule) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT FOR PROPOSALS OF MICROORGANISM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec RECEBIMENTO NO CASO DE UM DEPSITO</span>Primalco Ltd. Biotec RECEIPT IN CASE OF A DEPOSIT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Valta-Akseli ORIGINAL FIN-05200 Rajamki expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>Valta-Akseli ORIGINAL FIN-05200 Rajamki issued in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the depositary authority was obtained internationally.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSM2-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSM2-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec ESTABELECIMENTO DA VIABILIDADE</span>Primalco Ltd. Biotec FEASIBILITY SETTING</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Valta-Akseli expedido de acordo com a Regra 10.2 pela FIN-05200 Rajamki AUTORIDADE DEPOSITRIA INTERNACIO- NAL _____ identificada na parte inferior desta pgina_ 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Valta-Akseli issued in accordance with Rule 10.2 by FIN-05200 Rajamki INTERNATIONAL DEPOSITARY AUTHORITY _____ Identified at the bottom of this page_ 1 Indicate the date of the original deposit or, where a new deposit or transfer has been made, the relevant date. most recent (new deposit date or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/9 (pgina nica) 0196 INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13/ws) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSMZ-BP / 9 (single page) 0196 INDICATIONS CONCERNING A DEPOSITED MICROORGANISM (PCT Rule 13 / ws) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT FOR MICROORGANISMS FOR PROPOSALS PROCEDURE</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli RECEBIMENTO NO CASO DE UM DEPSITO</span>Primalco Ltd. Biotec Valta-Akseli RECEIPT IN CASE OF A DEPOSIT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIN-05200 Rajamki ORIGINAL</span>FIN-05200 Rajamki ORIGINAL</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>issued in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSMZ-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli ESTABELECIMENTO DA VIABILIDADE FIN-05200 Rajamki expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos. i Formulrio DSMZ-BP/9 (pgina nica) 0196 INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Primalco Ltd. Biotec Valta-Akseli ESTABLISHMENT OF FEASIBILITY FIN-05200 Rajamki issued in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 Indicate the date of the original deposit or, where a new deposit or transfer has been made. , the most recent relevant date (new deposit date or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results. i Form DSMZ-BP / 9 (single page) 0196 PARTICULARS RELATING TO A DEPOSITED MICROORGANISM (PCT 13bis Rule) Form PCT RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT FOR PROPOSALS FOR PROPOSALS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli FIN-05200 Rajamki RECEBIMENTO NO CASO DE UM DEPSI- TO ORIGINAL</span>Primalco Ltd. Biotec Valta-Akseli FIN-05200 Rajamki RECEIVING IN THE CASE OF AN ORIGINAL DEPOSIT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA</span>issued in accordance with Rule 7.1 by the DEPOSITORY AUTHORITY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">INTERNACIONAL _____________________________________identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>INTERNATIONAL _____________________________________identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSMZ-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli ESTABELECIMENTO DA VIABILIDADE FIN-05200 Rajamki expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL irtontifirarla na narta infarinr riacta rvnina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Primalco Ltd. Biotec Valta-Akseli ESTABLISHMENT OF FEASIBILITY FIN-05200 Rajamki issued in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY irtontifirarla narta infarinr riacta rvnina 1 Indicate the date of the original deposit or where a new deposit or transfer has been made. , the most recent relevant date (new deposit date or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/9 (pgina nica) 0196 INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSMZ-BP / 9 (single page) 0196 PARTICULARS RELATING TO A DEPOSITED MICROORGANISM (PCT 13bis Rule) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT FOR PROPOSALS OF MICROORGANISM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli RECEBIMENTO NO CASO DE UM DEPSI- FIN-05200 Rajamki TO ORIGINAL</span>Primalco Ltd. Biotec Valta-Akseli RECEIPT IN THE CASE OF A DEPOSIT FIN-05200 Rajamki TO ORIGINAL</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL _________________________________________identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>issued in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY _________________________________________identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO</span>Form DSMZ-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PROCEDURES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DE PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec ESTABELECIMENTO DA VIABILIDADE</span>Primalco Ltd. Biotec FEASIBILITY SETTING</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Valta-Akseli expedido de acordo com a Regra 10.2 pela FIN-05200 Rajamki AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Indicara data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Valta-Akseli issued in accordance with Rule 10.2 by FIN-05200 Rajamki INTERNATIONAL DEPOSITORY AUTHORITY identified at the bottom of this page 1 Indicates the date of original deposit or, where a new deposit or transfer has been made, the most recent relevant date (date the new deposit or the date of the transfer). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/9 (pgina nica) 0196 INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 13bis) Formulrio PCT R/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO DE</span>Form DSMZ-BP / 9 (single page) 0196 INDICATIONS CONCERNING A DEPOSITED MICROORGANISM (PCT 13bis Rule) PCT Form R / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT FOR PROPOSALS OF MICROORGAN PROPOSALS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli RECEBIMENTO NO CASO DE UM DEPSITO</span>Primalco Ltd. Biotec Valta-Akseli RECEIPT IN CASE OF A DEPOSIT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIN-05200 Rajamki ORIGINAL expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>FIN-05200 Rajamki ORIGINAL issued in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was obtained. .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO DE</span>Form DSMZ-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PURPOSES OF PROCEDURE</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli ESTABELECIMENTO DA VIABILIDADE FIN-05200 Rajamki expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL i/ipntifinaria na narta infarinr riacta nnina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Primalco Ltd. Biotec Valta-Akseli ESTABLISHMENT OF FEASIBILITY FIN-05200 Rajamki issued in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY i / ipntifinaria narta infarinr riacta nnina 1 Indicate the date of original deposit or, where a new deposit or transfer has the most recent relevant date (new deposit date or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/9 (pgina nica) 0196 INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT 1 3j/s) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO DE</span>Form DSMZ-BP / 9 (single page) 0196 PARTICULARS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 1 3jj / s) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT FOR MICROORGANISM PROPOSALS PROCEDURE OF</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli RECEBIMENTO NO CASO D UM DEPSITO</span>Primalco Ltd. Biotec Valta-Akseli RECEIPT IN CASE OF DEPOSIT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIN-05200 Rajamki ORIGINAL</span>FIN-05200 Rajamki ORIGINAL</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL ___________identificada na parte inferior desta pgina_ 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>issued in accordance with Rule 7.1 by the International Depositary Authority ___________identified at the bottom of this page_ 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO DE</span>Form DSMZ-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PURPOSES OF PROCEDURE</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli ESTABELECIMENTO DA VIABILIDADE FIN-05200 Rajamki expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da.transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Primalco Ltd. Biotec Valta-Akseli FEASIBILITY ESTABLISHMENT FIN-05200 Rajamki dispatched in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page 1 Indicate the date of original deposit or, where a new deposit or transfer has been made , the most recent relevant date (new deposit date or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/9 (pgina nica) 0196 INDICAES REFERENTES A UM MICROORGANISMO DEPOSITADO (Regra do PCT13bis) Formulrio PCT RO/184 (julho de 1992) TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO DE</span>Form DSMZ-BP / 9 (single page) 0196 PARTICULARS RELATING TO A DEPOSITED MICROORGANISM (PCT13bis Rule) PCT Form RO / 184 (July 1992) BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT FOR PROPOSAL OF MICROORGANISMS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli RECEBIMENTO NO CASO DE UM DEPSI- FIN-05200 Rajamki TO ORIGINAL</span>Primalco Ltd. Biotec Valta-Akseli RECEIPT IN THE CASE OF A DEPOSIT FIN-05200 Rajamki TO ORIGINAL</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">expedido de acordo com a Regra 7.1 pela AUTORIDADE DEPOSITRIA INTERNACIONAL ___________________ identificada na parte inferior desta pgina 1 Onde a Regra 6.4 (d) aplicar-se, tal data  a data na qual a situao legal da autoridade depositria internacional foi obtida.</span>issued in accordance with Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY ___________________ identified at the bottom of this page 1 Where Rule 6.4 (d) applies, such date is the date on which the legal position of the international depositary authority was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSM2-BP/4 (pgina nica) 0196 TRATADO DE BUDAPESTE SOBRE O RECONHECIMENTO INTERNACIONAL DO DEPSITO DE MICROORGANISMOS PARA OS PROPSITOS DE PROCEDIMENTO DE</span>Form DSM2-BP / 4 (single page) 0196 BUDAPEST TREATY ON INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR PURPOSES OF PROCEDURE</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PATENTE</span>PATENT</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FORMULRIO INTERNACIONAL</span>INTERNATIONAL FORM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primalco Ltd. Biotec Valta-Akseli ESTABELECIMENTO DA VIABILIDADE FIN-05200 Rajamki expedido de acordo com a Regra 10.2 pela AUTORIDADE DEPOSITRIA INTERNACIONAL identificada na parte inferior desta pgina_ 1 Indicar a data do depsito original ou, onde um novo depsito ou uma transferncia tiver sido feita, a data relevante mais recente (data do novo depsito ou a data da transferncia). 2 Nos casos referidos na Regra 10.2(a) (ii) e (iii), referir-se ao teste de viabilidade mais recente. 3 Marcar com uma cruz o quadrado aplicvel. 4 Preencher se a informao tiver sido requerida e se os resultados do teste forem negativos.</span>Primalco Ltd. Biotec Valta-Akseli FEASIBILITY ESTABLISHMENT FIN-05200 Rajamki issued in accordance with Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page_ 1 Indicate the date of original deposit or, where a new deposit or transfer has been made , the most recent relevant date (new deposit date or transfer date). 2 In the cases referred to in Rule 10.2 (a) (ii) and (iii), refer to the most recent feasibility test. 3 Mark the applicable square with a cross. 4 Fill in if required and negative test results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulrio DSMZ-BP/9 (pgina nica) 0196 REIVINDICAES</span>Form DSMZ-BP / 9 (single page) 0196 CLAIMS</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(14)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Portuguese</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM122420150" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Vetor, caracterizado pelo fato de que contm o DNA genmico de celulase 20K representado pela SEQ ID NO: 30 contendo regies codifi-cantes de cdons 33-115, 187-435 e 506-881 e codificando o polipeptdeo 20K maduro representado pelos aminocidos 22 a 235 (214 aminocidos) da SEQ ID NO: 31.</span>1. Vector, characterized in that it contains the 20K cellulase genomic DNA represented by SEQ ID NO: 30 containing coding regions of codons 33-115, 187-435 and 506-881 and encoding the mature 20K polypeptide represented by amino acids. 22 to 235 (214 amino acids) of SEQ ID NO: 31.</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Microorganismo transformado, caracterizado pelo fato de que compreende o vetor de expresso contendo tal cDNA de celulase representado pelos cdons 33-115, 187-435 e 506-881 da SEQ ID NO: 30 e codificando o polipetdeo maduro.</span>Transformed microorganism, characterized in that it comprises the expression vector containing such cellulase cDNA represented by codons 33-115, 187-435 and 506-881 of SEQ ID NO: 30 and encoding the mature polypeptide.</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. Microorganismo transformado de acordo com a reivindicao 2, caracterizado pelo fato de que o cDNA est ligado de forma opervel s seqncias de controle da expresso permitindo a expresso no dito microorganismo transformado.</span>Transformed microorganism according to claim 2, characterized in that the cDNA is operably linked to expression control sequences allowing expression in said transformed microorganism.</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. Microorganismo transformado de acordo com a reivindicao 2, caracterizado pelo fato de que pertence aos fungos filamentosos.</span>Processed microorganism according to claim 2, characterized in that it belongs to filamentous fungi.</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. Microorganismo transformado de acordo com a reivindicao 4, caracterizado pelo fato de que pertence ao gnero Trichoderma ou Asper-gillus.</span>Processed microorganism according to Claim 4, characterized in that it belongs to the genus Trichoderma or Asper-gillus.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. Microorganismo transformado de acordo com a reivindicao 5, caracterizado pelo fato de que  o Trichoderma reesei.</span>Transformed microorganism according to claim 5, characterized in that it is Trichoderma reesei.</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. Mtodo para o biotratamento com pedras, caracterizado pelo fato de que compreende a etapa de adio da preparao de enzima compreendendo um polipeptdeo 20K compreendendo a seqncia de aminoci-do SEQ ID NO: 31 ou um polipeptdeo codificado por uma seqncia de nu-cleotdeo SEQ ID NO: 30 ao tecido ou roupas contendo algodo.</span>A method for stone biotreatment comprising the step of adding the enzyme preparation comprising a 20K polypeptide comprising the amino acid sequence of SEQ ID NO: 31 or a polypeptide encoded by a nu-cleotide sequence. SEQ ID NO: 30 to fabric or clothing containing cotton.</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. Mtodo de acordo com a reivindicao 7, caracterizado pelo fato de que o tecido ou as roupas  o brim.</span>Method according to claim 7, characterized in that the fabric or clothing is the denim.</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. Mtodo para o bioacabamento, caracterizado pelo fato de que compreende a etapa de adio da preparao de enzima compreendendo um polipeptdeo 20K compreendendo a seqncia de aminocido SEQ ID NO: 31 ou um polipeptdeo codificado por uma seqncia de nucleotdeo SEQ ID NO: 30 aos materiais txteis como os tecidos ou as roupas ou o fio.</span>A method for the bio-finishing comprising the step of adding the enzyme preparation comprising a 20K polypeptide comprising the amino acid sequence SEQ ID NO: 31 or a polypeptide encoded by a nucleotide sequence SEQ ID NO: 30 to textile materials such as fabrics or clothing or yarn.</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. Mtodo de acordo com a reivindicao 9, caracterizado pelo fato de que os materiais txteis so fabricados de fibras contendo celulose natural ou fibras contendo celulose feitas pelo homem ou so misturas das mesmas.</span>A method according to claim 9, characterized in that the textile materials are made from natural cellulose-containing fibers or man-made cellulose-containing fibers or are mixtures thereof.</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. Mtodo de acordo com a reivindicao 10, caracterizado pelo fato de que os materiais txteis so combinaes de fibras sintticas e fibras contendo celulose.</span>A method according to claim 10, characterized in that the textile materials are combinations of synthetic fibers and cellulose-containing fibers.</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. Composio detergente, caracterizada pelo fato de que compreende a preparao de enzima compreendendo um polipeptdeo 20K compreendendo a seqncia de aminocido SEQ ID NO: 31 ou um polipeptdeo codificado por uma seqncia de nucleotdeo SEQ ID NO: 30 e um agente ativo de superfcie ou tensoativo.</span>A detergent composition, characterized in that it comprises the enzyme preparation comprising a 20K polypeptide comprising the amino acid sequence SEQ ID NO: 31 or a polypeptide encoded by a nucleotide sequence SEQ ID NO: 30 and a surface active agent or surfactant.</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Mtodo para o tratamento de material txtil contendo fibra celulsica, caracterizado pelo fato de que compreende misturar o dito material txtil com a composio detergente como definida na reivindicao 12.</span>A method for treating cellulosic fiber-containing textile material, comprising comprising mixing said textile material with the detergent composition as defined in claim 12.</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Mtodo para o tratamento de polpa ou fibra derivada de madeira, caracterizado pelo fato de que compreende a etapa de adicionar a preparao de enzima compreendendo um polipeptdeo 20K compreendendo a seqncia de aminocido SEQ ID NO: 31 ou um polipeptdeo codificado por uma seqncia de nucleotdeo SEQ ID NO: 30  polpa ou fibra secundria mecnica ou qumicamente derivada de madeira.</span>A method for treating wood-derived pulp or fiber which comprises the step of adding the enzyme preparation comprising a 20K polypeptide comprising the amino acid sequence SEQ ID NO: 31 or a polypeptide encoded by a sequence. nucleotide SEQ ID NO: 30 to mechanically or chemically derived wood pulp or secondary fiber.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2232245C/en"><a id="link" href="#" class="style-scope state-modifier">CA2232245C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-06-07</span>
                    <span class="td style-scope patent-result">Cellulases, the genes encoding them and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU639570B2/en"><a id="link" href="#" class="style-scope state-modifier">AU639570B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-07-29</span>
                    <span class="td style-scope patent-result">A cellulase preparation comprising an endoglucanase enzyme 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3554322B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3554322B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-08-18</span>
                    <span class="td style-scope patent-result">
  Method for stonewashing a fabric utilizing endoglucanase
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0553280B2/en"><a id="link" href="#" class="style-scope state-modifier">EP0553280B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-08-11</span>
                    <span class="td style-scope patent-result">Methods for treating cotton-containing fabrics with cellulase 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BRPI0620318A2/en"><a id="link" href="#" class="style-scope state-modifier">BRPI0620318A2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-11-08</span>
                    <span class="td style-scope patent-result">
  enzymes
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1992006221A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1992006221A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-04-16</span>
                    <span class="td style-scope patent-result">Methods for treating cotton-containing fabrics with cellulase 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1992006183A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1992006183A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-04-16</span>
                    <span class="td style-scope patent-result">Methods for treating cotton-containing fabrics with cellulase 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7323326B2/en"><a id="link" href="#" class="style-scope state-modifier">US7323326B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-01-29</span>
                    <span class="td style-scope patent-result">Cellulases, the genes encoding them and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH06506829A/en"><a id="link" href="#" class="style-scope state-modifier">JPH06506829A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-08-04</span>
                    <span class="td style-scope patent-result">
  Method for treating cotton-containing fabrics with cellulase
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6184019B1/en"><a id="link" href="#" class="style-scope state-modifier">US6184019B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-02-06</span>
                    <span class="td style-scope patent-result">Cellulases, the genes encoding them and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FI121576B/en"><a id="link" href="#" class="style-scope state-modifier">FI121576B</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-01-14</span>
                    <span class="td style-scope patent-result">
  Methods for treating non-cotton fabrics with cellulase
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU4229893A/en"><a id="link" href="#" class="style-scope state-modifier">AU4229893A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-11-29</span>
                    <span class="td style-scope patent-result">Methods for treating cotton-containing fabrics with cbh i enriched cellulase 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH06506359A/en"><a id="link" href="#" class="style-scope state-modifier">JPH06506359A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-07-21</span>
                    <span class="td style-scope patent-result">
  Method for treating cotton-containing fabrics with cellulase
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20010036910A1/en"><a id="link" href="#" class="style-scope state-modifier">US20010036910A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-01</span>
                    <span class="td style-scope patent-result">Cellulase preparation comprising an endoglucanase enzyme 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BRPI9611114B1/en"><a id="link" href="#" class="style-scope state-modifier">BRPI9611114B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-08-01</span>
                    <span class="td style-scope patent-result">
  METHOD FOR THE BIOTRATING WITH STONES, METHOD FOR THE BIOACCURATION, DETERGENT COMPOSITION, METHOD FOR THE TREATMENT OF TEXTILE MATERIAL CONTAINING CELLULOSE FIBER AND METHOD FOR THE TREATMENT OF WOOD PULP OR FIBER DERIVED FROM WOOD
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0699249B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0699249B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-06-13</span>
                    <span class="td style-scope patent-result">Methods for treating non-cotton-containing fabrics with cellulase 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (7)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US020840<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1987-03-02</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US533595A<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1995-10-17</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US005335<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1995-10-17</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US792695A<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1995-12-04</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US007926<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1995-12-04</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US2084096A<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1996-06-28</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1997014804A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/FI1996/000550</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1996-10-17</span>
                    <span class="td style-scope patent-result">Cellulases, the genes encoding them and uses thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2837319201" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2837319201" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=798599054" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>